JPH022104B2 - - Google Patents
Info
- Publication number
- JPH022104B2 JPH022104B2 JP1488879A JP1488879A JPH022104B2 JP H022104 B2 JPH022104 B2 JP H022104B2 JP 1488879 A JP1488879 A JP 1488879A JP 1488879 A JP1488879 A JP 1488879A JP H022104 B2 JPH022104 B2 JP H022104B2
- Authority
- JP
- Japan
- Prior art keywords
- hormone
- detection agent
- agent according
- progesterone
- dye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- 229940088597 hormone Drugs 0.000 claims description 65
- 239000005556 hormone Substances 0.000 claims description 65
- 102000015694 estrogen receptors Human genes 0.000 claims description 56
- 108010038795 estrogen receptors Proteins 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 52
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 50
- 201000011510 cancer Diseases 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 239000000975 dye Substances 0.000 claims description 37
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 31
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 29
- 150000003431 steroids Chemical class 0.000 claims description 29
- 238000001514 detection method Methods 0.000 claims description 28
- 229960005309 estradiol Drugs 0.000 claims description 28
- 239000000186 progesterone Substances 0.000 claims description 28
- 229960003387 progesterone Drugs 0.000 claims description 27
- 239000000262 estrogen Substances 0.000 claims description 26
- 229940011871 estrogen Drugs 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 102000003998 progesterone receptors Human genes 0.000 claims description 21
- 108090000468 progesterone receptors Proteins 0.000 claims description 21
- -1 albuminoids Proteins 0.000 claims description 19
- 239000003270 steroid hormone Substances 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000000969 carrier Substances 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 150000003146 progesterones Chemical class 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 108091008039 hormone receptors Proteins 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- JBBNFGYRYNBDIH-DBGGZKJISA-N 11alpha-hydroxyprogesterone hemisuccinate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2OC(=O)CCC(O)=O JBBNFGYRYNBDIH-DBGGZKJISA-N 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
- SCPADBBISMMJAW-UHFFFAOYSA-N (10S)-3c.17t-Dihydroxy-10r.13c-dimethyl-17c-((R)-1-hydroxy-aethyl)-(5tH.8cH.9tH.14tH)-hexadecahydro-1H-cyclopenta[a]phenanthren Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)(O)C1(C)CC2 SCPADBBISMMJAW-UHFFFAOYSA-N 0.000 claims description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 2
- 229930182834 17alpha-Estradiol Natural products 0.000 claims description 2
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 claims description 2
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 claims description 2
- SCPADBBISMMJAW-UHHUKTEYSA-N 5beta-Pregnane-3alpha,17alpha,20alpha-triol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@]([C@@H](O)C)(O)[C@@]2(C)CC1 SCPADBBISMMJAW-UHHUKTEYSA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010068370 Glutens Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000006947 Histones Human genes 0.000 claims description 2
- 108010033040 Histones Proteins 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- YDIKCZBMBPOGFT-PWUSVEHZSA-N Malvidin 3-galactoside Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-PWUSVEHZSA-N 0.000 claims description 2
- 108010063312 Metalloproteins Proteins 0.000 claims description 2
- 102000010750 Metalloproteins Human genes 0.000 claims description 2
- 102000001621 Mucoproteins Human genes 0.000 claims description 2
- 108010093825 Mucoproteins Proteins 0.000 claims description 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims description 2
- 108010080698 Peptones Proteins 0.000 claims description 2
- 108010089430 Phosphoproteins Proteins 0.000 claims description 2
- 102000007982 Phosphoproteins Human genes 0.000 claims description 2
- YWYQTGBBEZQBGO-BERLURQNSA-N Pregnanediol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-BERLURQNSA-N 0.000 claims description 2
- PXUQTDZNOHRWLI-QOPOCTTISA-O Primulin Natural products O(C)c1c(O)c(OC)cc(-c2c(O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O3)cc3c(O)cc(O)cc3[o+]2)c1 PXUQTDZNOHRWLI-QOPOCTTISA-O 0.000 claims description 2
- 102000007327 Protamines Human genes 0.000 claims description 2
- 108010007568 Protamines Proteins 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 claims description 2
- CPUMJJMOTBXNBQ-UHFFFAOYSA-N [6-amino-9-(2-ethoxycarbonylphenyl)-7-methylxanthen-3-ylidene]-dimethylazanium;chloride Chemical compound [Cl-].CCOC(=O)C1=CC=CC=C1C(C1=CC(C)=C(N)C=C1O1)=C2C1=CC(=[N+](C)C)C=C2 CPUMJJMOTBXNBQ-UHFFFAOYSA-N 0.000 claims description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims description 2
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- KSCQDDRPFHTIRL-UHFFFAOYSA-N auramine O Chemical group [H+].[Cl-].C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 KSCQDDRPFHTIRL-UHFFFAOYSA-N 0.000 claims description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 2
- 229940093265 berberine Drugs 0.000 claims description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 2
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 2
- 229960001348 estriol Drugs 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- 229960000901 mepacrine Drugs 0.000 claims description 2
- 235000019319 peptone Nutrition 0.000 claims description 2
- 229940066779 peptones Drugs 0.000 claims description 2
- 239000000583 progesterone congener Substances 0.000 claims description 2
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 claims description 2
- 229940070353 protamines Drugs 0.000 claims description 2
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 2
- 229940043267 rhodamine b Drugs 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 claims description 2
- CZIRZNRQHFVCDZ-UHFFFAOYSA-L titan yellow Chemical compound [Na+].[Na+].C1=C(C)C(S([O-])(=O)=O)=C2SC(C3=CC=C(C=C3)/N=N/NC3=CC=C(C=C3)C3=NC4=CC=C(C(=C4S3)S([O-])(=O)=O)C)=NC2=C1 CZIRZNRQHFVCDZ-UHFFFAOYSA-L 0.000 claims description 2
- 150000003857 carboxamides Chemical group 0.000 claims 4
- 150000002433 hydrophilic molecules Chemical class 0.000 claims 2
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims 1
- PEJLNXHANOHNSU-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride Chemical compound [Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 PEJLNXHANOHNSU-UHFFFAOYSA-N 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 229940098773 bovine serum albumin Drugs 0.000 claims 1
- NAXWWTPJXAIEJE-UHFFFAOYSA-N chembl1398678 Chemical compound C1=CC=CC2=C(O)C(N=NC3=CC=C(C=C3)C3=NC4=CC=C(C(=C4S3)S(O)(=O)=O)C)=CC(S(O)(=O)=O)=C21 NAXWWTPJXAIEJE-UHFFFAOYSA-N 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000003688 hormone derivative Substances 0.000 claims 1
- 229960000249 pregnenolone Drugs 0.000 claims 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims 1
- 108060006613 prolamin Proteins 0.000 claims 1
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 32
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
- 208000026310 Breast neoplasm Diseases 0.000 description 23
- 206010006187 Breast cancer Diseases 0.000 description 22
- 229930182833 estradiol Natural products 0.000 description 22
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000000093 cytochemical effect Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 229960003604 testosterone Drugs 0.000 description 12
- 108010071390 Serum Albumin Proteins 0.000 description 11
- 102000007562 Serum Albumin Human genes 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 244000309466 calf Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000002923 oximes Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 238000001794 hormone therapy Methods 0.000 description 7
- BFZHCUBIASXHPK-QJSKAATBSA-N 11alpha-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)C[C@H]2O BFZHCUBIASXHPK-QJSKAATBSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 206010039897 Sedation Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 108010006205 fluorescein isothiocyanate bovine serum albumin Proteins 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 230000036280 sedation Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 238000012742 biochemical analysis Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000011546 protein dye Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
- AWARIMYXKAIIGO-UYGYUSPXSA-N 2-[(z)-[(8r,9s,13s,14s,17s)-3,17-dihydroxy-13-methyl-8,9,11,12,14,15,16,17-octahydro-7h-cyclopenta[a]phenanthren-6-ylidene]amino]oxyacetic acid Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3C\C(=N\OCC(O)=O)C2=C1 AWARIMYXKAIIGO-UYGYUSPXSA-N 0.000 description 3
- REXFWMANWYNMPV-AJYQEWAOSA-N 3,17beta-Diacetoxyestra-1,3,5(10)-trien-6-one Chemical compound C1C(=O)C2=CC(OC(C)=O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 REXFWMANWYNMPV-AJYQEWAOSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000003370 receptor cell Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 229940014800 succinic anhydride Drugs 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- ZHTDDOWJIRXOMA-YVEZLPLXSA-N (8r,9s,13s,14s,17s)-3,17-dihydroxy-13-methyl-8,9,11,12,14,15,16,17-octahydro-7h-cyclopenta[a]phenanthren-6-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC(=O)C2=C1 ZHTDDOWJIRXOMA-YVEZLPLXSA-N 0.000 description 2
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000007659 Fibroadenoma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 239000012052 hydrophilic carrier Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- AUGZRBAFFHVOND-WMSSUOLPSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-16-bromo-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(Br)[C@H](C(=O)C)[C@@]1(C)CC2 AUGZRBAFFHVOND-WMSSUOLPSA-N 0.000 description 1
- HFSZYSZYZVKKOX-UHPWKVKZSA-N (8s,9s,10r,13s,14s,17s)-17-acetyl-6-bromo-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C(Br)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 HFSZYSZYZVKKOX-UHPWKVKZSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 1
- TYRGTHQUZVMKOF-UHFFFAOYSA-N 16,17-dihydro-15h-cyclopenta[a]phenanthrene Chemical class C1=CC=C2C3=CC=C4CCCC4=C3C=CC2=C1 TYRGTHQUZVMKOF-UHFFFAOYSA-N 0.000 description 1
- HUPDIVYMUZMPMO-UHFFFAOYSA-N 2,4,5-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC([N+]([O-])=O)=C([N+]([O-])=O)C=C1[N+]([O-])=O HUPDIVYMUZMPMO-UHFFFAOYSA-N 0.000 description 1
- WXAWNCDYPXVODT-ZAKIEOBNSA-N 2-[(e)-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-ylidene]amino]oxyacetic acid Chemical compound OC(=O)CO/N=C/1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C\1 WXAWNCDYPXVODT-ZAKIEOBNSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- VQHQLBARMFAKSV-AANPDWTMSA-N [(8r,9s,13s,14s,17s)-3-acetyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(OC(C)=O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 VQHQLBARMFAKSV-AANPDWTMSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- HDFRDWFLWVCOGP-UHFFFAOYSA-N carbonothioic O,S-acid Chemical class OC(S)=O HDFRDWFLWVCOGP-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000005182 dinitrobenzenes Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 125000000251 estriol group Chemical group 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229960001858 norethynodrel Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940077150 progesterone and estrogen Drugs 0.000 description 1
- 108010066545 progesterone-11-bovine serum albumin Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- SRPWOOOHEPICQU-UHFFFAOYSA-N trimellitic anhydride Chemical compound OC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 SRPWOOOHEPICQU-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æè¿ãè
«ççµç¹å質äœã®çŽ°èãŸã«èçœäžã®ãšã¹
ããã²ã³å容äœïŒERïŒç¹æ§ã®åæããä¹³çãé²
ãã§ããæ£è ãéžã³åºããå¯èœãªãã«ã¢ã³çæ³ã
ãšãããã«æå¹ãªæ段ã§ããããšã蚌æãããŠã
ããäŸãã°ãN.Engl.J.Medã291ïŒ1252â1253
ïŒ1974ïŒãåç §ããŠé ãããããšã¹ããã²ã³å容
äœåæã§éžã°ããæ£è ã¯ãåã«èšåºåºæºã«ãã€ãŠ
éžã°ããæ£è ã§ã¯åã«20ïŒ ãã30ïŒ ã®åå¿ã§ãã
ã®ã«å¯Ÿãã32ïŒ ãã60ïŒ ã®å®¢èŠ³çé®éçã瀺ãã
ãšãå ±åãããŠãããäŸãã°ãCancerã39ïŒ
2934â2947ïŒ1977ïŒïŒCancer 23ïŒ145â151ïŒ1969ïŒ
åJAMAã172ïŒ1271â1283ïŒ1960ïŒã倫ã åç §
ããããã ããããªããããšã¹ããã²ã³å容äœã«å¯Ÿãéœæ§
ãšã¿ãªãããè «çããã€ãæ£è ã«æŒãŠãé«ãåå¿
çãåŸãããšãåºæ¥ãªãããšãåã³é¡èãªãšã¹ã
ãã²ã³å容äœã®ãªãä¹³çæ£è ã®çŽ10ïŒ ãçš®ã ã®ãš
ã³ãã¯ãªã³çæ³ã«ããŸãåå¿ããŠãããšããäºå®
ãããæœåšçãªãã«ã¢ã³å容äœä¹³çãæ€åºããè
å¥ããããã«ãçŸç¶ã®æ¹æ³ãæŽã«æ¹åãããšãã
ããšãå¿ èŠã§ããããšã瀺ããŠããã çŸåšã®çååŠçåææ¹æ³ã¯ãçµç¹å質äœã®çŽ°è
ãŸã«ãã©ã¯ã·ãšã³äžã®èçœè³ªã®ãšã¹ãã©ãžãªãŒã«
çµåèœåã枬å®ãããåŸã€ãŠãã®çµæã¯ãåæã«
äŸãããçµç¹äžã®çã®ãããŸãã®äºå®äžã®å€§ãã
ãã现èãŸã«äžã«æœåºãããçå容äœèçœè³ªã®æ¯
çãããã®ä»éççµç¹æåããæœåºãããèçœè³ª
ã«åœ±é¿ããããçµæãšããŠããããã®èŠå ã®å€å
ã«ãã€ãŠãæçµçãªãšã¹ããã²ã³å容äœå€ã®ã°ã
ã€ãã倧ãããªãããã®çµæãç现èæ°ã®çå®ã®
ççåŠçç¶æ ãäžæ£ç¢ºãšãªã€ãŠããã äžè¿°ã®ããã«ããšã¹ããã²ã³å容äœåæã«ãã€
ãŠéžã°ããæ£è ã¯ã32ïŒ ãã60ïŒ ã®æçœãªé®éç
ã瀺ããŠãããããã®ããšã¯ããã®æ¹æ³ã«ãã€ãŠ
éžã°ããæ£è ã®68ïŒ ãã40ïŒ ã¯ããŸã ãã«ã¢ã³ç
æ³ãããŸããã€ãŠãªããšããããšãæå³ãããæ£
è éžææ³ãæ¹åããããã«ãæœåšçãªãã«ã¢ã³å
å¿ä¹³çã®èå¥ã®ããã®ç¬¬ïŒã®å°ãšããŠãè «ç现è
ãŸã«äžã®ããã²ã¹ããã³å容äœã®åæãæ¡çšãã
ãŠããã ããã²ã¹ããã³å容äœã¯ãä¹³çã®30â60ïŒ ã«æŒ
ãŠå ±åãããŠããïŒæ£åžžåããªãã©ã¹ãã€ãã¯çµ
ç¹ã«æŒããããã²ã¹ããã³å容äœã«ã€ããŠãW.
L.McQuireãJ.P.RuynaudãE.E.BaulieuãP171ã
New YorkãRavin Pressã1977ïŒãåæããã«
ãšã¹ããã²ã³å容äœã«å¯Ÿãéœæ§ã§ããè «çã«ã€ã
ãŠã®ã¿èµ·ãïŒEuropean Journal of Cancer
13ïŒ1205ã1977ïŒãåæã®ããŒã¿ã¯ãšã¹ããã²ã³
å容äœãããã²ã¹ããã³å容äœãåãè «çäžã«èŠ
åºããããšããããšã¯ããã«ã¢ã³åå¿ãšäžå±€å¯æ¥
ã«é¢é£ããŠããããšãèããããããšã瀺ããŠã
ãããã ããããšãŒãããã·ãªãŒãºã§ã¯ãããã
ãã¯ã¬ãŒã ã¯æ¯æããªãã€ãã«ãæãããããã®
ãããªåæçãªçååŠçåæã®åºç€ã®äžã§ããã
ã²ã¹ããã³å容äœã¯ãä»åŸã®ç 究ã§ãã®ãããªæ±º
å®ã®èŠéã確ç«ããå¿ èŠãããã®ã ãããã«ã¢ã³
åå¿ä¹³çã«å¯Ÿãã第äºã®ãããã¥ãéå ·ãšãªãã§
ãããã ããã²ã¹ããã³å容äœã®æµè¡ã®çååŠçåæ
ã¯ããšã¹ããã²ã³å容äœã«ã€ããŠãã§ã«è°è«ãã
ãã®ãšåããããªå°é£ãããã€ãããæ ããšã¹ã
ãã²ã³å容äœã«ã€ããŠãšåãããã«ãç现èéå£
ã«å¯Ÿããããã²ã¹ããã³å容äœéœæ§çŽ°èã®å²åã
枬å®ã§ãããåçŽã§ãã€ãšæ£ç¢ºãªçŽ°èååŠçæè¡
ãå¿ èŠãšãããŠããã æŽã«ãä»ã®ã¿ã€ãã®çãåãã«ã¢ã³çæ³ã«ææ
ã§ããããåäžè¬ã«ãæªæ§ã®çµç¹ã«æŒããã«ã¢ã³
å容äœã®æ€åºãšåå®ã容æã«ãããããªéèŠãªæ€
åºå€ãå¿ èŠãšãããŠããã æ¬çºæã®ç®çãšãããã¯ããã«ã¢ã³çæ³ã«å¯Ÿã
ãæ£è ã®éžæã«å¯Ÿããäºè æäžåã¯è£è¶³çäºèšãš
ããŠãåç现èã®ãšã¹ããã²ã³ãšããŠåããã²ã¹
ããã³ãä»ã®ãã«ã¢ã³çµåã®ç 究ãšåå®ã«æå¹ãª
æ¹æ³ãšçŽæ¥ã®çŽ°èååŠå€ãéçºããããšã§ããã åºç€çã«ã¯ãæ¬çºæã¯ãçµç¹ã®ãããŸãäžã®ã
ãã¿ã€ãã®ä¹³çã®ååšããèŠèŠçãªæ¹æ³ã§éžæç
ã«ææããããšã®ã§ããèãã䟿å©ãªèœåãã
ã¡ãåãåé¡ã®æ£è ã«é©åãªãã«ã¢ã³å»çã®æè¬
ã®äžã§ãé®éãããããªãããçš®ã®ãã«ã¢ã³âè
çœâææè€åå€ã®çºèŠãšéçºãå«ãã§ãããäº
å®ãåçµçäžã§åé¢ãããã¹ãããã人éã®ä¹³ç
现èäžã®ãšã¹ããã²ã³ãããŠåããã²ã¹ããã³å
容äœãæ€åºããæ¬çºæã«ãããããååŠçãã¬ãŒ
ãµãŒãæåºãããŠãããæŽã«ãæ¬çºæã¯ãçš®ã ã®
ä»ã®ã¿ã€ãã®æªæ§ç©äžã®çžåœããå容äœçŽ°èã®æ€
åºã«éããä»ã®ãã«ã¢ã³å€ã®å©çšãå«ãã§ããã
æ¬çºæã¯ãçããŠããçè «ã®é®éããªãããã«é©
åœãªã¿ã€ãã®çæ³ã®æ±ºå®ã«å€§ããªé²æ©ããªãããš
ãçŽæããã æ¬çºæã®å®æœäŸã¯ããšã¹ããã²ã³å容äœã«é¢ã
ãŠæåã«ç€ºããã®ãšåæ§ã«ã次ã®ããã«æçãã«
èŠçŽã§ããïŒ åæåã¯è»¢ç§»ããä¹³çè «ãå«ããåã¯å«ããšæ
ãããçµç¹çãå€ç§æè¡ã«ããæ£è ããåãé€
ããåçµããããã®çµç¹çã次ã«ãçŽ14ÎŒã®åã
ã«åããé¡åŸ®é¡ã®ã¹ã©ã€ãã«ããã€ããæŽã«ãçŽ
ïŒæéïŒçŽïŒâããïŒâãŸã§ïŒå·èµåº«ã§ä¹Ÿç¥ãã
ããããããããªã³é žå¡©âç·©è¡¡åããã塩溶液
ïŒããšãã°0.01Mãªã³é žå¡©ãå«ã0.85ïŒ NaCl溶液ã
PH7.4ïŒã§æçãã«ãããã§åæ°ŽåããåŸããã®
çµç¹æšæ¬ãäŸãã°ãè¢å ãšã¹ãã©ãžãªãŒã«è€åå€
ïŒåŸã«è©³è¿°ããïŒã§è¢«èŠããæŽã«å®€æž©ïŒçŽ16âã
ã22âïŒã§çŽïŒæé湿æ°ã®ãã宀ã§åé€ããã ãã®è¢«èŠããè€åäœãããã®çµç¹æšæ¬ããåã
é€ãããã®çŽ°çããªã³é žå¡©ç·©è¡¡ããå¡©ã§åã³éã
ã«ãããããããŠãçŽïŒæéãå¡©äžã«æµžæŒ¬ããã
ãã®å Žåãæ°é®®ãªæŽæµæ¶²ã§äžåºŠäº€æããã®ãæå©
ã§ããã次ãã§ããªã³é žå¡©âç·©è¡¡ããã°ãªã»ãª
ã³ãPH7.2â7.8åã³ã¹ã©ã€ãã«ããŒã¹ãªããã§ã«
ããŒããããšãè¢å é¡åŸ®é¡ã§ãã¹ãããã è¢å ãšã¹ãã©ãžãªãŒã«ã§ã®ãã®ãããªåŠçåŸã
åºãŸã€ãŠããªãåã€ã现çäžã®ä¹³ç现èã¯ãè¢å
é¡åŸ®é¡ã§ãã¹ããããšãããã«ïŒã€ã®äž»ãªç¯çã«
åé¢ããããå³ã¡æ¬æ¥çãªçŽ°è質è¢å ã§ããçŸã
ãç·è²ã瀺ãç现èãšè¢å ããåã¯ããŠã極å°ã§
ããéšåãšã§ããã ããããåŠçåŸã®çŽ°èã®è¢å ã®ååšã¯ãçµç¹ã«
ãããè€åäœã®ãšã¹ãã©ãžãªãŒã«æ®åºã®è¡šé¢çãª
çµåã®çµæã§ãããšè§£éãããåãã®äžã«ãšã¹ã
ãã²ã³å容äœã®ååšã瀺ã蚌æ ãšããŠåããšãã
ããã 现èã®ãšã¹ããã²ã³å容äœã®ç¹å¥ã®çè²ã®éœæ§
é°æ§ã®ããããã³ã°ãã也ããåçµãã现çã®ã
ã¬ã€ã³ããŠããŒã·ãšã³ã«ãã€ãŠãã¹ãããããã®
ãã¹ãã¯ãããšãã°è¢å æææåãæ¬ ããåæ§ã®
ãšã¹ãã©ãžãªãŒã«ååç©äžã§ããµã€ãã«ç·©è¡¡ãã
ãåçã®è¡æž ã¢ã«ããã³ïŒâBSAâïŒæº¶æ¶²äžã§ã
ããããè¢å ãšã¹ãã©ãžãªãŒã«è€åäœã®åŒ·åºŠãªçš
éãšããïŒæéåã«å®æœãããããã现çã¯ãæŽ
ã«äžè¿°ã®åŠãå¹é€ããæŽæµãããã¹ãããã å®å šã«ç¹ç°æ§ã®ããããããã³ã°ãåŸãããã«
ã¯ãè¢å ãšã¹ãã©ãžãªãŒã«è€åäœãçšéãããå
ã¯ã¹ããã€ãïŒèçœè³ªã®æ¯ãäœãããŠãçšããç
è²äžã®ãšã¹ãã©ãžãªãŒã«æ®åºã®æ¿åºŠãã¹ããã€
ãïŒèçœè³ªã®æ¯ã20â25ã§ããããããã³ã°æº¶æ¶²
äžã§ã¯ãã®1/10ãè¶ããªãããã«ããããšãå¿ èŠ
ã§ããããšãããã€ããããããã³ã°å€ãšããŠé
è€åã®17βâãšã¹ãã©ãžãªãŒã«åã¯17βâãšã¹ã
ã©ãžãªãŒã«âïŒâCMOã䜿çšããè©Šã¿ã¯ãèçœ
質ãã€ãªã¢ãŒååšãªãã«ãçŽPH7.4ã®æ°Žæº¶æ¶²äžã§
ã®ãããã®ååŠç©è³ªã®æº¶è§£åºŠã¯ãERéœæ§ç现è
ã®çµååŽãæºè¶³ããã®ã«å åã§ãªãã€ãã®ã§ãæ
åããªãã€ãã è¢å ãšã¹ãã©ãžãªãŒã«è€åäœã¯ãç²è žçã®çµç¹
çãææ¡è ºãçµè žåèã®çè «ã¯ãé°æ§ã®å¯Ÿç §äŸãš
ããŠåãããã«æºåããããçè²ããªãã€ãã ããã²ã¹ããã³å容äœãå«ã现èã«é¢ããŠãå
æ§ã®åŠçæ¹æ³ãçšãããããè¢å é¡åŸ®é¡çšã«ãã®
çµç¹çãçè²ããŠæºåããæè¡ã¯ããã®å Žåã«ã¯
è¢å ããã²ã¹ããã³è€åäœã现èååŠå€ãšããŠçš
ãããã以å€ã¯ãšã¹ããã²ã³å容äœã«å¯Ÿããå Žå
ãšåãã§ããã å ã«è¿°ã¹ãããã«ãæ¬çºæã¯ã人éã®ä¹³æ¿çµç¹
ã®åçµçãžã®ãšã¹ããã²ã³ãšåããã²ã¹ããã³ã®
çµåèœåã蚌æããããã®æ°ãã现èååŠå€ãšæ¹
æ³ãçŽæããããã®æ¹æ³ã¯ãæ¬è³ªçã«ã¯ãã«ã¢ã³
ãšã¹ãã©ãžãªãŒã«åã¯ããã²ã¹ããã³ã¹ããã€ã
ååç©ãšè¢å ææååç©ãšã§ãããã«ã©ãã«ãã
ãèçœè³ªãã€ãªã¢ãŒããæãæ°èŠãªå容äœã®ãã¬
ãŒãµãŒã®èª¿è£œã«æåããããšã«ããã ãã®èçœè³ªãã€ãªã¢ãŒã¯ããã®ã¢ããé žæ®åºãš
å ±æçµåããŠãã¹ããã€ãã氎溶液äžã«éã³ã现
èååŠçåæ±ããããå åãªé«ãæ¿åºŠãšãªãã®ã§
ãã®ãã€ãªã¢ãŒã¯ãã®ãã¬ãŒãµãŒã®å¿ é ã®æåã§
ãããšæãããã ä»ã®ãã«ã¢ã³ïŒã¹ããã€ãæåããèçœä»¥å€ã®
å€å®èœã®èŠªæ°Žæ§ãã€ãªã¢ãŒãšåãããã®ååã«å©
çšãããã ã¹ããã€ããã«ã¢ã³ãããããããã€ãªã¢ãŒãš
ã€ãªãããšãããã®å€©ç¶ã®ååé 眮ã«æŒããã«ã¢
ã³ã®ç¹ç°æ§ãç¶æããããªãã°ããã®çççå®èœ
åºããã®ãŸãŸã«ããŠããããŠããããšããäžå¯æ¬
ã§ããã17βâãšã¹ãã©ãžãªãŒã«ã®å ŽåãïŒã®äœ
眮ã®ååŠçæã«ããåçã®è¡æž ã¢ã«ããã³ãšã®çµ
åã¯ããã§ã«ãå ç«åŠçç¹ç°æ§ã®ä¿æã«æåããŠ
ããïŒäŸãã°ãSteroidsã18ïŒ593â603ïŒ1971ïŒïŒ
Steroidsã19ïŒ357â375ïŒ1972ïŒãåããããªã¢ã
ããŒããããã§çšããè€åäœã調補ããã®ã«æ¡çš
ãããŠããããããçš®ã®æé ããé«ååææïŒè
çœè³ªæ¯åã³ã¹ããã€ãïŒèçœè³ªæ¯ãéæãããã
ã«ä¿®æ£ãããŠãããå¹³åããŠãæ¬çºæã®å¥œãŸãã
äŸã§ã¯ãçŽ11ã¢ã«ã®è¢å ææãš24ã¢ã«ã®ãã«ã¢ã³
ãïŒã¢ã«ã®èçœè³ªïŒäŸãã°âBSAâïŒã«æå¹ã«ã
ã€ã€ãã è¢å ããã²ã¹ããã³è€åäœã®ååŠçåæã¯ãã
ãããæŽã«è©³çŽ°ã«è¿°ã¹ãããã«ãäŸãã°åçã®è¡
æž ã¢ã«ããã³ãã«ãªãã¯ããŒã ææè€åäœã«ãäŸ
ãã°ã¹ããã€ããã«ã¢ã³ã®ïŒã®äœçœ®åã¯11ã®äœçœ®
ã®ãããããšããããã«ããã²ã¹ããã³ååãå
æ§ã«ãã€ã€ããããšã«ãã€ãŠãéæããããšãã§
ããã ãšã¹ããã²ã³ã®å ·äœäŸ 17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒ¯âã«ã«ãã
ã·ã¡ãã«ïŒãªãã·ã ã®åæ ãã³ã°ãŠãšã«ãšãŠã€ã³ã¿ãŒã¹ãã€ããŒãã
Biol.Chem.133ïŒ219â229ïŒ1940ïŒã«è¿°ã¹ãããŠ
ããããã«ã17βâãšã¹ãã©ãžãªãŒã«ã»ãžã¢ã»ã
ã€ãïŒ10ïœïŒãæ°·é ¢é žïŒ34.5mlïŒã«æº¶è§£ããæ°Ž
ïŒ6.9mlïŒãšæ°·é ¢é žïŒ51mlïŒäžã«ã¯ãããŠã ããªãª
ããµã€ãïŒ8.5ïœïŒããšããã溶液ããã«å ããã
æ··åç©ãã宀枩ã§24æéæ¹æããæ°Žã§500mlã«åž
éããåã 500mlã®ãšãŒãã«ã䜿ã€ãŠïŒåæœåºã
ãã倧éšåã®é ¢é žã¯ãããããªãã³ã¯è²ãæ°Žå±€ã«
çŸãããŸã§é£œåããNaHCO3溶液ã§æŽãããšã«
ããã䜵çšããããšãŒãã«æœåºç©ããé€å»ããã
ãšãŒãã«å±€ãæŽã«ãïŒïŒ ã®Na2CO3ãšé£œå
NaHCO3溶液ã®ïŒïŒïŒæ··å溶液ã«ãã€ãŠåŸ¹åºç
ã«æŽããã€ãã§ãæ°Žã§æŽãããããã也ç¥ãããŸ
ã§èžçºããããæ®ããé ¢é žãšãã«âç³æ²¹ãšãŒãã«
ïŒb.p.60â100âïŒã®ïŒïŒïŒæ··åç©ïŒ200mlïŒã«æº¶
解ãã22Ã4.5cmã®ã·ãªã«ã²ã«ã«ã©ã äžãéããã
ã«ã©ã ã¯æ¬¡ã«ïŒã®é ¢é žãšãã«âãããµã³ã®ïŒïŒ
ïŒæ··åç©ã§æŽãããããã200mlã®çåãéããã ãã®åæã¯ãé»è²ããã€ããæããã«éé žåã
ããå¯ç£ç©ïŒå€åã±ãé žãšãã®èªå°äœïŒã®æº¶é¢ã«
å ç«ã€ãŠåŸãããçåäžã®ïŒâã±ãâ17βâãšã¹
ãã©ãžãªãŒã«ã»ãžã¢ã»ãã€ãã®æº¶é¢ã«æé«ã®çµæ
ã瀺ããã 溶åºæº¶å€ã®èžçºåŸãç²ïŒâã±ãâ17βâãšã¹ã
ã©ãžãªãŒã«ã»ãžã¢ã»ããŒãçåã¯ããŸãšããŠç¡æ°Ž
ãšã¿ããŒã«ããåçµæ¶ãã2.5ïœã®éç¶çµæ¶ïŒm.
p.çŽ173âïŒãåŸãã ïŒâã±ãâ17βâãšã¹ãã©ãžãªãŒã«ã調補ãã
ããã«ãïŒâã±ãâ17βâãšã¹ãã©ãžãªãŒã«ã»ãž
ã¢ã»ãã€ãïŒ2.5ïœïŒããçªçŽ ã¬ã¹äžã§24æé宀
æž©ã§ãã¡ãã«ã¢ã«ã³ãŒã«äž75mlã®20ïŒ KOHã§å
æ°Žå解ãããé»è²ããã€ã溶液ãåŸãããæ°Žã§çŽ
400mlã«åžéããå¡©é žã§PHïŒãŸã§é žæ§ã«ããåã
500mlã®ãšãŒãã«ã§ïŒåæœåºããããšãŒãã«æœåº
ç©ãåããŠãNaHCO3ã§é£œåããïŒïŒ Na2CO3ã§
æŽããããããæ°Žã§æŽã€ãã也ç¥ãããŸã§èžçºã
ããåŸãç²çæç©ãç¡æ°Žãšã¿ããŒã«ã§ïŒåºŠåçµæ¶
ããããšãçµæ¶æ¿ïŒm.p.çŽ280âïŒçæé1.5ïœïŒ
ãåŸãããã ã¢ãŒã©ã³ãžã€ãŒçã«ãããMethods in
Immunology and ImmunochemistryãEd
Welliams CAãClase MW.Academic Pressã
New YorkãVol.1ã144â159ãïŒ1967ïŒäžã§è¿°
ã¹ãäžè¬çãªæ¹æ³ã¯ã17βâãšã¹ãã©ãžãªãŒã«â
ïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãªãã·ã ã調補ã
ãããã«æ¬¡ã«çšãããããïŒâã±ãâ17βâãšã¹
ãã©ãžãªãŒã«ïŒ1.5ïœïŒããšã¿ããŒã«ïŒ75mlïŒå
ã³2NKOHïŒ6.8mlïŒã«æº¶è§£ãã次ã§ã«ã«ããã·ã¡
ããã·ã«ã¢ãã³ã»ãããã€ããã¯ãã©ã€ãïŒ94
ïŒ ïŒ1.5ïœïŒãå ãããæ··åç©ãïŒæééæµãã
åŸãã¢ã«ã³ãŒã«ãèžçºããããæ®ãã溶解ããã
ããã«æ°ŽïŒ150mlïŒãå ããåŸã«ããã®æº¶æ¶²ãPH
8.5ã«èª¿æŽããé溶解ç©ãé€ãããã«éãã
åã 30mlã®é ¢é žãšãã«ã§ïŒåºŠæœåºãããHClã§PH
ïŒã«é žæ§åããåŸãçœãæ²æŸ±ç©ãçæãããåŸè
ããéã§éãã37âã®ã€ã³ããŠããŒã¿ãŒã§ä¹Ÿç¥
ããã¢ã»ãã³ã§ïŒåºŠåçµæ¶ããããšã1.4ïœã®é
ç¶çµæ¶ïŒm.p.196â199âïŒãçæããã17βâãš
ã¹ãã©ãžãªãŒã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒ
ãªãã·ã ãšãã®å é§ç©è³ªã®åå®ã¯ãèç¹ãšã·ã«ã«
ã²ã«ãã¬ãŒãã§èå±€ã¯ãã³ãã°ã©ãã€ãŒïŒæº¶åª
ç³»ïŒé ¢é žãšãã«ïŒïœâãããµã³ïŒãšã¿ããŒã«ïŒé ¢
é žã®æ¯ã72ïŒ13.5ïŒ4.5ïŒ10ïŒã§å®æœãããæç®
ïŒäŸãã°Steroidsã18ïŒ593â603ïŒ1971ïŒå19ïŒ
357â375ïŒ1972ïŒïŒã«å ±åãããŠããããã«ããã®
å€ã¯ãããã®ååŠç©è³ªã«äºæ³ãããã®ã«çžåœãã
ããšãããã€ãã ãã«ãªã¬ãã»ã³ ã€ãœã·ã¢ããŒãïŒFITCïŒâ
åçè¡æž ã¢ã«ããã³ïŒBSAïŒååç©ïŒFITCâ
BSAïŒã®èª¿è£œãAm.J.Path.ã34ïŒ1081â1097
ïŒ1958ïŒã®äžè¬çãªæ¹æ³ãé«ãFITCâBSAæ¯ã
çšãã以å€ã¯ãåæ§ã«ããŠçšããã詳现ã«ã¯ã
BSAïŒïŒïœïŒã·ã°ãã±ãã«ã«ç€Ÿè£œã®ãã®ã§çµæ¶å
ããŠåçµä¹Ÿç¥ãããã®ïŒã10mlã®0.5Mã®ã«ã«ã
ããŒãâãã«ã«ãããŒã緩衡液ïŒPH9.5ïŒã«æº¶è§£
ãããã»ã©ã€ãïŒ10ïŒ ç©ïŒã·ã°ãã±ãã«ã«ç€Ÿè£œïŒ
äžã®FITCïŒïŒïœïŒããã®æº¶æ¶²ã«å ãã宀枩ã§ïŒ
æéæ¹æãããé å¿åé¢ã«ããã»ã©ã€ããé€å»
åŸãFITCâBSAè€åäœããããããã0.05Mãª
ã³é žå¡©ç·©è¡¡æ¶²ïŒPH7.8ïŒã§å¹³è¡¡ã«ããã»ãã¢ãã
ã¯ã¹ïŒ§â25ã«ã©ã ãéãã次ãã§ãããçµåãã
FITCãå®å šã«é€å»ããããåã緩衡液ã§48æé
éæããããã®èçœè³ªéã¯ãããŠãŒã¬ããåå¿ã§
決å®ããããã«ãªã¬ãã»ã³ïŒèçœè³ªã®å¹³åååé
æ¯ã¯ã495nïœã§ã®0.1N NaOHäžã§ã®çŽç²FITC
ã®åžåãã11.2ïŒÂ±0.5ïŒã§ãããšèšç®ãããã 17βâãšã¹ãã©ãžãªãŒã«âïŒâCMOâBSAâ
FITCè€åäœïŒãã«ãªã¬ãã»ã³ã»ãšã¹ãã©ãžãªãŒ
ã«è€åäœïŒã®èª¿è£œãäžè¿°ã®ããã«ããŠåŸãããã
èçœè³ªïŒ200mgïŒãïŒâãšãã«âïŒâïŒïŒâãžã¡ã
ã«ã¢ãããããã«ïŒã«ã«ããžã€ããã»ãã€ããã¯
ãã©ã€ãïŒ200mgïŒåã³ãžãªããµã³ïŒmlã«æº¶è§£ã
ã17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒâã«ã«ãã
ã·ã¡ãã«ïŒãªãã·ã ïŒ200mgïŒãå«ããªã³é žå¡©ç·©
衡液ã«å«ãŸããFITCâBSAè€åäœã®äžéšãïŒml
ã®æ°Žã0.05Mãªã³é žå¡©ç·©è¡¡æ¶²ã®é©éãããªããPH
7.8ã§å šé21mlã«ãããã®ã宀枩ã§20æéæ¹æã
ãããã®éçšã§ããšã¹ãã©ãžãªãŒã«ã¯ãâBSAâ
èçœè³ªäžã®Îµâã¢ããåºãšãã¹ããã€ãã®ãªãã·
ã èªå°äœã®ã«ã«ããã·ã«åºã®éã®ããã¿ã€ãçµå
ã®çæã«ããBSAã«çµåããã 次ãã§ãã®è€åäœããŸãæ°Žã§åŸ¹åºçã«éæãã
次ã§ã48æéãªã³é žå¡©ã§ç·©è¡¡åãã塩溶液
ïŒPBSïŒïŒPH7.4ïŒã§éæãã次ã«é å¿åé¢ïŒ28000
Ãïœã15åïŒããããã®äžæŸæ¶²ãéãã¢ãžåãã
ãªãŠã ãé²è å€ãšããŠæçµæ¿åºŠïŒmgïŒmlã«ãªãã
ãã«å ããã ãã®æº¶æ¶²ã¯äœ¿çšåã«PBSã§ææã®æ¿åºŠãŸã§æŽ
ã«çšéããã è©Šéšãã¹ãä¹³ççµç¹æšæ¬ãäžè¿°ã®ããã«åçµã
ã现çãšããŠèª¿è£œããŠãããããããããåºå®ã
ããªãç¶æ ã«ä¿ããã°ãªããªããäŸãã°ããããš
ã¹ããã²ã³å容äœïŒERïŒéœæ§ç现èãå«ãçµç¹
çããå·ã¢ã»ãã³ïŒâ20âïŒã3.7ïŒ ã®ç·©è¡¡æ¶²åã
ããã«ã ã¢ã«ãããåã¯ïŒïŒ ã°ã«ã¿ãŒã«ã¢ã«ãã
ãäžã§åºå®ãããã°ã现èã®ãšã¹ãã©ã²ã³çµåèœ
åãå®å šã«ãªããªããšããããšã«ããªãããã æŽã«ã现èãšã¹ããã²ã³å容äœã«æŒããä¿åå¹
æã調ã¹ãããã«ãERéœæ§è «çãããšã€ãå¥ã
ã®çµç¹çãåã ïŒâããïŒâã®PBSäžã«ä¿åãã
äžæ¹ã¯â20âã§åçµãããåçµçã¯ã24æééé
ã§ããã®ãããŸãããã«ãããããšã¹ããã²ã³å
容äœã®æ€åºã®ããã«çè²ãããçµç¹ã®ãããŸãã
åçµããã«2ãâïŒâéã§ä¿åãããæã24æé以
å ã§ã¯ç现èã®ãšã¹ããã²ã³çµåèœåã«ã¯æãã
ãªæžå°ã¯ãªããã72æéã§ã¯ããªãã®æžå°ãã¿ã
ããERéœæ§ã®ç现èã®å²åãæããã«äœããªã€
ãã â20âã§åçµããçµç¹ã®ãããŸãã¯ã现èååŠ
çç 究ã«ã¯äžé©åœã§ããããšãåã€ãïŒåçµåã³
解åãããããããšãæããã«çµç¹çãããšã¹ã
ãã²ã³å容äœèçœè³ªãåé¢ããããã§ããã æ¬çºæã®å®æœã«åœã€ãŠãçµç¹çãäžè¿°ã®ããšã
å¿ã«ãšããŠèª¿è£œãç 究ããªããã°ãªããªãã ããããŠã现èã®ãšã¹ããã²ã³å容äœã¯ã¢ã»ã
ã³åã³ã¢ã«ãããå®ç液ã«ãçæéããããã ã
ã§ããçãæ®ããªãããšãæããã§ãããåŸã€
ãŠãåºå®ãããªãåçµçã®ã¿ãããã®æè¡ã«æšå¥š
ã§ãããè¢å ãšã¹ãã©ãžãªãŒã«è€åäœãšã®ã€ã³ã
ãŠããŒã·ãšã³ã«å ç«ã¡ãïŒæéã®éå·èµåº«å ã§ã¹
ã©ã€ãäžã®çŽ°çã也ç¥ããããšã¯ãåºå®ãããªã
湿ã€ãåçµçãæ±ãããšã¯ãéåžžã«æè¡çã«ãã¥
ãããã®ã§ã蚱容ããã劥åæ¡ã§ããã ãããŸã§ããªãã现èååŠæ€æ»ã®ããã«ãææ
ãå ¥æããæè¯ã®ææã¯ãæ¥åžžã®èšºæãã¹ãåçµ
çã調補ãããæã§ããã现èæ¯éå£ã®åå®ã®ã
ãã«è¿æ¥ããé£ç¶çããããããã·ãªã³ãšãšãªã·
ã³æ³ã§çè²ããããšãã§ãããããããªãããæš
æ¬ã移éããªããã°ãªããªãå Žåã«ã¯ãçµç¹å¡ã¯
2ãâïŒâã§ä¿ããã24æé以å ã«åŠçããããšã
æãŸãããåçµãšè§£åãããããããšããšã¹ãã
ã²ã³å容äœã®æŽ»æ§ãæžå°ããã貯èµæéãã®ã³ã
ã«åŸã€ãŠçããæ»åŸå€åããåæ§ãªéå¹æããã
ããã èšåºã®çç©è³ªã®ãã®çŽ°èååŠæ³ã®é©å¿ã¯ããã¹
ãŠç°ãªãæ£è ãããšã€ã17äŸã®åæã®æµžé管ç
è «ãïŒäŸã®è äžã®ãªã³ãè ºã«ç§»è»¢ããä¹³çãïŒäŸ
ã®ç¹ç¶çã10äŸã®è¯æ§ã®ãfibrocystic
mastopathyã åã³ïŒäŸã®å¥³æ§ã®ä¹³è ºè «ãå«ãã èžã®æå·ã®ç 究
ã«ããäŸèšŒãããã ãããã®çµç¹æšæ¬ã®éåžžã®çè²æ³ãšããŠãäžè¿°
ã®ããã«ããŠåŸãéæããè¢å ãšã¹ãã©ãžãªãŒã«
è€åäœããæåŸæ¿åºŠãmlåœã0.5ÎŒMïŒÂ±10ïŒ ïŒã®
FITCãšåœéã«ãªãããã«PBSïŒPH7.4ïŒã§çšéã
ãããã®çšé液ã¯ãæšæºç©è³ªãšããŠãè€åããŠã
ãªããªãã·ã ãšçŽç²ãªFITCã®0.1NâNaOH溶液
ãçšããå Žåã«ã340nïœãš495nïœã§ã®ãããã
ã®åžåïŒ0.1N NaOHäžïŒã«ãã€ãŠç€ºããããã
ã«17βâãšã¹ãã©ãžãªãŒã«âïŒâCMOïŒFITCå
åéæ¯ã¯2.2ïŒÂ±10ïŒ ïŒã瀺ãã ãããã®æº¶æ¶²äžã«ã¯ãéé¢ã®ãã«ã¢ã³ãè¢å æ
æã¯èå±€ã¯ãããã°ã©ãã€ãŒã§ã¯æ€åºãããªãã€
ãã ãã®ããã«ç 究ããã19äŸã®ä¹³çã®äžãïŒäŸã®
çè «ïŒïŒã€ã¯åæã®ä»ã¯æºéçïŒã®ã¿ã现è質äž
ã§ã¯è¢å ãšã¹ãã©ãžãªãŒã«è€åäœãç²ãéãæ²æŸ±
ç©ãçãã现èæ žäžã§ã¯æ¯èŒçå°ããšããç¹åŸŽã
ãã€åŒ·åã«ERéœæ§ãªç现èã®æ®ãã©å質ã®æ¯é
å£ããæãç«ã€ãŠãããééãããªã³ãçãå€åœ¢
æ æ žçœè¡çãçµç¹çãå圢質现èãè¡ç®¡åä»åšã
ãã¡å¯ãªç¹ç¶ç¶ã®çµåçµç¹ã¯ãã©ããªç¹ç°ãªè¢å
ãã瀺ããªãã€ãã æ®ã15ã®ä¹³çè «ïŒ14äŸã¯åæã§ïŒäŸã¯æºéçïŒ
ã¯ãè¢å ã®çšåºŠãå€åããå®å šã«é°æ§ã®çŽ°èãã
匷ãéœæ§ã®çŽ°èãŸã§ã°ãã€ããåãè «çã®åã ã®
现èéãšåããç°ãè «çéã§ãç°ã€ããã«ã¢ã³çµ
åèœåã瀺ãç现èããæã€ãŠãããç现èæ ž
ã¯ãçè²ãããå Žåãçè²ãããªãå Žåã现è質
ãããææ床ã¯äœããïŒäŸã®åæçã®ã¿ããæ®ã
ã©éçè²ç现èããæ§æãããŠãããšããããšã
èŠåºãããERé°æ§è «çãšã¿ãªãããšãã§ããã
ããããªããããããåŸè ã®å Žåã§ããçµæçã«
ã¯æ³šææ·±ã調ã¹ãŠã¿ããšãåé¢ããERéœæ§ç现
èãå°éçŸããã ä¹³è ºåã³å°èã®è¯æ§ã®äžç®çŽ°èã¯åãå質ã§ãª
ããšã¹ããã²ã³çµåèœåã瀺ããããããã®éã
ãªãã©ã¹ããã¯çŽ°èäžã®è¢å æ²æŸ±ç©ã®æ¿åºŠã¯ã倧
æµã®ERéœæ§ç现èäžã§èŠ³å¯ããããããã¯ãã
ã«äœããäžç®çŽ°èã®å€§éšåã¯ãERé°æ§ã§ããã
ERãµã€ããæ®ãã©ãã€ãŠããªãã®ã§ããã®æ¹æ³
ã§ã¯æ€åºããããšãã§ããªãã€ããçž®äžç®çŽ°èå
ã³ãã®è¿ãã®ç¹ç¶çµåçµç¹ã§ã¯ãæ®ãã©ãå šããš
ã¹ããã²ã³çµåèœåã¯èŠ³å¯ãããªãã€ãããã®ç¶
æ ã¯ãERéœæ§ç现èã§ãããŸããç¯å²ã§ããã
å šãå€ããªãã€ããäžå®ã®ãšã¹ããã²ã³çµåã瀺
ãè¯æ§ã®äžç®çŽ°èã¯ãåã ã®è «çéã®è¢å æ¿åºŠã
é¡å¥ããæã«ãçµç¹çäžã®â匱éœæ§âã®ã³ã³ãã
ãŒã«ãšããŠäœ¿ãã®ã䟿å©ã§ããã ç¹ç¶è ºè «åã³ä¹³è ºè «ã®çµæã¯ããããã®é害ã
ãã€ãããšå¢å ãããšã¹ããã²ã³çµåèœåããã€
ã现èå¢æ®ç®¡ã®äžç®çŽ°èãå«ãããã«ã¿ããç¹ã
åã³ãããã®æ¡ä»¶ã®ãããã«ãã现èå¢æ®ç®¡ããš
ããããã§æ確ã«äŸèšŒã§ãããšã¹ããã²ã³å容äœ
ãæããåºè³ªçŽ°èãããç¹ã§äŒŒãŠããã 0.5ÎŒM FITCïŒmlãšåœéã®æ¿åºŠã«çšéãã
FITCâBSAè€åäœã ããããŸããé°æ§ã®éç¹ç°
æ§ã®çè²ã³ã³ãããŒã«ãšããŠçšããããã®ç©è³ª
ã¯ãERéœæ§ç现èãçè²ããã®ã«å€±æãããã
ã®çŽ°èååŠæè¡ã®ç¹ç°æ§ã¯ããã®è€åäœãç²è ž
çãæé è ºåèè žç³»çµ±ã®çè «ãå«ããããç¥ãã
ãâéæšçâçµç¹ãçè²ã§ãããåããã®æšç现
èïŒERéœæ§ã®ä¹³ç现èïŒã®çè²ã¯ãéè¢å ã®17β
âãšã¹ãã©ãžãªãŒã«âïŒâCMOâBSAã«ãã€ãŠ
劚ãããããšããäºå®ã«ãã€ãŠæ¯æã§ãããç¹ç°
çè²ãå®å šã«åŠšå®³ããããã«ãçŽ10åã®éè¢å ã¹
ããã€ãæ¿åºŠãå¿ èŠã§ããããã®ããšã¯ã3Hâ
ãšã¹ãã©ãžãªãŒã«ã®çµåã8S现èãŸã«èçœè³ªå
容äœã«ãã€ãŠæããããã«ã¯ãçŽ100åã®éå°ãª
éæŸå°æ§ãšã¹ãã©ãžãªãŒã«ãå¿ èŠã§ãããšããå®
枬ã«ãããïŒJ.Clin.Enocrinol.Metab.37ïŒ986â
989ïŒ1973ïŒåç §ïŒ æªæ§ã®è»¢ç§»ãèµ·ããšãä¹³ç现èã¯ããã«ã¢ã³ã®
å容äœã®éåžžã®æ¯éå£ã®ãã¹ãŠåã¯äžéšåãä¿æ
ããŠãããERéœæ§è «çã«çºå±ãããšããããšã
äžè¬çã«èŠãªãããŠãããããããªãããåãè¯
æ§ã®ä¹³æ¿çµç¹ã¯çååŠçåæã«ããæ€åºãããå
åãªãšã¹ããã²ã³å容äœããã€ãã«å«ãŸãªããšã
ãããšãããç¥ãããŠãããïŒåç §Cancer Res.ã
30ïŒ692â698ïŒ1970ïŒïŒ åŸã€ãŠããã®âä¿æâçè«ã§ã¯é«ãšã¹ããã²ã³
å容äœå€ããERéœæ§çã®ããã€ãã§èŠåºããã
ãšããããšã説æããã®ã¯ãã¥ããããæ¬çŽ°èå
åŠç 究ã®çºèŠã¯ãERéœæ§ç现èã¯ä¿æããã®ã¿
ãªããããã°ãã°çŸå®åé¡ãšããŠã®éåžžã®ãšã¹ã
ãã²ã³çµåèœåãããé«ããã®ãèŠããè¯æ§ã®èŠª
ã®100åãã1000åã®å€§ããã«ããªãããããšã
ãããšã瀺ããäžå¹Žåã¯é«éœ¢ã®å¥³æ§æ£è ã®ä¹³æ¿çµ
ç¹ã§ã¯ã管åã³å°èã®è£ã®äžç®çŽ°èã®å°æ°ã®ã¿
ããäœããã®æå³ã®ãããšã¹ããã²ã³çµåã瀺
ãã æ¬çºæã®å®æœã®çµæã¯åãä¹³çãåçŽã«ERéœ
æ§åã¯ERé°æ§è «çãã§åé¡ããããšãã§ããªã
ãšããããšã瀺ãããªããªãã°ãä¹³çã®å€§éšå
ã¯ãæ··åå²åãããããã§ããããERéœæ§åER
é°æ§çŽ°èãããããæ··ããã€ãç°ããšã¹ããã²ã³
å容åã®ç现èã®ç°çš®ã®æ¯éå£ããæç«ã€ãŠãã
ããã§ãããå€ååžžã«ã©ã®ERéœæ§è «çäžã«ãER
é°æ§çŽ°èãèŠåºãããšã¯ã§ããã§ããããããŠã
ã®éãåæ§ã§ãããããæ ãç现èæ¯éå£äžã®
ERéœæ§çŽ°èã®çŸåçã«ãã€ãŠä¹³çãé¡å¥ããã
ãšãããé©åœãšæãããã æããã«ããã«ã¢ã³çæ³ã®ååŸã§é€å»ããè «ç
ã§åŸããã现èååŠããŒã¿ãæ¯èŒç 究ããã°ãç
现èçæåŠã«é¢ãã深淵ã§éèŠãªçåç¹ã«ã€ããŠ
æŽã«æ å ±ãåŸãããã§ããããäŸãã°ãå åæ³åŠ
çããç现èæ¯éå£ã®ERéœæ§çŽ°èã®çŸåçããž
ããããšãã§ãããªãã°ãäžè¬ã«æªæ§çŽ°èã®ãã«
ã¢ã³äŸå床åã³ãã«ã¢ã³å容床éã®é¢é£ã«ãšã€ãŠ
匷åãªèšŒæ ãšãªãã ããããã®ããšã¯åãäœæ ã
ãã€ãã®ERéœæ§è «çã¯å®å šã«èªçºçç¶æ ã«é²è¡
ããåã«ãã«ã¢ã³çæ³æéäžéšåçåã¯çæéã®
ã¿é®éãããã説æããããšãã§ãããåç §
Cancerã39ïŒ2934â2947ïŒ1977ïŒããããå容äœ
é°æ§è «çãŸã§å€æ¿ããããã«ã¢ã³äŸå床ã¯é£ç¶åŸ
é ã®æŠå¿µããåããã§ã«ææ¡ãããŠãã
ïŒCancerã39ïŒ1971â1977ïŒ1977ïŒïŒã æ¬çºæãçšããã°ããã®ãããªç 究ã«åœ¹ç«ã€èŠ³
å¯ãå¯èœãšãªããäŸãã°ãæ¬çºæã«ããã°å®éã
倧æµã®ä¹³çè «ã¯ãERéœæ§ç现èãå«ã¿ãçãã
ãåæšæ¬ã®æªæ§åºŠãæ±ããšãã«ãä¹³çãèå¥ãã
ã®ã«å©ããšãªããšããããšã瀺ãããŠããã æŽã«ãæ£è ã®äœæ¶²äžã埪ç°ããŠããå çã®ãšã¹
ããã²ã³ã¯ãè «çã®ãšã¹ããã²ã³å容ãµã€ããå
ãåã¯é£œåããŠããŠãå容äœã®åæã劚害ãããš
ããããšãèããããã æ¬çºæã®å®æœäŸã«ã€ããŠç€ºãããããŠäžè¿°ãã
ããã«ãåã ã®ç现èã®éã«çµåããŠããå質ãª
ãšã¹ããã²ã³ã®æ¬ ä¹ã¯ãè «çã®çå®ã®ãšã¹ããã²
ã³å容åã®æž¬å®ã®éã®äž»ãªé害ã§ããã®ã§ãå²åŒ
ããŠçŸããã ïŒããããªãããããã¯ãäœçœ®çã«è «çå ã§ç
ç£ãããåã ã®çŽ°èã®äžæ§ã§ãªã飜åãå°ããŠã
ããã«ã¢ã³ã«ãã圹å²ãä»ãããã®ã§ãªããïŒ æ¬çºæã®å®æœã«ããåŸããã现èååŠçããŒã¿
ã¯åãç¹ç¶è ºè «åã³å¥³æ§ã®ä¹³è ºè «ã®èžã®çµç¹ãã
äžç®çŽ°èã«ãåºè³ªçŽ°èã«ããä»æ€åºãããããšã
ãã®ãšã¹ããã²ã³å容åãå¢å ããããšãã芳å¯
ãæ¯æããã ãåãã®ããã«ãæ¬çºæã¯ãäŸãã°ãç¹å¥ã®å
ç §äŸãšããŠ17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒâ
ã«ã«ããã·ã¡ãã«ïŒãªãã·ã ïŒåçã®è¡æž ã¢ã«ã
ãã³ïŒãã«ãªã¬ãã»ã³ã»ã€ãœããªã·ã¢ããŒãè€å
äœã®å©çšã«ã€ããŠè¿°ã¹åäŸèšŒããããã®è€åå€ã®
ååæ§é ã¯æ¬¡ã®ããã«å³ç€ºã§ããã ããã²ã¹ããã³ã®å ·äœäŸ äžè¿°ã®ããã«ãæ¬çºæã¯åãããã²ã¹ããã³â
èçœè³ªâææè€åäœãçšããŠãå®æœã§ããããã®
å ·äœçãªæ¹æ³ãããã§è¿°ã¹ãå³ç€ºãããã æ¹æ³ïŒ11âäœã®ããã²ã¹ããã³çµå 11αâãã€ãããã·ããã²ã¹ããã³ã»ãããµã¯ã·
ãã€ãã®åæ ãšã«ã©ã³ã¬ãŒçïŒå ç«åŠåå ç«ååŠã®æ¹æ³ã
å·»ãp.148ãC.A.WilliamsåM.W.Chaseèãã¢ã«
ãããã¯ãã¬ã¹ãN.Y.ã1967ïŒåãããã€çïŒJ.
Med.Chem.10ïŒ199ã1967ïŒã«ãã€ãŠèŠçŽããã
äžè¬çãªåçã«åŸã€ãŠã11αâãã€ãããã·ãã
ã²ã¹ããã³ïŒ10ïœïŒïŒSigma Chem.Co.ãSt.
LouisãMOïŒãšç¡æ°Žã³ãã¯é žïŒ10ïœïŒã®ä¹Ÿç¥ã
ãªãžã³ïŒ100mlïŒæº¶æ¶²ã調補ãã20æéçªçŽ ã¬ã¹
äžã§éæµãããå·åŽããåå¿æ··å液ãç æ°·ãå«ã
ã å·ãå¡©é žæ°Žæº¶æ¶²ïŒ3N.500mlïŒã«æ³šãå ¥ããã¯
ãããã«ã ã§æœåºãããã¯ãããã«ã ãèžçºãã
åŸãæ®äœãã¢ã»ãã³âãããµã³ãåã³ã¢ã»ãã³ã§
ãããããåçµæ¶ãããšãèç¹ã148â152âã®çœ
ãçµæ¶ã4.5ïœïœåŸãããã0.1NâNaOHäžã§ã®
åžåã®æ倧ã¯243nïœã§ãã€ãããããã®ç¹åŸŽã¯
11αâãã€ãããã·ããã²ã¹ããã³ãããµã¯ã·ã
ãŒãã«å¯Ÿããæç®ïŒãªã³ãããŒçSteroids 19ïŒ
357â375ã1972ïŒã«æžããããã®ãšäžèŽããŠã
ãã FITCâBSAè€åäœã®èª¿è£œ äžè¿°ãšåãæ¹æ³ãåã³æ¡çšã§ããã 11αâãã€ãããã·ããã²ã¹ããã³ã»ãããµã¯ã·
ããŒãâBSAâFITCïŒè¢å ããã²ã¹ããã³â11
âè€åäœïŒã®èª¿è£œ 17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒâã«ã«ãã
ã·ã¡ãã«ïŒãªãã·ã ã®ä»£ãã«ã11αâãã€ããã
ã·ããã²ã¹ããã³ã»ãããµã¯ã·ããŒããçšãã以
å€ã¯ãè¢å ãšã¹ãã©ãžãªãŒã«è€åäœã®èª¿è£œã«çšã
ãäžè¿°ã®æ¹æ³ãåã³çšããããšãã§ããã çããæçµè€åäœã®æ§é ãäžèšã«ç€ºãã ãã®æçµã®è¢å ã®ããããã²ã¹ããã³â11âè€
åäœã«éçããã¹ããã€ãæ®åºã®æ°ã¯ããšã«ã©ã³
ã¬ãŒçã«ããæ¹æ³ïŒJ.Biol.Chem.228ïŒ713ã
1957ïŒãçšããŠããžãããããšããŒã«åã«ãã決
å®ããããå¹³åããŠã11ã¢ã«ã®è¢å ææãš26ã®ã
ã«ã¢ã³ãïŒã¢ã«ã®åçã®è¡æž ã¢ã«ããã³ã«éçã
ãã ãã®æè¡ã®ç¹å¹æ§ã¯ãè¢å ããã²ã¹ããã³è€å
äœã§ç现èäžã®ããã²ã¹ããã³å容äœã®çè²ã¯ã
éè¢å 11αâãã€ãããã·ããã²ã¹ããã³ã»ãã
ãµã¯ã·ããŒãâåçã®è¡æž ã¢ã«ããã³ååç©ã«æŒ
ãçµç¹çã®äºãã€ã³ããŠããŒã·ãšã³ã«ãã€ãŠããŸ
ã劚ãããããšããäºå®åã³è¢å ããã²ã¹ããã³
è€åäœã¯ããç¥ãããéç®ççµç¹ãäŸãã°ãæé
è ºãè«æ§çªèµ·ããªã³ãè ºçµç¹åèè žç®¡ã®çè «ã®ã
ããªãã®ãçè²åºæ¥ãªããšããäºå®ã«ãã€ãŠæ¯æ
ã§ããã æ¹æ³ïŒïŒâäœã®ããã²ã¹ããã³çµå ïŒâããã¢ããã²ã¹ããã³ã®åæ ãŸã³ããã€ããŒçã®æ¹æ³ïŒJ.Am.Chem.
Soc.75ïŒ4712ã1953ïŒã«ãããããã²ã¹ããã³
ïŒ10ïœïŒãšïŒ®âããã¢ãµã¯ã·ã³ã€ããïŒïŒïœïŒã
ïŒæéåå¡©åççŽ ïŒ250mlïŒäžã§ç°æµããããã®
æ··å液ãéåŸã溶åªãèžçºãããæ®ã€ããã®ã
ãããµã³ã§æ©ç ãããšãèç¹ãçŽ139â142âã®ïŒ
âããã¢ããã²ã¹ããã³ãïŒïœåŸããããã¢ã»ã
ã³âãããµã³ããçµæ¶ãããããããŠãèç¹ã
141â144âã®åæãµã³ãã«ãšããã ããã²ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒã
ãªãšãŒãã«ã®åæ ãªã³ãããŒçã®æ¹æ³ïŒSteroids 19ïŒ357ã
1972ïŒã«ãã€ãŠãïŒâããã¢ããã²ã¹ããã³
ïŒ2.4ïœïŒãšããªã°ãªã³ãŒã«é žïŒ0.8ïœïŒããKOH
ïŒïŒïœïŒãå«ãã¡ã¿ããŒã«ïŒ100mlïŒã«å ãããã
ã®æ··å液ãïŒæéç°æµãããã¡ã¿ããŒã«ã®å€§éšå
ãèžçºãããåŸãæ®ããæ°ŽïŒ100mlïŒã§ãšãããŠ
ãããPHïŒã«ãªããŸã§HClïŒ10ïŒ ïŒã§é žæ§ã«ãã
ãšãŒãã«ã§æœåºããããããããšãŒãã«å±€ã
NaHCO3æ°ŽïŒ0.1NïŒã§æœåºãããHClïŒ10ïŒ ïŒã§
ã¢ã«ã«ãªæœåºç©ãé žæ§ã«ãããšãæ²æŸ±ãçããã®
ã§ããããéããŠéããæ°ŽæŽãã也ç¥ããé ¢é ž
ãšãã«âç³æ²¹ãšãŒãã«ã§åçµæ¶ããããæçµçæ
ç©ïŒ0.55ïœïœïŒã¯146â149âã®èç¹ããã€ãŠã
ãã ããã²ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒâã
ãªãšãŒãã«âBSAâFITCïŒè¢å ããã²ã¹ããã³
âïŒâè€åäœïŒã®èª¿è£œ ãžã¡ãã«ãã«ã ã¢ã«ãããïŒïŒmlïŒäžã®ããã²
ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒããªãšãŒ
ãã«ïŒ100mgïŒãšãæ°ŽïŒ10mlïŒäžã®ïŒâãšãã«â
ïŒâïŒïŒâãžã¡ãã«âã¢ãããããã«ïŒã«ã«ããž
ã€ããã»ãã€ããã¯ãã©ã€ãïŒ100mgïŒã®æ··å液
ãã宀枩ã§20åéæ¹æãããªã³é žå¡©ç·©è¡¡æ¶²ãçšã
ãªãã§åœéã®èçœè³ª100mgãå«ãåçã®è¡æž ã¢ã«
ããã³âãã«ãªã¬ãã»ã³ã»ã€ãœããªã·ã¢ããŒã
ïŒ10mlïŒã®æ°Žæº¶æ¶²ã«å ããããããïŒâã§ïŒæ¥é
æ¹æããåŸãNaHCO3ïŒ0.05MïŒæº¶æ¶²ã§äžæ¥éæ
ãã次ã«ïŒæ¥éããªã³é žå¡©ã§ç·©è¡¡åããå¡©ïŒPH
7.4ïŒã§æŽã«éæããããã®æçµè€åäœãæ²æŸ±ã
é€ãããã«é å¿åé¢ããããã®äžæŸæ¶²ã«ãé²è å€
ãšããŠã¢ãžåãããªãŠã ãïŒmgïŒmlã®æ¿åºŠã«ãªã
ããã«å ããã æçµçãªè€åäœã®æ§é ã次ã«ç€ºãã æçµçãªè¢å ããã²ã¹ããã³âïŒâè€åäœã«é
çããã¹ããã€ãæ®åºã®æ°ã¯ããšã«ã©ã³ã¬ãŒçã®
æ¹æ³ïŒJ.Biol.Chem.228ïŒ713ã1957ïŒã«ãããžã
ããããšãã«åã«ãã決å®ãããå¹³åããŠ11ã¢ã«
ã®è¢å ææãš26ã¢ã«ã®ãã«ã¢ã³ãåçã®è¡æž ã¢ã«
ããã³ïŒã¢ã«ã«éçããã ç现èããã²ã¹ããã³å容äœãæ€åºããããã®
è¢å ããã²ã¹ããã³âïŒâè€åäœã®äœ¿çšæ¹æ³ã¯ã
è¢å ãšã¹ãã©ãžãªãŒã«è€åäœåã³è¢å ããã²ã¹ã
ãã³â11âè€åäœã«ã€ããŠäžè¿°ããã®ãšåãã§ã
ãã çè²ã®ç¹ç°æ§ã«ã€ããŠã¯ãéè¢å ããã²ã¹ãã
ã³âïŒâBSAè€åäœåã¯ãéè¢å ããã²ã¹ãã
ã³â11âBSAè€åäœãçšããæè¡ã«ããããã®
è€åäœãäžã«è¿°ã¹ãããã«éæšççµç¹ãçè²ã§ã
ãªãã€ãããšã«ããæ¯æãããã ïŒã€ã¯11ã®äœçœ®ãããïŒã€ã¯ïŒã®äœçœ®ã§ã®ãã
ãïŒã€ã®è¢å ããã²ã¹ããã³è€åäœã®èª¿è£œã«æå
ããããšã¯ã人éã®çµç¹ã«æŒããã«ã¢ã³å容äœã®
æ€åºãžã®çŽ°èååŠçãªå¯èœæ§ã瀺ããèçœè³ªãã€
ãªã€ãŒã«ã€ããŠããã°ãè¢å è€åäœäžã®ã¹ããã€
ããã«ã¢ã³ã®æ¿åºŠã¯ã人éã®äœæ¶²äžã®ççåŠçæ¿
床ã®10äžåãã100äžåã«éããããã®é«æ¿åºŠã¯ã
ççåŠçPHç¯å²ã®æ°Žæº¶æ¶²äžã«ããããã溶ããŠã
ããã«ãªã¬ãã»ã³âã¹ããã€ãååç©ããã€ããš
ããŠãã现èååŠçå容äœã®ãã¬ãŒãµãŒãšããŠã
æå¹ã«æ¡çšããããšã¯åºæ¥ãªããããå¿ ç¶çã§ã
ãã ãããïŒã€ã®è¢å è€åäœã®ãã¡ã11αâãã€ã
ããã·ããã²ã¹ããã³ã»ãããµã¯ã·ããŒãâ
BSAâFITCïŒæ¹æ³ïŒã¯å®¹æã«èª¿è£œã§ããåè
çœè³ªã®ããªãã®éãããã²ã¹ããã³âïŒâïŒã«ã«
ããã·ã¡ãã¬ã³ïŒããªãšãŒãã«âBSAâFITC
ïŒæ¹æ³ïŒã®èª¿è£œã®éã®æçµæ®µéã§å€æ§ãåãã
ã®ã§ãåéãé«ããããããªãããäž¡æ¹ã®äŒãŠã¯
å ±ã«ã䟿å©ãªããã²ã¹ããã³å容äœã®ãã¬ãŒãµãŒ
ã調補ããã®ã«å©çšãããããããã¯ããªã³ã°
ïŒïŒã®äœçœ®ïŒããªã³ã°ïŒ11ã®äœçœ®ïŒãã¹ããã€
ããã«ã¢ã³âããã²ã¹ããã³ã®ç¹ç°ãªæ©èœããã€
åºã«åœ±é¿ãäžããªãååŠçãªæãšããŠå©çšã§ãã
ãšããå ç«åŠç芳枬ãšäžèŽããŠããã ãã®å¿é¡è ã«ãã11äŸã®äººéã®ä¹³çã®ç 究ã¯ã
ããã²ã¹ããã³å容äœã¯ãã¯ããè «ç现èã®çŽ°è
æ žã«äœçœ®ããŠããŠããšã¹ããã²ã³å容äœéœæ§ç现
èããå«ãçã«æŒãŠèµ·ãããã«ã¿ãããšããããš
ã瀺ãããã®ã¯èå³æ·±ããããã²ã¹ããã³å容äœ
åã³ãšã¹ããã²ã³å容äœã®ã©ã¡ãããåžžã«äºã«äŒŽ
ã€ãŠçãããããŠåã现èäžã«ååšãããã©ãã
ã¯ããŸã å šã確ãããããŠããªãã ãšã¹ããã²ã³å容äœãšããã²ã¹ããã³å容äœçŽ°è
ã®åææ€åº æ¬çºæã®å®æœäŸã¯æŽã«ããšã¹ããã²ã³å容äœãš
ããã²ã¹ããã³å容äœçŽ°èã®åææ€åºã«ã€ããŠæ¬¡
ã«è§£èª¬ããã ããã§çšããããè©Šè¬ãšããŠãè©Šè¬ïŒ¡ã¯ã17β
âãšã¹ãã©ãžãªãŒã«âïŒâCMOâBSAâFITC
ãäžã«æŠç¥èª¬æããããã«ããŠèª¿è£œããã è©Šè¬ïŒ¢ã¯ã11αâãã€ãããã·ããã²ã¹ãã
ã³ã»ãããµã¯ã·ããŒãâBSAâããã©ã¡ãã«ã
ãŒããã³ã»ã€ãœããªã·ã¢ããŒãã§ããã ãã®è©Šè¬ã¯ãããã©ã¡ãã«ããŒããã³ã»ã€ãœã
ãªã·ã¢ããŒãããã«ãªã¬ãã»ã³ã»ã€ãœããªã·ã¢ã
ãŒãã®ä»£ãã«çšãã以å€ã¯11αâãã€ãããã·ã
ãã²ã¹ããã³ã»ãããµã¯ã·ããŒãâBSAâFITC
ã«ã€ããŠäžã«è¿°ã¹ãã®ãšåãæ¹æ³ã§èª¿è£œããã è©Šè¬ïŒ¡ãšè©Šè¬ïŒ¢ã¯æ¬¡ã«ãåœã¢ã«æ··åããçãã
æ··å液ã10-4ãã10-3Mã®çµåãããšã¹ãã©ãžãª
ãŒã«åã³ãããšã»ãŒåæ¿åºŠã®çµåããããã²ã¹ã
ãã³ãå«ããã®ãšãããã¹ããã€ã ãã«ã¢ã³æ
åã®ãã«ãªãã¯ããŒã ææåäœã«å¯Ÿããå¹³ååå
æ¯ã¯ãçŽïŒïŒïŒãšïŒïŒïŒã®éã§ãäžè¬ã«ã¯çŽïŒïŒ
ïŒã§ããã çè²ã®æ¹æ³ 次ã«æ€æ»ãã¹ãçµç¹çŽ°çãåããè©Šè¬ïŒ¡ãšè©Šè¬
ã®äžè¿°ã®æ··å液ã§çè²ããã ãã®ããã«ããŠçè²ãããçµç¹çã¯ã次ã«ïŒã»
ããã®ãã€ã«ã¿ãŒã§ãïŒã€ã¯ãã«ãªã¬ãã»ã³ã»ã€
ãœããªã·ã¢ããŒãã®åºæ¿ïŒåèµ·ïŒã«å¯ŸããŠéžææ§
ããããããïŒã€ã¯ãããŒããã³ã»ã€ãœãã¢ããŒ
ãã®åºæ¿ã«å¯Ÿãéžææ§ã®ãããã®ãè£ åããè¢å
é¡åŸ®é¡ã§æ€æ»ããããã®ãããªãã€ã«ã¿ãŒã䜿ã€
ãå©ç¹ã¯ããšã¹ããã²ã³å容äœäœçœ®ã¯ãèŒããã
ãªç·è²ã瀺ããäžæ¹ããã²ã¹ããã³å容äœäœçœ®
ã¯ãæããããªã¬ã³ãžè²âèµ€è²ã®è¢å ã瀺ããšã
ãããšã§ããããã®æè¡ã«ãããäžè¿°ã®æ··å液ã
䜿ã€ãŠããšã¹ããã²ã³å容äœãšããã²ã¹ããã³å
容äœãšäž¡æ¹ã®ååšãåæã«æ€åºã§ããããååäž
çµç¹æšæ¬ã§ç®ã§èŠãªããæ€æ»ã§ããã çµ æ æ¬çºæã®åèšã®å ·äœäŸã䜿ã€ãŠã12äŸã®ä¹³çå
ã³ïŒäŸã®åå®®å èçããã®ååãããå容äœåæ
æ¹æ³ã§æ€æ»ããããã®ç 究ã«ãããåã ã®ãã«ã¢
ã³ã«å¯Ÿããåäžç现èã®çµåèœåã¯ãåäžã¬ãã«
ã§ã¯ãªããããããªããã倧æµã®ãšã¹ããã²ã³å
容äœéœæ§ç现èã¯ãå®ã«ããã²ã¹ããã³å容äœã
å«ããšãã芳枬ã確ãããããã匱ããšã¹ããã²
ã³çµåã瀺ãè¯æ§ã®åºè³ªçŽ°èã¯ã女æ§ã®ä¹³æ¿ã®å Ž
åã«ã¯ãããã²ã¹ããã³çµåèœåãæã€ãŠããã
ãã«ã¯ã¿ããªããïŒäŸã®åå®®å èçã¯ãéåžžã«åŒ·
ãåºè³ªã®ããã²ã¹ããã³å容äœæŽ»æ§ã§ãã€ããã
åºè³ªäžã«ã¯ãå ±åãããšã¹ããã²ã³çµåã¯ãªãã€
ãã ãã®çµæã¯æŽã«ãïŒéšè€åååãšããŠçµåãã
æãè¢å ã¹ããã€ããã«ã¢ã³ã¯ããšã¹ããã²ã³å
容äœãšã¯å¥ãªå容äœåä¹³çãšã¯å¥ãªçµç¹ã®æ€æ»å
ã³åå®ã«äœ¿çšããããšããããšãå®èšŒããŠããã è¢å ããã²ã¹ããã³è€åäœã®åæã«é¢ããæ¬å®
éšã¯åãæ¬çºæã®å®æœããä»ã®å€©ç¶åã¯åæã®ã¹
ããã€ã ãã«ã¢ã³ïŒäŸãã°ããã¹ãã¹ããã³ã®
ãããªã¢ã³ããã²ã³ãã«ã¢ã³ãã17αâãã€ãã
ãã·ã³ã«ãã³ã¹ããã³ïŒå³ã¡ããã€ããã³ã«ããŸ
ã³ãã³ã«ããŸãŒã«ïŒã®ãããªã¢ãã¬ïŒã³ã«ãã»ã
ã«ã¢ã³ã®ïŒéšåè€åäœã䜿ããšããããšãå«ãã
ãšãæ瀺ããŠããããã¹ãã¹ããã³èçœè³ªææãš
ã³ã«ããŸãŒã«âèçœè³ªææã®è€åäœã調補ããã
ãã®å®éšæé ã¯ã次ã«ç€ºãéãã§ããã è¢å ãã¹ãã¹ããã³è€åäœã®èª¿è£œ æ¹æ³ïŒ11ã®äœçœ®ã®ãã¹ãã¹ããã³çµå 11αâãã€ãããã·ãã¹ãã¹ããã³â11âãã
ãµã¯ã·ããŒãã¯ãäŸãã°ã¹ãã©ãã€ã瀟ããŠã€ã«
ãœã³ãããŠãŒãã³ãã·ã€ãŒïŒãããå ¥æããããš
ãã§ããããããã·ãŠïŒã¹ããã€ãã23ïŒ699â
711ã1974ïŒã«åŸã€ãŠåæããããšãã§ããã 11αâãã€ãããã·ãã¹ãã¹ããã³â11âãã
ãµã¯ã·ããŒã BSAâFITCïŒè¢å ãã¹ãã¹ãã
ã³â11âè€åäœïŒã®èª¿è£œã¯ã11âãã€ãããã·ã
ã¹ãã¹ããã³â11âãããµã¯ã·ããŒããã11αâ
ãã€ããããã²ã¹ããã³ã»ãããµã¯ã·ããŒãã®ä»£
ãã«äœ¿ããã以å€ã¯äžè¿°ã®è¢å ããã²ã¹ããã³â
11âè€åäœã®èª¿è£œãšåãæ¹æ³ã§å®æãããã çããæçµè€åäœã®æ§é ãã次ã«ç€ºãã æ¹æ³ïŒïŒã®äœçœ®ã®ãã¹ãã¹ããã³çµå ãã¹ãã¹ããã³â7αâã«ã«ããã·ã¡ãã« ã
ãªãšãŒãã«ã¯ããŠãšã€ã³ã¹ãã€ã³ã®æ¹æ³ïŒã¹ãã
ã€ãã20ïŒ789â812ã1972ïŒã«åŸã€ãŠèª¿è£œããã
ãšãã§ããã ãã®åŸãã¹ãã¹ããã³âïŒâïŒã«ã«ããã·ãšã
ã«ïŒããªãšãŒãã«âBSAâFITCïŒè¢å ãã¹ãã¹
ããã³âïŒâè€åäœïŒã®èª¿è£œã¯ããžã¡ãã«ãã«ã
ã¢ãããå«ãåªäœäžã§ãçµåå€ãšããŠïŒâãšãã«
âïŒâïŒïŒâãžã¡ã«ã¢ãããããã«ïŒãçšããŠå®
æãããããããæ¹æ³ã¯ããã¹ãã¹ããã³â7α
âã«ã«ããã·ãšãã« ããªãšãŒãã«ãããã®å Ž
åãããã²ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒ
ããªãšãŒãã«ã®ä»£ãã«çšãããã以å€ã¯ãâïŒäœ
眮ã®ããã²ã¹ããã³çµåâã«å¯Ÿããæ¹æ³ãšããŠ
äžè¿°ããæ¹æ³ã«ãªããã çããæçµè€åäœã®æ§é ã¯æ¬¡ã«ç€ºãã ã³ã«ãŸããŸã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãª
ãã·ã âBSAâFITCè€åäœïŒè¢å ã³ã«ããŸã«è€
åäœã®èª¿è£œïŒ ã³ã«ããŸã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãª
ãã·ã ã¯ãã¢ãŒãã«ããšãžãšãŒã ã¹ã®æ¹æ³ïŒã¹ã
ãã€ã 18ïŒ789ã1971ïŒåã³ããã¢ãŒãã€çã®
æ¹è¯æ³ïŒã¹ããã€ã 26ïŒ267ã1975ïŒãçšããŠ
åæã§ããã ã³ã«ããŸã«âïŒâCMOâBSAâFITCã®èª¿è£œ
ã¯ãã³ã«ããŸã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒ
ãªãã·ã ãã17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒ¯
âã«ã«ããã·ã¡ãã«ïŒãªãã·ã ã®ä»£ãã«çšããã
ã以å€ã¯ãã¯ããè¿°ã¹ã17βâãšã¹ãã©ãžãªãŒã«
âïŒâCMOâBSAâFITCè€åäœãšåãæ¹æ³ã
çšããŠå®æããã æçµè€åäœã®æ§é ã¯æ¬¡ã«ç€ºãã ãã¹ãã¹ããã³åã¯ã³ã«ããŸã«ãå«ãæçµè¢å
è€åäœã«éçããFITCååã®æ°ã¯ã0.1Nâ
NaOHäž495nïœã§ã®è€åäœã®åžåããèšç®ã§ã
ããæçµè€åäœã«éçããã¹ããã€ãæ®åºã®æ°
ã¯ããšã«ã©ã³ã¬ãŒçã®æ¹æ³ïŒClin.Chem.16ïŒ24ã
1970ïŒãçšãããžãããããšãã«ååã¯ãããªã
ãããã³ãŒã³ã¹ã«ãã³é žã«ããã¢ããåºã®æ±ºå®æ¹
æ³ïŒClin.Chem.16ïŒ24ã1970ïŒãçšããŠæ±ºå®ã§
ãããè€åäœã®åçã®è¡æž ã¢ã«ããã³ã®ååå
ã¯ãé«ãã¹ããã€ãïŒæææ¯ãšã溶液äžã®æå¹çµ
åã¹ããã€ããã«ã¢ã³ã®é«æ¿åºŠã確ä¿ãããã
ã«ã20ãã30ã®ãã¹ãã¹ããã³åã¯ã³ã«ããŸã«æ®
åºåã³ïŒãã11ååã®ãã«ãªã¬ãã»ã³ãæ ãã ä»æ¥ãŸã§èç©ãããçµéšãããåçµçµç¹çŽ°çäž
ã®å容äœããããåºããããè¢å ã¹ããã€ããã«
ã¢ã³è€åäœã䜿ãããã«ã¯ãïŒéšã®è€åäœããå
容äœã«å¯Ÿããé«ã芪ååãä¿æããããã¹ããã€
ãæ®åºã®é©åœãªæ°ãæ ãçã§ãããããã€ãªã¢ãŒ
ãŠãããã«éçãããã«ãªãã¯ããŒã ææååã®
æ°ã¯ãã»ã©æ±ºå®çã§ãªããšããããšãåã€ãŠã
ãããã€ãªã€ãŒãšããŠåçã®è¡æž ã¢ã«ã ãã³ã䜿
çšããå Žåã«ããã«ãªãã¯ããŒã ãšãã«ã¢ã³ã®æ¯
ã¯äžè¬çã«ã¯çŽïŒïŒïŒãããïŒïŒ25ãæå°ã§ã
ïŒïŒ50ã®ç¯å²å ã§ããã åç«è ºçµç¹åé è¡çµç¹ã«æŒããè¢å ãã¹ãã¹ã
ãã³åè¢å ã³ã«ããŸã«è€åäœã®é©çšã¯ããã§ã«è¿°
ã¹ãã®ãšåãäžè¬çæ¹æ³ã«åŸã€ãŠåæ±ãããã æ¬çºæã®ä»ã®å®æœäŸã«ã€ããŠè¿°ã¹ãã ãããããã¡ããã®ããšãšããŠã(a)äŸãã°ã«ã«
ããã·ã«åºãªã©ãæããããããéã®ãããªãç
æã®å¯èœæ§ã®ããé©åœãªèŠªæ°Žæ§ãã€ãªã¢ãŒæå
(b)ãäžè¿°ã®ãã€ãªã¢ãŒïŒäŸãã°ããããµã¯ã·ããŒ
ãåã¯ã«ã«ããã·ã¡ãã¬ã³ ããªãšãŒãã«èªå°äœ
ã®åœ¢ã§ã®ãšã¹ããã²ã³ãåãããã¹ãã¹ããã³ã
ã³ã«ãã«ã«ãã«ã¢ã³èªå°äœçïŒãžã®çµåã«å¯Ÿãé©
åœãªååŠçãªæããã€æŽ»æ§ãã«ã¢ã³å€ããããŠ
(c)ãåè¿°ã®èçœè³ªæåã«çµåãããã«ãªãã¯ããŒ
ã æææãšããæ¬è³ªçãªç¹åŸŽããã®è©Šè¬ããã€é
ãããã®ãããªè©Šè¬ã®æ¹åŒãå€ããããåæ¬çºæ
ã®ç¯å²å ã§ããã«ã¢ã³âãã€ãªã¢ãŒâãã«ãªãã¯
ããŒã ææã®ä»ã®ååç©ã®çµåããå©çšããããš
ãã§ãããšããããšã¯ç解ã§ããã§ãããã äžã«ç€ºãããããªå ·äœäŸã®çš®ã ã®ç¹å¥ã®æ¹è¯ã¯
åœæ¥è ã«ãã€ãŠé©å®æ¡çšãããã§ãããã äŸãã°ããã«ã¢ã³æåãšãããŠãã«ãªãã¯ããŒ
ã ææãå³ã¡ã倧å€æ°ã®ã¢ããåºãå«ããããã®
èçœè³ªãšåæ§ã®ååŠçååç©ãšäž¡æ¹ãšçµåããå¯
èœæ§ããã€ã¢ããåºãå«ããªãã°ãä»ã®èçœè³ªã
ã€ãªã¢ãŒãéžãã§ãããã ãããã亀äºã®èçœè³ªãã€ãªã¢ãŒã®äŸãšããŠæ¬¡
ã«ååããããã åçŽèçœè³ªïŒã¢ã«ããã³é¡ãã°ãããªã³é¡ãã°ã«
ããªã³é¡ããããã©ã³é¡ãã¢ã«ãããã€ãé¡ã
ãã¹ãã³é¡åã³ããã¿ãã³é¡ã è€åäœèçœè³ªïŒæ žèçœè³ªãç³èçœè³ªãã ã³èçœ
質ããªã³èçœè³ªãè²çŽ èçœè³ªããªãèçœè³ªåã³
éå±èçœè³ªã èªå°èçœè³ªïŒç©ççååŠçæ¹æ³ã«ããå€æ§ããè
çœè³ªãããããªãŒã¹é¡ããããã³é¡ããããã
é¡ãïŒã€ã®ã¢ããæ³ã®ãžã±ãããã©ãžã³ç°ç¶ç¡
æ°Žç©ã å°ããšãïŒã€ã®ç¬¬äžçŽã¢ããïŒâNH2ïŒåºã
ãã€ã¢ããé žããèªå°ããããªããããé¡ã¯ãç
ããè€åäœãå å溶解æ§ããããªãã°ãããèªäœ
èçœè³ªã®ä»£ãã«å©çšã§ããã å ããŠãäºè æäžçã«ãäŸãã°ããªã°ãªã³ãŒã«
ãããªã°ãªã»ããŒã«ã®ãããªå€æ°ã®æ°Žé žåºããã€
ä»ã®æ°Žåæ§ååããã€ãªã¢ãŒïŒäŸãã°ãšã¹ãã«ã
ãšãŒãã«éãéããŠããã§çµåããïŒãšããŠå©çš
ã§ããã ä»ããã«ãªã¬ãã»ã³ããèªèº«ãéžæå©çšããã
ææã§ããäžæ¹ãããããã®ä»ã®ãã«ãªãã¯ããŒ
ã ææãã(1)ããã«è¿°ã¹ãçšéã«ä¿æãããããª
ãã¯ã€ããããè¢å ç¹æ§åã³(2)åè¿°ã®ããªâã¢ã
ãâã¿ã€ãã®èçœè³ªãã€ãªã¢ãŒç©è³ªãšçµåããå¯
èœæ§ãšããåºç€çãªèŠæ±ã«å¿ããããããã°ã圩
çšã§ãããããããŠæ¡çšãããŠããããã«ãªãã¯
ããŒã ææãäžèšã«ç€ºãã ãªãŒã©ãã³ïŒ¯ãããŒããã³ïŒ¢ãããŒããã³3Gã
ã¢ã¯ãªã°ã©ãã³ãã¢ã¯ãªãžã³ã»ãªã¬ã³ãžãã³ãªã
ã¹ãã€ã³ãã¢ã¯ãªãžã³ã»ã€ãšããŒãããªã¹ãã€
ã³ããã³ãŸãã©ãã³ãããªãã©ãã³TCNããã
ã€ã³ãã€ã³ããã°ãã©ã¬ããããã«ããªã³ããã
ã¯ãªã³ããªãããŒã«ãããã©ãµã€ã¯ãªã³ããã¢ãž
ã³ã¬ããããã¢ãŸãŒã« ã€ãšããŒïŒ§ãã³ã³ãŽã¬
ãããã¢ã·ãããã¯ã·ã³ãã¹ã«ããªããŒããã³
ããšãªã·ã³ïŒ¹ãããªã ãªã³ãããªãã©ãã³ïŒ³ã
ããã©ã¡ãã«ããŒããã³åã³ãžãããã«ã¢ãã³ã¹
ã«ãã³é žã æŽã«ãä»ã®ãšã¹ããã²ã³åãã«ã¢ã³ã17βâãš
ã¹ãã©ãžãªãŒã«ã®ä»£ãã«æ¡çšã§ãããããã¯ããš
ã¹ãã©ãžãªãŒã«ã¯ããšã¹ãã©ã²ã³ã®ãã¡ã®ïŒã€
ïŒæãéèŠãªåœ¢ã§ãããïŒã«ãããªãããæ¬çºæ
ã®å®æœã«åœã€ãŠã倧åãªããšã¯ãçæã®ç现èã
å容ãããããšã¹ããã²ã³ãæ¡çšãããšããããš
ã§ãããä»ã®ãã®ãããªååç©ãšããŠã¯ããã¡ã
ãããã®ïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãªãã·ã
èªå°äœã®åœ¢ã§ã®17αâãšã¹ãã©ãžãªãŒã«ãã¯ãã
ã«æããããšãã§ããã ãã®ååç©ã¯ãäžã®äŸã§ãæ¡çšãã17βååç©
ã«æºæ ããããã¹ããã€ãç°ã®é¢ããäžã®17äœçœ®
ã«ãã«ã¢ã³ã®æ°Žé žåºã®ããååç©ã§ãããåºæ¬ç
ã«ã¯ãã·ã¯ããã³ããããšãã³ã¹ã¬ã³æ žãå«ã¿ã
ãã€ãïŒââã«ã«ããã·ã¡ãã« ãªãã·ã èªå°
äœãçæããèœåããã€ã©ããªãšã¹ããã²ã³åã
ãã¹ããã€ããã«ã¢ã³ã§ããæ¬çºæã®åè¿°ã®ãšã¹
ãã©ãžãªãŒã«ã®ãšããã«æ¡çšããŠãããããã
ã¯ããšã¹ããªãªãŒã«ããšã¹ããã³ãåæ§ã®ååç©
ãå«ãã§ããã åæ§ã«ãããã²ã¹ããã³ããã¬ã°ãã³ãžãªãŒ
ã«ããã¬ã°ãã³ããªãªãŒã«ãåã³ãã¬ã°ããããŒ
ã³ã®ãããªå€©ç¶ã®ããã²ãã·ãšã³ãã«ã¢ã³ããå
åç©R5020ããã«ãšãã³ããã³ããã«ãšãããã¬
ã«çãå«ãåæã®ããã²ã¹ããã³ãå«ããä»ã®ã
ãã²ã¹ããã³ ãã«ã¢ã³ã䜿ãããšãã§ãããã
ããã®ååç©ã¯ãããã²ã¹ããã³ã«ã€ããŠäžè¿°ã
ãåæ§ã®æ¹æ³ã§ãïŒäœçœ®åã¯11äœçœ®ã«ååŠççµå
ã«ãã€ãŠããã¿ã€ããã€ãªã¢ãŒã«çµåãããã ãã®ããã«ããŠãç现èäžã®ãã«ã¢ã³å容äœã
æ¢ãåºãããã«ïŒåæååè€åäœã䜿ããã®æ¹æ³
ã¯ãè¢å é¡åŸ®é¡ã§ãã®çžåœããå容äœãåŸãåºã
æ€åºããã®ã«é©åœãªããã²ã¹ããã³ããã¹ãã¹ã
ãã³ãã³ã«ããŸãŒã«ïŒè³¢èµç®è³ªãã«ã¢ã³ããã€ã
ãã³ã«ããŸã«ãšããŠãç¥ãããïŒãå«ãè¢å è€å
äœãåæããã®ã«é©å¿ããããšãã§ããããšãæ
ãããšãªãã ããã äžè¿°ã®å®äŸã¯ãäŸãã°ãïŒäŸã®å¥³æ§ãã«ã¢ã³
ïŒãšã¹ãã©ãžãªãŒã«åããã²ã¹ããã³ïŒãïŒäŸã®ç·
æ§ãã«ã¢ã³ïŒãã¹ãã¹ããã³ïŒåã³ïŒäŸã®è èç®
質ãã«ã¢ã³ïŒã³ã«ããŸãŒã«ïŒã䜿çšããå Žåãå«
ãã§ããããæ¬çºæããããã ãã«éå®ããŠè§£é
ããã¹ãã§ãªãã åæã§è¿°ã¹ãã®ã¯ãåµå·£ãçŸäžžåã³è èã®ç®è³ª
ã«æŒãŠå€©ç¶ã«çæããæãéèŠãªã¹ããã€ããã«
ã¢ã³ã§ããããä¹³æ¿ããéé¢ããããåã¯ååŠç
ã«åæãããŠãåµå·£ãçŸäžžåè èç®è³ªã«ããçæ
ãããã¹ããã€ããã«ã¢ã³ã«ããçããã®ãšåæ§
ã®ççåŠçæ©èœãåãããããšã®ã§ããå€ãã®ã
ã«ã¢ã³å é§ç©è³ªããã«ã¢ã³ä»£è¬ç©è³ªãåã³ãã«ã¢
ã³é¡äŒŒç©ããããæããã«ãäžã«äŸèšŒãããšã¹ã
ã©ãžãªãŒã«ãããã²ã¹ããã³ããã¹ãã¹ããã³å
ã³ã³ã«ããŸãŒã«ã®ä»£çšã«çšãããããååŠç©è³ªã®
ãã¹ãŠãæ£ç¢ºã«ãªã¹ãããããšã¯äžå¯èœãªããšã§
ããããæ¬çºæããäŸãã°äººéã®æªæ§ã®çµç¹äžã®
察å¿ããå容äœã®æ€åºåå¿ã«é©åœã§ããïŒéšè€å
äœã®åœ¢ã®ä»ã®å€©ç¶åã³åæãšã¹ããã²ã³ã倩ç¶ã
ãã²ã¹ããã³ååæã®ããã²ã¹ãã€ã·ãšã³å€ãã
ããŠå€©ç¶åã³åæã®è èç®è³ªã¹ããã€ãåã¯ã¹ã
ãã€ãé¡äŒŒäœã®ãã¹ãŠã䜿çšããããšãŸã§æ倧é
åºãæŠå¿µã«æ¡å€§ãããšããããšããã®éã®å°é家
ã§ããã°ãèªèã§ããã ãããïŒåç §ãäŸãã°ã
ããã«ããšã€ããŒããŒèãççååŠè©è«ã第11
çãã©ã³ã²ããã€ã«ã« ãããªã±ã€ã·ãšã³ãºãã
ã¹ã¢ã«ãã¹ãã«ãªããªã«ãã¢ã1967ãã®436â
437ãå444ããŒãžã®ããããªååç©ã®äŸç€ºïŒ æŽã«ãèçœè³ªãã€ãªã¢ãŒã§ã€ãªããããã«çšã
ãååŠçãªæããæãéèŠãªå€©ç¶ã®çççæ©èœåº
ãšããã«ã¢ã³ååé 眮ãä¿æããããã«ã¹ããã€
ãååã®ïŒâãïŒâã7αâãããŠïŒåã¯11αâäœ
ã«äœçœ®ãããããšãã§ããã ããããªããããã®ååŠçãªæããããã«éå®
ããããã®ã§ã¯ãªãããååã®9αâã17âãå
ã³21äœãå«ãã¹ããã€ããã«ã¢ã³ã®ä»ã®å Žåã«ã
äœçœ®ããããšãã§ããã åäžã«è¿°ã¹ãããã«ãè€åäœäžã®èçœè³ªååã«
éçããå°ããšãïŒã€ã®ãã«ãªãã¯ããŒã ææå
åãšå°ããšãïŒã€ã®ãã«ã¢ã³ååãååšãããã
ãã®è€åäœãçšããããšã¯äŸ¿å©ã§ãããçµç¹å容
äœãžã®è€åäœã®èŠªååã匷ããããã«ãææåå
ã«å¯Ÿãããã«ã¢ã³ååã®æ¯ã¯ïŒä»¥äžã§ããããšã
æãŸãããåŸã€ãŠããã«ã¢ã³ã«å¯Ÿãããã«ãªãã¯
ããŒã ã®ååæ¯ã¯çŽïŒïŒïŒããïŒïŒ25ã®é床å ã§
ããã¹ãã§ãããçŽïŒïŒïŒããïŒïŒ10ãæãŸã
ãã äŸãã°25000ãã100000ã®å¹³åååéããã€è
çœè³ªãã€ãªã¢ãŒã«ã€ããŠã¯ãè€åäœäžã®èçœè³ªå
åã«å¯Ÿãããã«ãªãã¯ããŒã ææåååãã«ã¢ã³
ååã®æ¯ã¯ããã«ãªãã¯ããŒã ã«å¯ŸããŠã¯çŽïŒïŒ
ïŒãã20ïŒïŒããã«ã¢ã³ã«å¯ŸããŠã¯çŽ10ïŒïŒãš
40ïŒïŒã®éã®ç¯å²å ã§å€ããããã®ã¯äŸ¿å©ãªããš
ã§ããã æ¬æ¹æ³ã«é¢ãããããã¯äžã§ç¹ã«äŸç€ºãã以å€
ã®ååŠççµåããè€åæ§é ã«ãã«ã¢ã³æåãçµå
ãããããã«æ¡çšããŠãåãããšã§ãããšããã
ãšãå°é家ã§ããã°èªèããã ãããäŸãã°ãã«
ã«ããã·ã¡ãã«ã¢ãã³ã®ãšããã«ãåæã®ã¢ãã³
æ©èœåã³ã«ã«ããã·æ©èœããã€ä»ã®è£œå€ãããã®
ã¢ãã³ãã€ãã³æ§é æåãçæãããåã¯ãã«ã¢
ã³å®äœãšã®çµåãçæãããããŠãã«ã«ããã·åº
ãææå®äœãšã®ã«ã«ããã·ã¢ããçµåãšããŠãã®
åŸã®çµåã«å©çšã§ãããªãã°ãæ¡çšã§ããããã
ããè©Šè¬ã¯ã HO2CïŒCH2ïŒxONH2 ããã§ïœã¯ãäŸãã°ïŒä»¥äžã®å°ããæŽæ°ã§ãã
ãããªå€åãå«ãã æŽã«ãç¡æ°Žç¥çé žã®ä»£ãã«ã11âããã²ã¹ãã
ã³ãããµã¯ã·ããŒãèªå°äœãçæããããã«ãç¡
æ°Žã¢ãžãã³é žããããã¯ãåŽéã眮æããç¡æ°Žç¥
çé žãç¡æ°Žã¢ãžãã³é žã®ãããªä»ã®è©Šè¬ããç¡æ°Ž
ãã¿ãŒã«é žãç¡æ°Žããªã¡ãªããé žã®ãããªç¡æ°Žè³
éŠæé žãšåãæ§ã«æ¡çšã§ãããããªã°ãªã³ãŒã«é ž
ã®ä»£ãã«ãäºè æäžçã«ãä»ã®ã¡ã«ã«ããâã«ã«
ããã·é žããïŒâããã²ã¹ããã³èªå°äœãäŸãã°
βâã¡ã«ã«ããããããªã³é žãã¡ã«ã«ããç¥ç
é žãåã³ããªå®æ¯éŠé žã®ãããªèªå°äœãçæãã
ããã«ã䜿çšãããããã®ããã«ãè€åäœãã€ã
ãã®ã«äœ¿ããããã«ã¢ã³æåã¯æ¬¡ã®æ§é ããã€ã
ãšãæ©æ¢°çãªå¿ èŠæ¡ä»¶ã§ããã ãhormoreãââCO2H ããã§ïŒ¡ã¯ãã¹ããã€ãæ žãžã®ã«ã«ããã·ã«åº
ã®çµåã®çºã«æ¡çšãããè©Šè¬ã®ååæ®åºã§ããã æŽã«ãã«ã«ããžã€ããã¯ãçµåå€ã®å¯äžã®åºã§
ãããä»ã®ã¯ãã¹âãªã³ãã³ã°ã®ååŠçåå¿ãã
é©åœãªååŠçãªæã芪ååã«å°å ¥ããããªãã°ã
ãã€ãªã¢ãŒãšã¹ããã€ãåã¯ææãšãã€ãªã¢ãŒã®
çµåã«å©çšã§ããããã®äŸã¯äŸãã°ã (1) ããªãŒã«âããã«ã¢ãã³ãšã€ãœããã«ã¯ãã
ã«ã«ãããŒããçšããæ··åã¢ã³ãã€ãã©ã€ãæ³
ïŒãšã«ã©ã³ã¬ãŒçãJ.Biol.Chem.228ïŒ713ã
1958åã³J.Biol.Chem.234ïŒ1909ã1959ïŒ (2) ã·ã³ã¬ãŒãšã·ãã¯ã«ããå©çšããããžã€ãœã·
ã¢ããŒãæ³ïŒJ.BiophysãBnochem.Cytol.9ïŒ
519ã1961ïŒïŒ (3) ã¢ã¬ããµã³ããŒçã«ãããžããã²ã³åãããž
ããããã³ãŒã³æ³ïŒBio chem.J.52ïŒ177ã
1952ïŒïŒ ãå«ãã ãã«ã¢ã³ããã€ãªã¢ãŒãã«ãªãã¯ããŒã ææè€
åäœã«éçããåã«ããã«ãªãã¯ããŒã ææãæ
åã«ãã€ãªã¢ãŒååã«çµåããããšãçµåã®é åº
ãšããŠéèŠãªããšã§ãããšããããšã¯èšæ¶ããã¹
ãã§ãããã€ãœã·ã¢ããŒãåã³ã€ãœããªã·ã¢ããŒ
ããã¹ããã€ãã®ããªãŒã®ãã€ãããã·ã«åºãšå¥
ã«çž®åããå Žåãããã®ã§ãç¹ã«ããã«ãªãã¯ã
ãŒã ææã®ã€ãœã·ã¢ããŒãåã¯ã€ãœããªã·ã¢ããŒ
ãé¡ãè¢å æ瀺è¬ãšããŠçšããããæã«ã¯ããã
ãã¹ããã€ãã®æ°Žé žåºã®ãããªã¹ããã€ããã«ã¢
ã³ã®çççãªå®èœåºã®æ¶æ» ãé¿ããã ããããã
åŸè ã®åå¿ãèµ·ããªãã°ãå容äœã®ãã¬ãŒãµãŒãš
ããŠã®æåŸã®è¢å è€åäœã®ç¹ç°æ§ã¯åœ±é¿ããã
ããæèšããã°ãæçµã®ïŒæåè€åäœã¯ããã€ãª
ã¢ãŒâãã«ã¢ã³âææåã¯ããã«ã¢ã³âææâã
ã€ãªã¢ãŒè€åäœã®åœ¢ãããããããã«ã¢ã³âãã€
ãªã¢ãŒâææã®åœ¢ã§ããã¹ãã§ããã åŸã€ãŠããšã¹ããã²ã³åã¯ããã²ã¹ããã³åã¯
ä»ã®ã¹ããã€ãã®åã¯ãã«ã¢ã³ã®å容äœèœåãã
ã€ãšçãããŠããä¹³çåã¯ä»ã®çè «çµç¹ãµã³ãã«
ã«æŒãŠãæªæ§çŽ°èã®æ±ºå®ãšåå®ã®æ¹è¯ã«ãçŸåšå ¬
éãããŠããæ¹æ³ãšæè¡ã«ãã€ãŠæ¡çšããããæ°
ããã¯ã©ã¹ã®è¬å€ããæ¬çºæãæäŸããããšã¯ã
å è¿°ã®è°è«ããåãã§ãããã ããããŠã蚺çåã³èšºæãžã®éèŠãªè²¢ç®ãšã
ãŠããã«ã¢ã³çæ³ã®å©çšã«ããé®éã«ææãªæªæ§
ç©ããã€ä¹³çåã³ä»ã®çæ£è ã®æ€åºãšåå®ã®éã®
å©ããšããŠçºå±ããã ãã¡ãããç¹èš±è«æ±ã®ç¯å²ã®çæãšç®çã®ç¯å²
å ã§ãããã§è¿°ã¹ãæ¬çºæã®è²¢ç®ã®ç¹å¥ã®å®æœãš
å©çšã¯ããã¶ãããã®äžã§äŸç€ºããããã«å©çšã
ããç¹å¥ã®å ·äœçãªããæ¹ããé¢ããå€åããã§
ãããããšã¯ãå°é家ã§ããã°åšç¥ã®ããšã§ã
ãã ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äºã€ã®å§é»æ¯ååãšã äžèšäºã€ã®å§é»æ¯ååã®éã«åŒµèšããŠããæ¯æ
éšæãšã ãã®æ¯æéšæã«è£ çãããééãšã äžèšäºã€ã®å§é»æ¯ååã®ãããããçºæ¯ããã
äºã€ã®çºæ¯åè·¯ãšã äžèšäºã€ã®çºæ¯åè·¯ã®åºååšæ³¢æ°ã®å·®ããšãå
è·¯ãšãå ·åãã äžèšåºååšæ³¢æ°ã®å·®ããšãåè·¯ã®åºåã«ããå
é床ã枬å®ããããšãç¹åŸŽãšããå é床ã»ã³ãµã
ããã²ã³å容äœïŒERïŒç¹æ§ã®åæããä¹³çãé²
ãã§ããæ£è ãéžã³åºããå¯èœãªãã«ã¢ã³çæ³ã
ãšãããã«æå¹ãªæ段ã§ããããšã蚌æãããŠã
ããäŸãã°ãN.Engl.J.Medã291ïŒ1252â1253
ïŒ1974ïŒãåç §ããŠé ãããããšã¹ããã²ã³å容
äœåæã§éžã°ããæ£è ã¯ãåã«èšåºåºæºã«ãã€ãŠ
éžã°ããæ£è ã§ã¯åã«20ïŒ ãã30ïŒ ã®åå¿ã§ãã
ã®ã«å¯Ÿãã32ïŒ ãã60ïŒ ã®å®¢èŠ³çé®éçã瀺ãã
ãšãå ±åãããŠãããäŸãã°ãCancerã39ïŒ
2934â2947ïŒ1977ïŒïŒCancer 23ïŒ145â151ïŒ1969ïŒ
åJAMAã172ïŒ1271â1283ïŒ1960ïŒã倫ã åç §
ããããã ããããªããããšã¹ããã²ã³å容äœã«å¯Ÿãéœæ§
ãšã¿ãªãããè «çããã€ãæ£è ã«æŒãŠãé«ãåå¿
çãåŸãããšãåºæ¥ãªãããšãåã³é¡èãªãšã¹ã
ãã²ã³å容äœã®ãªãä¹³çæ£è ã®çŽ10ïŒ ãçš®ã ã®ãš
ã³ãã¯ãªã³çæ³ã«ããŸãåå¿ããŠãããšããäºå®
ãããæœåšçãªãã«ã¢ã³å容äœä¹³çãæ€åºããè
å¥ããããã«ãçŸç¶ã®æ¹æ³ãæŽã«æ¹åãããšãã
ããšãå¿ èŠã§ããããšã瀺ããŠããã çŸåšã®çååŠçåææ¹æ³ã¯ãçµç¹å質äœã®çŽ°è
ãŸã«ãã©ã¯ã·ãšã³äžã®èçœè³ªã®ãšã¹ãã©ãžãªãŒã«
çµåèœåã枬å®ãããåŸã€ãŠãã®çµæã¯ãåæã«
äŸãããçµç¹äžã®çã®ãããŸãã®äºå®äžã®å€§ãã
ãã现èãŸã«äžã«æœåºãããçå容äœèçœè³ªã®æ¯
çãããã®ä»éççµç¹æåããæœåºãããèçœè³ª
ã«åœ±é¿ããããçµæãšããŠããããã®èŠå ã®å€å
ã«ãã€ãŠãæçµçãªãšã¹ããã²ã³å容äœå€ã®ã°ã
ã€ãã倧ãããªãããã®çµæãç现èæ°ã®çå®ã®
ççåŠçç¶æ ãäžæ£ç¢ºãšãªã€ãŠããã äžè¿°ã®ããã«ããšã¹ããã²ã³å容äœåæã«ãã€
ãŠéžã°ããæ£è ã¯ã32ïŒ ãã60ïŒ ã®æçœãªé®éç
ã瀺ããŠãããããã®ããšã¯ããã®æ¹æ³ã«ãã€ãŠ
éžã°ããæ£è ã®68ïŒ ãã40ïŒ ã¯ããŸã ãã«ã¢ã³ç
æ³ãããŸããã€ãŠãªããšããããšãæå³ãããæ£
è éžææ³ãæ¹åããããã«ãæœåšçãªãã«ã¢ã³å
å¿ä¹³çã®èå¥ã®ããã®ç¬¬ïŒã®å°ãšããŠãè «ç现è
ãŸã«äžã®ããã²ã¹ããã³å容äœã®åæãæ¡çšãã
ãŠããã ããã²ã¹ããã³å容äœã¯ãä¹³çã®30â60ïŒ ã«æŒ
ãŠå ±åãããŠããïŒæ£åžžåããªãã©ã¹ãã€ãã¯çµ
ç¹ã«æŒããããã²ã¹ããã³å容äœã«ã€ããŠãW.
L.McQuireãJ.P.RuynaudãE.E.BaulieuãP171ã
New YorkãRavin Pressã1977ïŒãåæããã«
ãšã¹ããã²ã³å容äœã«å¯Ÿãéœæ§ã§ããè «çã«ã€ã
ãŠã®ã¿èµ·ãïŒEuropean Journal of Cancer
13ïŒ1205ã1977ïŒãåæã®ããŒã¿ã¯ãšã¹ããã²ã³
å容äœãããã²ã¹ããã³å容äœãåãè «çäžã«èŠ
åºããããšããããšã¯ããã«ã¢ã³åå¿ãšäžå±€å¯æ¥
ã«é¢é£ããŠããããšãèããããããšã瀺ããŠã
ãããã ããããšãŒãããã·ãªãŒãºã§ã¯ãããã
ãã¯ã¬ãŒã ã¯æ¯æããªãã€ãã«ãæãããããã®
ãããªåæçãªçååŠçåæã®åºç€ã®äžã§ããã
ã²ã¹ããã³å容äœã¯ãä»åŸã®ç 究ã§ãã®ãããªæ±º
å®ã®èŠéã確ç«ããå¿ èŠãããã®ã ãããã«ã¢ã³
åå¿ä¹³çã«å¯Ÿãã第äºã®ãããã¥ãéå ·ãšãªãã§
ãããã ããã²ã¹ããã³å容äœã®æµè¡ã®çååŠçåæ
ã¯ããšã¹ããã²ã³å容äœã«ã€ããŠãã§ã«è°è«ãã
ãã®ãšåããããªå°é£ãããã€ãããæ ããšã¹ã
ãã²ã³å容äœã«ã€ããŠãšåãããã«ãç现èéå£
ã«å¯Ÿããããã²ã¹ããã³å容äœéœæ§çŽ°èã®å²åã
枬å®ã§ãããåçŽã§ãã€ãšæ£ç¢ºãªçŽ°èååŠçæè¡
ãå¿ èŠãšãããŠããã æŽã«ãä»ã®ã¿ã€ãã®çãåãã«ã¢ã³çæ³ã«ææ
ã§ããããåäžè¬ã«ãæªæ§ã®çµç¹ã«æŒããã«ã¢ã³
å容äœã®æ€åºãšåå®ã容æã«ãããããªéèŠãªæ€
åºå€ãå¿ èŠãšãããŠããã æ¬çºæã®ç®çãšãããã¯ããã«ã¢ã³çæ³ã«å¯Ÿã
ãæ£è ã®éžæã«å¯Ÿããäºè æäžåã¯è£è¶³çäºèšãš
ããŠãåç现èã®ãšã¹ããã²ã³ãšããŠåããã²ã¹
ããã³ãä»ã®ãã«ã¢ã³çµåã®ç 究ãšåå®ã«æå¹ãª
æ¹æ³ãšçŽæ¥ã®çŽ°èååŠå€ãéçºããããšã§ããã åºç€çã«ã¯ãæ¬çºæã¯ãçµç¹ã®ãããŸãäžã®ã
ãã¿ã€ãã®ä¹³çã®ååšããèŠèŠçãªæ¹æ³ã§éžæç
ã«ææããããšã®ã§ããèãã䟿å©ãªèœåãã
ã¡ãåãåé¡ã®æ£è ã«é©åãªãã«ã¢ã³å»çã®æè¬
ã®äžã§ãé®éãããããªãããçš®ã®ãã«ã¢ã³âè
çœâææè€åå€ã®çºèŠãšéçºãå«ãã§ãããäº
å®ãåçµçäžã§åé¢ãããã¹ãããã人éã®ä¹³ç
现èäžã®ãšã¹ããã²ã³ãããŠåããã²ã¹ããã³å
容äœãæ€åºããæ¬çºæã«ãããããååŠçãã¬ãŒ
ãµãŒãæåºãããŠãããæŽã«ãæ¬çºæã¯ãçš®ã ã®
ä»ã®ã¿ã€ãã®æªæ§ç©äžã®çžåœããå容äœçŽ°èã®æ€
åºã«éããä»ã®ãã«ã¢ã³å€ã®å©çšãå«ãã§ããã
æ¬çºæã¯ãçããŠããçè «ã®é®éããªãããã«é©
åœãªã¿ã€ãã®çæ³ã®æ±ºå®ã«å€§ããªé²æ©ããªãããš
ãçŽæããã æ¬çºæã®å®æœäŸã¯ããšã¹ããã²ã³å容äœã«é¢ã
ãŠæåã«ç€ºããã®ãšåæ§ã«ã次ã®ããã«æçãã«
èŠçŽã§ããïŒ åæåã¯è»¢ç§»ããä¹³çè «ãå«ããåã¯å«ããšæ
ãããçµç¹çãå€ç§æè¡ã«ããæ£è ããåãé€
ããåçµããããã®çµç¹çã次ã«ãçŽ14ÎŒã®åã
ã«åããé¡åŸ®é¡ã®ã¹ã©ã€ãã«ããã€ããæŽã«ãçŽ
ïŒæéïŒçŽïŒâããïŒâãŸã§ïŒå·èµåº«ã§ä¹Ÿç¥ãã
ããããããããªã³é žå¡©âç·©è¡¡åããã塩溶液
ïŒããšãã°0.01Mãªã³é žå¡©ãå«ã0.85ïŒ NaCl溶液ã
PH7.4ïŒã§æçãã«ãããã§åæ°ŽåããåŸããã®
çµç¹æšæ¬ãäŸãã°ãè¢å ãšã¹ãã©ãžãªãŒã«è€åå€
ïŒåŸã«è©³è¿°ããïŒã§è¢«èŠããæŽã«å®€æž©ïŒçŽ16âã
ã22âïŒã§çŽïŒæé湿æ°ã®ãã宀ã§åé€ããã ãã®è¢«èŠããè€åäœãããã®çµç¹æšæ¬ããåã
é€ãããã®çŽ°çããªã³é žå¡©ç·©è¡¡ããå¡©ã§åã³éã
ã«ãããããããŠãçŽïŒæéãå¡©äžã«æµžæŒ¬ããã
ãã®å Žåãæ°é®®ãªæŽæµæ¶²ã§äžåºŠäº€æããã®ãæå©
ã§ããã次ãã§ããªã³é žå¡©âç·©è¡¡ããã°ãªã»ãª
ã³ãPH7.2â7.8åã³ã¹ã©ã€ãã«ããŒã¹ãªããã§ã«
ããŒããããšãè¢å é¡åŸ®é¡ã§ãã¹ãããã è¢å ãšã¹ãã©ãžãªãŒã«ã§ã®ãã®ãããªåŠçåŸã
åºãŸã€ãŠããªãåã€ã现çäžã®ä¹³ç现èã¯ãè¢å
é¡åŸ®é¡ã§ãã¹ããããšãããã«ïŒã€ã®äž»ãªç¯çã«
åé¢ããããå³ã¡æ¬æ¥çãªçŽ°è質è¢å ã§ããçŸã
ãç·è²ã瀺ãç现èãšè¢å ããåã¯ããŠã極å°ã§
ããéšåãšã§ããã ããããåŠçåŸã®çŽ°èã®è¢å ã®ååšã¯ãçµç¹ã«
ãããè€åäœã®ãšã¹ãã©ãžãªãŒã«æ®åºã®è¡šé¢çãª
çµåã®çµæã§ãããšè§£éãããåãã®äžã«ãšã¹ã
ãã²ã³å容äœã®ååšã瀺ã蚌æ ãšããŠåããšãã
ããã 现èã®ãšã¹ããã²ã³å容äœã®ç¹å¥ã®çè²ã®éœæ§
é°æ§ã®ããããã³ã°ãã也ããåçµãã现çã®ã
ã¬ã€ã³ããŠããŒã·ãšã³ã«ãã€ãŠãã¹ãããããã®
ãã¹ãã¯ãããšãã°è¢å æææåãæ¬ ããåæ§ã®
ãšã¹ãã©ãžãªãŒã«ååç©äžã§ããµã€ãã«ç·©è¡¡ãã
ãåçã®è¡æž ã¢ã«ããã³ïŒâBSAâïŒæº¶æ¶²äžã§ã
ããããè¢å ãšã¹ãã©ãžãªãŒã«è€åäœã®åŒ·åºŠãªçš
éãšããïŒæéåã«å®æœãããããã现çã¯ãæŽ
ã«äžè¿°ã®åŠãå¹é€ããæŽæµãããã¹ãããã å®å šã«ç¹ç°æ§ã®ããããããã³ã°ãåŸãããã«
ã¯ãè¢å ãšã¹ãã©ãžãªãŒã«è€åäœãçšéãããå
ã¯ã¹ããã€ãïŒèçœè³ªã®æ¯ãäœãããŠãçšããç
è²äžã®ãšã¹ãã©ãžãªãŒã«æ®åºã®æ¿åºŠãã¹ããã€
ãïŒèçœè³ªã®æ¯ã20â25ã§ããããããã³ã°æº¶æ¶²
äžã§ã¯ãã®1/10ãè¶ããªãããã«ããããšãå¿ èŠ
ã§ããããšãããã€ããããããã³ã°å€ãšããŠé
è€åã®17βâãšã¹ãã©ãžãªãŒã«åã¯17βâãšã¹ã
ã©ãžãªãŒã«âïŒâCMOã䜿çšããè©Šã¿ã¯ãèçœ
質ãã€ãªã¢ãŒååšãªãã«ãçŽPH7.4ã®æ°Žæº¶æ¶²äžã§
ã®ãããã®ååŠç©è³ªã®æº¶è§£åºŠã¯ãERéœæ§ç现è
ã®çµååŽãæºè¶³ããã®ã«å åã§ãªãã€ãã®ã§ãæ
åããªãã€ãã è¢å ãšã¹ãã©ãžãªãŒã«è€åäœã¯ãç²è žçã®çµç¹
çãææ¡è ºãçµè žåèã®çè «ã¯ãé°æ§ã®å¯Ÿç §äŸãš
ããŠåãããã«æºåããããçè²ããªãã€ãã ããã²ã¹ããã³å容äœãå«ã现èã«é¢ããŠãå
æ§ã®åŠçæ¹æ³ãçšãããããè¢å é¡åŸ®é¡çšã«ãã®
çµç¹çãçè²ããŠæºåããæè¡ã¯ããã®å Žåã«ã¯
è¢å ããã²ã¹ããã³è€åäœã现èååŠå€ãšããŠçš
ãããã以å€ã¯ãšã¹ããã²ã³å容äœã«å¯Ÿããå Žå
ãšåãã§ããã å ã«è¿°ã¹ãããã«ãæ¬çºæã¯ã人éã®ä¹³æ¿çµç¹
ã®åçµçãžã®ãšã¹ããã²ã³ãšåããã²ã¹ããã³ã®
çµåèœåã蚌æããããã®æ°ãã现èååŠå€ãšæ¹
æ³ãçŽæããããã®æ¹æ³ã¯ãæ¬è³ªçã«ã¯ãã«ã¢ã³
ãšã¹ãã©ãžãªãŒã«åã¯ããã²ã¹ããã³ã¹ããã€ã
ååç©ãšè¢å ææååç©ãšã§ãããã«ã©ãã«ãã
ãèçœè³ªãã€ãªã¢ãŒããæãæ°èŠãªå容äœã®ãã¬
ãŒãµãŒã®èª¿è£œã«æåããããšã«ããã ãã®èçœè³ªãã€ãªã¢ãŒã¯ããã®ã¢ããé žæ®åºãš
å ±æçµåããŠãã¹ããã€ãã氎溶液äžã«éã³ã现
èååŠçåæ±ããããå åãªé«ãæ¿åºŠãšãªãã®ã§
ãã®ãã€ãªã¢ãŒã¯ãã®ãã¬ãŒãµãŒã®å¿ é ã®æåã§
ãããšæãããã ä»ã®ãã«ã¢ã³ïŒã¹ããã€ãæåããèçœä»¥å€ã®
å€å®èœã®èŠªæ°Žæ§ãã€ãªã¢ãŒãšåãããã®ååã«å©
çšãããã ã¹ããã€ããã«ã¢ã³ãããããããã€ãªã¢ãŒãš
ã€ãªãããšãããã®å€©ç¶ã®ååé 眮ã«æŒããã«ã¢
ã³ã®ç¹ç°æ§ãç¶æããããªãã°ããã®çççå®èœ
åºããã®ãŸãŸã«ããŠããããŠããããšããäžå¯æ¬
ã§ããã17βâãšã¹ãã©ãžãªãŒã«ã®å ŽåãïŒã®äœ
眮ã®ååŠçæã«ããåçã®è¡æž ã¢ã«ããã³ãšã®çµ
åã¯ããã§ã«ãå ç«åŠçç¹ç°æ§ã®ä¿æã«æåããŠ
ããïŒäŸãã°ãSteroidsã18ïŒ593â603ïŒ1971ïŒïŒ
Steroidsã19ïŒ357â375ïŒ1972ïŒãåããããªã¢ã
ããŒããããã§çšããè€åäœã調補ããã®ã«æ¡çš
ãããŠããããããçš®ã®æé ããé«ååææïŒè
çœè³ªæ¯åã³ã¹ããã€ãïŒèçœè³ªæ¯ãéæãããã
ã«ä¿®æ£ãããŠãããå¹³åããŠãæ¬çºæã®å¥œãŸãã
äŸã§ã¯ãçŽ11ã¢ã«ã®è¢å ææãš24ã¢ã«ã®ãã«ã¢ã³
ãïŒã¢ã«ã®èçœè³ªïŒäŸãã°âBSAâïŒã«æå¹ã«ã
ã€ã€ãã è¢å ããã²ã¹ããã³è€åäœã®ååŠçåæã¯ãã
ãããæŽã«è©³çŽ°ã«è¿°ã¹ãããã«ãäŸãã°åçã®è¡
æž ã¢ã«ããã³ãã«ãªãã¯ããŒã ææè€åäœã«ãäŸ
ãã°ã¹ããã€ããã«ã¢ã³ã®ïŒã®äœçœ®åã¯11ã®äœçœ®
ã®ãããããšããããã«ããã²ã¹ããã³ååãå
æ§ã«ãã€ã€ããããšã«ãã€ãŠãéæããããšãã§
ããã ãšã¹ããã²ã³ã®å ·äœäŸ 17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒ¯âã«ã«ãã
ã·ã¡ãã«ïŒãªãã·ã ã®åæ ãã³ã°ãŠãšã«ãšãŠã€ã³ã¿ãŒã¹ãã€ããŒãã
Biol.Chem.133ïŒ219â229ïŒ1940ïŒã«è¿°ã¹ãããŠ
ããããã«ã17βâãšã¹ãã©ãžãªãŒã«ã»ãžã¢ã»ã
ã€ãïŒ10ïœïŒãæ°·é ¢é žïŒ34.5mlïŒã«æº¶è§£ããæ°Ž
ïŒ6.9mlïŒãšæ°·é ¢é žïŒ51mlïŒäžã«ã¯ãããŠã ããªãª
ããµã€ãïŒ8.5ïœïŒããšããã溶液ããã«å ããã
æ··åç©ãã宀枩ã§24æéæ¹æããæ°Žã§500mlã«åž
éããåã 500mlã®ãšãŒãã«ã䜿ã€ãŠïŒåæœåºã
ãã倧éšåã®é ¢é žã¯ãããããªãã³ã¯è²ãæ°Žå±€ã«
çŸãããŸã§é£œåããNaHCO3溶液ã§æŽãããšã«
ããã䜵çšããããšãŒãã«æœåºç©ããé€å»ããã
ãšãŒãã«å±€ãæŽã«ãïŒïŒ ã®Na2CO3ãšé£œå
NaHCO3溶液ã®ïŒïŒïŒæ··å溶液ã«ãã€ãŠåŸ¹åºç
ã«æŽããã€ãã§ãæ°Žã§æŽãããããã也ç¥ãããŸ
ã§èžçºããããæ®ããé ¢é žãšãã«âç³æ²¹ãšãŒãã«
ïŒb.p.60â100âïŒã®ïŒïŒïŒæ··åç©ïŒ200mlïŒã«æº¶
解ãã22Ã4.5cmã®ã·ãªã«ã²ã«ã«ã©ã äžãéããã
ã«ã©ã ã¯æ¬¡ã«ïŒã®é ¢é žãšãã«âãããµã³ã®ïŒïŒ
ïŒæ··åç©ã§æŽãããããã200mlã®çåãéããã ãã®åæã¯ãé»è²ããã€ããæããã«éé žåã
ããå¯ç£ç©ïŒå€åã±ãé žãšãã®èªå°äœïŒã®æº¶é¢ã«
å ç«ã€ãŠåŸãããçåäžã®ïŒâã±ãâ17βâãšã¹
ãã©ãžãªãŒã«ã»ãžã¢ã»ãã€ãã®æº¶é¢ã«æé«ã®çµæ
ã瀺ããã 溶åºæº¶å€ã®èžçºåŸãç²ïŒâã±ãâ17βâãšã¹ã
ã©ãžãªãŒã«ã»ãžã¢ã»ããŒãçåã¯ããŸãšããŠç¡æ°Ž
ãšã¿ããŒã«ããåçµæ¶ãã2.5ïœã®éç¶çµæ¶ïŒm.
p.çŽ173âïŒãåŸãã ïŒâã±ãâ17βâãšã¹ãã©ãžãªãŒã«ã調補ãã
ããã«ãïŒâã±ãâ17βâãšã¹ãã©ãžãªãŒã«ã»ãž
ã¢ã»ãã€ãïŒ2.5ïœïŒããçªçŽ ã¬ã¹äžã§24æé宀
æž©ã§ãã¡ãã«ã¢ã«ã³ãŒã«äž75mlã®20ïŒ KOHã§å
æ°Žå解ãããé»è²ããã€ã溶液ãåŸãããæ°Žã§çŽ
400mlã«åžéããå¡©é žã§PHïŒãŸã§é žæ§ã«ããåã
500mlã®ãšãŒãã«ã§ïŒåæœåºããããšãŒãã«æœåº
ç©ãåããŠãNaHCO3ã§é£œåããïŒïŒ Na2CO3ã§
æŽããããããæ°Žã§æŽã€ãã也ç¥ãããŸã§èžçºã
ããåŸãç²çæç©ãç¡æ°Žãšã¿ããŒã«ã§ïŒåºŠåçµæ¶
ããããšãçµæ¶æ¿ïŒm.p.çŽ280âïŒçæé1.5ïœïŒ
ãåŸãããã ã¢ãŒã©ã³ãžã€ãŒçã«ãããMethods in
Immunology and ImmunochemistryãEd
Welliams CAãClase MW.Academic Pressã
New YorkãVol.1ã144â159ãïŒ1967ïŒäžã§è¿°
ã¹ãäžè¬çãªæ¹æ³ã¯ã17βâãšã¹ãã©ãžãªãŒã«â
ïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãªãã·ã ã調補ã
ãããã«æ¬¡ã«çšãããããïŒâã±ãâ17βâãšã¹
ãã©ãžãªãŒã«ïŒ1.5ïœïŒããšã¿ããŒã«ïŒ75mlïŒå
ã³2NKOHïŒ6.8mlïŒã«æº¶è§£ãã次ã§ã«ã«ããã·ã¡
ããã·ã«ã¢ãã³ã»ãããã€ããã¯ãã©ã€ãïŒ94
ïŒ ïŒ1.5ïœïŒãå ãããæ··åç©ãïŒæééæµãã
åŸãã¢ã«ã³ãŒã«ãèžçºããããæ®ãã溶解ããã
ããã«æ°ŽïŒ150mlïŒãå ããåŸã«ããã®æº¶æ¶²ãPH
8.5ã«èª¿æŽããé溶解ç©ãé€ãããã«éãã
åã 30mlã®é ¢é žãšãã«ã§ïŒåºŠæœåºãããHClã§PH
ïŒã«é žæ§åããåŸãçœãæ²æŸ±ç©ãçæãããåŸè
ããéã§éãã37âã®ã€ã³ããŠããŒã¿ãŒã§ä¹Ÿç¥
ããã¢ã»ãã³ã§ïŒåºŠåçµæ¶ããããšã1.4ïœã®é
ç¶çµæ¶ïŒm.p.196â199âïŒãçæããã17βâãš
ã¹ãã©ãžãªãŒã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒ
ãªãã·ã ãšãã®å é§ç©è³ªã®åå®ã¯ãèç¹ãšã·ã«ã«
ã²ã«ãã¬ãŒãã§èå±€ã¯ãã³ãã°ã©ãã€ãŒïŒæº¶åª
ç³»ïŒé ¢é žãšãã«ïŒïœâãããµã³ïŒãšã¿ããŒã«ïŒé ¢
é žã®æ¯ã72ïŒ13.5ïŒ4.5ïŒ10ïŒã§å®æœãããæç®
ïŒäŸãã°Steroidsã18ïŒ593â603ïŒ1971ïŒå19ïŒ
357â375ïŒ1972ïŒïŒã«å ±åãããŠããããã«ããã®
å€ã¯ãããã®ååŠç©è³ªã«äºæ³ãããã®ã«çžåœãã
ããšãããã€ãã ãã«ãªã¬ãã»ã³ ã€ãœã·ã¢ããŒãïŒFITCïŒâ
åçè¡æž ã¢ã«ããã³ïŒBSAïŒååç©ïŒFITCâ
BSAïŒã®èª¿è£œãAm.J.Path.ã34ïŒ1081â1097
ïŒ1958ïŒã®äžè¬çãªæ¹æ³ãé«ãFITCâBSAæ¯ã
çšãã以å€ã¯ãåæ§ã«ããŠçšããã詳现ã«ã¯ã
BSAïŒïŒïœïŒã·ã°ãã±ãã«ã«ç€Ÿè£œã®ãã®ã§çµæ¶å
ããŠåçµä¹Ÿç¥ãããã®ïŒã10mlã®0.5Mã®ã«ã«ã
ããŒãâãã«ã«ãããŒã緩衡液ïŒPH9.5ïŒã«æº¶è§£
ãããã»ã©ã€ãïŒ10ïŒ ç©ïŒã·ã°ãã±ãã«ã«ç€Ÿè£œïŒ
äžã®FITCïŒïŒïœïŒããã®æº¶æ¶²ã«å ãã宀枩ã§ïŒ
æéæ¹æãããé å¿åé¢ã«ããã»ã©ã€ããé€å»
åŸãFITCâBSAè€åäœããããããã0.05Mãª
ã³é žå¡©ç·©è¡¡æ¶²ïŒPH7.8ïŒã§å¹³è¡¡ã«ããã»ãã¢ãã
ã¯ã¹ïŒ§â25ã«ã©ã ãéãã次ãã§ãããçµåãã
FITCãå®å šã«é€å»ããããåã緩衡液ã§48æé
éæããããã®èçœè³ªéã¯ãããŠãŒã¬ããåå¿ã§
決å®ããããã«ãªã¬ãã»ã³ïŒèçœè³ªã®å¹³åååé
æ¯ã¯ã495nïœã§ã®0.1N NaOHäžã§ã®çŽç²FITC
ã®åžåãã11.2ïŒÂ±0.5ïŒã§ãããšèšç®ãããã 17βâãšã¹ãã©ãžãªãŒã«âïŒâCMOâBSAâ
FITCè€åäœïŒãã«ãªã¬ãã»ã³ã»ãšã¹ãã©ãžãªãŒ
ã«è€åäœïŒã®èª¿è£œãäžè¿°ã®ããã«ããŠåŸãããã
èçœè³ªïŒ200mgïŒãïŒâãšãã«âïŒâïŒïŒâãžã¡ã
ã«ã¢ãããããã«ïŒã«ã«ããžã€ããã»ãã€ããã¯
ãã©ã€ãïŒ200mgïŒåã³ãžãªããµã³ïŒmlã«æº¶è§£ã
ã17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒâã«ã«ãã
ã·ã¡ãã«ïŒãªãã·ã ïŒ200mgïŒãå«ããªã³é žå¡©ç·©
衡液ã«å«ãŸããFITCâBSAè€åäœã®äžéšãïŒml
ã®æ°Žã0.05Mãªã³é žå¡©ç·©è¡¡æ¶²ã®é©éãããªããPH
7.8ã§å šé21mlã«ãããã®ã宀枩ã§20æéæ¹æã
ãããã®éçšã§ããšã¹ãã©ãžãªãŒã«ã¯ãâBSAâ
èçœè³ªäžã®Îµâã¢ããåºãšãã¹ããã€ãã®ãªãã·
ã èªå°äœã®ã«ã«ããã·ã«åºã®éã®ããã¿ã€ãçµå
ã®çæã«ããBSAã«çµåããã 次ãã§ãã®è€åäœããŸãæ°Žã§åŸ¹åºçã«éæãã
次ã§ã48æéãªã³é žå¡©ã§ç·©è¡¡åãã塩溶液
ïŒPBSïŒïŒPH7.4ïŒã§éæãã次ã«é å¿åé¢ïŒ28000
Ãïœã15åïŒããããã®äžæŸæ¶²ãéãã¢ãžåãã
ãªãŠã ãé²è å€ãšããŠæçµæ¿åºŠïŒmgïŒmlã«ãªãã
ãã«å ããã ãã®æº¶æ¶²ã¯äœ¿çšåã«PBSã§ææã®æ¿åºŠãŸã§æŽ
ã«çšéããã è©Šéšãã¹ãä¹³ççµç¹æšæ¬ãäžè¿°ã®ããã«åçµã
ã现çãšããŠèª¿è£œããŠãããããããããåºå®ã
ããªãç¶æ ã«ä¿ããã°ãªããªããäŸãã°ããããš
ã¹ããã²ã³å容äœïŒERïŒéœæ§ç现èãå«ãçµç¹
çããå·ã¢ã»ãã³ïŒâ20âïŒã3.7ïŒ ã®ç·©è¡¡æ¶²åã
ããã«ã ã¢ã«ãããåã¯ïŒïŒ ã°ã«ã¿ãŒã«ã¢ã«ãã
ãäžã§åºå®ãããã°ã现èã®ãšã¹ãã©ã²ã³çµåèœ
åãå®å šã«ãªããªããšããããšã«ããªãããã æŽã«ã现èãšã¹ããã²ã³å容äœã«æŒããä¿åå¹
æã調ã¹ãããã«ãERéœæ§è «çãããšã€ãå¥ã
ã®çµç¹çãåã ïŒâããïŒâã®PBSäžã«ä¿åãã
äžæ¹ã¯â20âã§åçµãããåçµçã¯ã24æééé
ã§ããã®ãããŸãããã«ãããããšã¹ããã²ã³å
容äœã®æ€åºã®ããã«çè²ãããçµç¹ã®ãããŸãã
åçµããã«2ãâïŒâéã§ä¿åãããæã24æé以
å ã§ã¯ç现èã®ãšã¹ããã²ã³çµåèœåã«ã¯æãã
ãªæžå°ã¯ãªããã72æéã§ã¯ããªãã®æžå°ãã¿ã
ããERéœæ§ã®ç现èã®å²åãæããã«äœããªã€
ãã â20âã§åçµããçµç¹ã®ãããŸãã¯ã现èååŠ
çç 究ã«ã¯äžé©åœã§ããããšãåã€ãïŒåçµåã³
解åãããããããšãæããã«çµç¹çãããšã¹ã
ãã²ã³å容äœèçœè³ªãåé¢ããããã§ããã æ¬çºæã®å®æœã«åœã€ãŠãçµç¹çãäžè¿°ã®ããšã
å¿ã«ãšããŠèª¿è£œãç 究ããªããã°ãªããªãã ããããŠã现èã®ãšã¹ããã²ã³å容äœã¯ã¢ã»ã
ã³åã³ã¢ã«ãããå®ç液ã«ãçæéããããã ã
ã§ããçãæ®ããªãããšãæããã§ãããåŸã€
ãŠãåºå®ãããªãåçµçã®ã¿ãããã®æè¡ã«æšå¥š
ã§ãããè¢å ãšã¹ãã©ãžãªãŒã«è€åäœãšã®ã€ã³ã
ãŠããŒã·ãšã³ã«å ç«ã¡ãïŒæéã®éå·èµåº«å ã§ã¹
ã©ã€ãäžã®çŽ°çã也ç¥ããããšã¯ãåºå®ãããªã
湿ã€ãåçµçãæ±ãããšã¯ãéåžžã«æè¡çã«ãã¥
ãããã®ã§ã蚱容ããã劥åæ¡ã§ããã ãããŸã§ããªãã现èååŠæ€æ»ã®ããã«ãææ
ãå ¥æããæè¯ã®ææã¯ãæ¥åžžã®èšºæãã¹ãåçµ
çã調補ãããæã§ããã现èæ¯éå£ã®åå®ã®ã
ãã«è¿æ¥ããé£ç¶çããããããã·ãªã³ãšãšãªã·
ã³æ³ã§çè²ããããšãã§ãããããããªãããæš
æ¬ã移éããªããã°ãªããªãå Žåã«ã¯ãçµç¹å¡ã¯
2ãâïŒâã§ä¿ããã24æé以å ã«åŠçããããšã
æãŸãããåçµãšè§£åãããããããšããšã¹ãã
ã²ã³å容äœã®æŽ»æ§ãæžå°ããã貯èµæéãã®ã³ã
ã«åŸã€ãŠçããæ»åŸå€åããåæ§ãªéå¹æããã
ããã èšåºã®çç©è³ªã®ãã®çŽ°èååŠæ³ã®é©å¿ã¯ããã¹
ãŠç°ãªãæ£è ãããšã€ã17äŸã®åæã®æµžé管ç
è «ãïŒäŸã®è äžã®ãªã³ãè ºã«ç§»è»¢ããä¹³çãïŒäŸ
ã®ç¹ç¶çã10äŸã®è¯æ§ã®ãfibrocystic
mastopathyã åã³ïŒäŸã®å¥³æ§ã®ä¹³è ºè «ãå«ãã èžã®æå·ã®ç 究
ã«ããäŸèšŒãããã ãããã®çµç¹æšæ¬ã®éåžžã®çè²æ³ãšããŠãäžè¿°
ã®ããã«ããŠåŸãéæããè¢å ãšã¹ãã©ãžãªãŒã«
è€åäœããæåŸæ¿åºŠãmlåœã0.5ÎŒMïŒÂ±10ïŒ ïŒã®
FITCãšåœéã«ãªãããã«PBSïŒPH7.4ïŒã§çšéã
ãããã®çšé液ã¯ãæšæºç©è³ªãšããŠãè€åããŠã
ãªããªãã·ã ãšçŽç²ãªFITCã®0.1NâNaOH溶液
ãçšããå Žåã«ã340nïœãš495nïœã§ã®ãããã
ã®åžåïŒ0.1N NaOHäžïŒã«ãã€ãŠç€ºããããã
ã«17βâãšã¹ãã©ãžãªãŒã«âïŒâCMOïŒFITCå
åéæ¯ã¯2.2ïŒÂ±10ïŒ ïŒã瀺ãã ãããã®æº¶æ¶²äžã«ã¯ãéé¢ã®ãã«ã¢ã³ãè¢å æ
æã¯èå±€ã¯ãããã°ã©ãã€ãŒã§ã¯æ€åºãããªãã€
ãã ãã®ããã«ç 究ããã19äŸã®ä¹³çã®äžãïŒäŸã®
çè «ïŒïŒã€ã¯åæã®ä»ã¯æºéçïŒã®ã¿ã现è質äž
ã§ã¯è¢å ãšã¹ãã©ãžãªãŒã«è€åäœãç²ãéãæ²æŸ±
ç©ãçãã现èæ žäžã§ã¯æ¯èŒçå°ããšããç¹åŸŽã
ãã€åŒ·åã«ERéœæ§ãªç现èã®æ®ãã©å質ã®æ¯é
å£ããæãç«ã€ãŠãããééãããªã³ãçãå€åœ¢
æ æ žçœè¡çãçµç¹çãå圢質现èãè¡ç®¡åä»åšã
ãã¡å¯ãªç¹ç¶ç¶ã®çµåçµç¹ã¯ãã©ããªç¹ç°ãªè¢å
ãã瀺ããªãã€ãã æ®ã15ã®ä¹³çè «ïŒ14äŸã¯åæã§ïŒäŸã¯æºéçïŒ
ã¯ãè¢å ã®çšåºŠãå€åããå®å šã«é°æ§ã®çŽ°èãã
匷ãéœæ§ã®çŽ°èãŸã§ã°ãã€ããåãè «çã®åã ã®
现èéãšåããç°ãè «çéã§ãç°ã€ããã«ã¢ã³çµ
åèœåã瀺ãç现èããæã€ãŠãããç现èæ ž
ã¯ãçè²ãããå Žåãçè²ãããªãå Žåã现è質
ãããææ床ã¯äœããïŒäŸã®åæçã®ã¿ããæ®ã
ã©éçè²ç现èããæ§æãããŠãããšããããšã
èŠåºãããERé°æ§è «çãšã¿ãªãããšãã§ããã
ããããªããããããåŸè ã®å Žåã§ããçµæçã«
ã¯æ³šææ·±ã調ã¹ãŠã¿ããšãåé¢ããERéœæ§ç现
èãå°éçŸããã ä¹³è ºåã³å°èã®è¯æ§ã®äžç®çŽ°èã¯åãå質ã§ãª
ããšã¹ããã²ã³çµåèœåã瀺ããããããã®éã
ãªãã©ã¹ããã¯çŽ°èäžã®è¢å æ²æŸ±ç©ã®æ¿åºŠã¯ã倧
æµã®ERéœæ§ç现èäžã§èŠ³å¯ããããããã¯ãã
ã«äœããäžç®çŽ°èã®å€§éšåã¯ãERé°æ§ã§ããã
ERãµã€ããæ®ãã©ãã€ãŠããªãã®ã§ããã®æ¹æ³
ã§ã¯æ€åºããããšãã§ããªãã€ããçž®äžç®çŽ°èå
ã³ãã®è¿ãã®ç¹ç¶çµåçµç¹ã§ã¯ãæ®ãã©ãå šããš
ã¹ããã²ã³çµåèœåã¯èŠ³å¯ãããªãã€ãããã®ç¶
æ ã¯ãERéœæ§ç现èã§ãããŸããç¯å²ã§ããã
å šãå€ããªãã€ããäžå®ã®ãšã¹ããã²ã³çµåã瀺
ãè¯æ§ã®äžç®çŽ°èã¯ãåã ã®è «çéã®è¢å æ¿åºŠã
é¡å¥ããæã«ãçµç¹çäžã®â匱éœæ§âã®ã³ã³ãã
ãŒã«ãšããŠäœ¿ãã®ã䟿å©ã§ããã ç¹ç¶è ºè «åã³ä¹³è ºè «ã®çµæã¯ããããã®é害ã
ãã€ãããšå¢å ãããšã¹ããã²ã³çµåèœåããã€
ã现èå¢æ®ç®¡ã®äžç®çŽ°èãå«ãããã«ã¿ããç¹ã
åã³ãããã®æ¡ä»¶ã®ãããã«ãã现èå¢æ®ç®¡ããš
ããããã§æ確ã«äŸèšŒã§ãããšã¹ããã²ã³å容äœ
ãæããåºè³ªçŽ°èãããç¹ã§äŒŒãŠããã 0.5ÎŒM FITCïŒmlãšåœéã®æ¿åºŠã«çšéãã
FITCâBSAè€åäœã ããããŸããé°æ§ã®éç¹ç°
æ§ã®çè²ã³ã³ãããŒã«ãšããŠçšããããã®ç©è³ª
ã¯ãERéœæ§ç现èãçè²ããã®ã«å€±æãããã
ã®çŽ°èååŠæè¡ã®ç¹ç°æ§ã¯ããã®è€åäœãç²è ž
çãæé è ºåèè žç³»çµ±ã®çè «ãå«ããããç¥ãã
ãâéæšçâçµç¹ãçè²ã§ãããåããã®æšç现
èïŒERéœæ§ã®ä¹³ç现èïŒã®çè²ã¯ãéè¢å ã®17β
âãšã¹ãã©ãžãªãŒã«âïŒâCMOâBSAã«ãã€ãŠ
劚ãããããšããäºå®ã«ãã€ãŠæ¯æã§ãããç¹ç°
çè²ãå®å šã«åŠšå®³ããããã«ãçŽ10åã®éè¢å ã¹
ããã€ãæ¿åºŠãå¿ èŠã§ããããã®ããšã¯ã3Hâ
ãšã¹ãã©ãžãªãŒã«ã®çµåã8S现èãŸã«èçœè³ªå
容äœã«ãã€ãŠæããããã«ã¯ãçŽ100åã®éå°ãª
éæŸå°æ§ãšã¹ãã©ãžãªãŒã«ãå¿ èŠã§ãããšããå®
枬ã«ãããïŒJ.Clin.Enocrinol.Metab.37ïŒ986â
989ïŒ1973ïŒåç §ïŒ æªæ§ã®è»¢ç§»ãèµ·ããšãä¹³ç现èã¯ããã«ã¢ã³ã®
å容äœã®éåžžã®æ¯éå£ã®ãã¹ãŠåã¯äžéšåãä¿æ
ããŠãããERéœæ§è «çã«çºå±ãããšããããšã
äžè¬çã«èŠãªãããŠãããããããªãããåãè¯
æ§ã®ä¹³æ¿çµç¹ã¯çååŠçåæã«ããæ€åºãããå
åãªãšã¹ããã²ã³å容äœããã€ãã«å«ãŸãªããšã
ãããšãããç¥ãããŠãããïŒåç §Cancer Res.ã
30ïŒ692â698ïŒ1970ïŒïŒ åŸã€ãŠããã®âä¿æâçè«ã§ã¯é«ãšã¹ããã²ã³
å容äœå€ããERéœæ§çã®ããã€ãã§èŠåºããã
ãšããããšã説æããã®ã¯ãã¥ããããæ¬çŽ°èå
åŠç 究ã®çºèŠã¯ãERéœæ§ç现èã¯ä¿æããã®ã¿
ãªããããã°ãã°çŸå®åé¡ãšããŠã®éåžžã®ãšã¹ã
ãã²ã³çµåèœåãããé«ããã®ãèŠããè¯æ§ã®èŠª
ã®100åãã1000åã®å€§ããã«ããªãããããšã
ãããšã瀺ããäžå¹Žåã¯é«éœ¢ã®å¥³æ§æ£è ã®ä¹³æ¿çµ
ç¹ã§ã¯ã管åã³å°èã®è£ã®äžç®çŽ°èã®å°æ°ã®ã¿
ããäœããã®æå³ã®ãããšã¹ããã²ã³çµåã瀺
ãã æ¬çºæã®å®æœã®çµæã¯åãä¹³çãåçŽã«ERéœ
æ§åã¯ERé°æ§è «çãã§åé¡ããããšãã§ããªã
ãšããããšã瀺ãããªããªãã°ãä¹³çã®å€§éšå
ã¯ãæ··åå²åãããããã§ããããERéœæ§åER
é°æ§çŽ°èãããããæ··ããã€ãç°ããšã¹ããã²ã³
å容åã®ç现èã®ç°çš®ã®æ¯éå£ããæç«ã€ãŠãã
ããã§ãããå€ååžžã«ã©ã®ERéœæ§è «çäžã«ãER
é°æ§çŽ°èãèŠåºãããšã¯ã§ããã§ããããããŠã
ã®éãåæ§ã§ãããããæ ãç现èæ¯éå£äžã®
ERéœæ§çŽ°èã®çŸåçã«ãã€ãŠä¹³çãé¡å¥ããã
ãšãããé©åœãšæãããã æããã«ããã«ã¢ã³çæ³ã®ååŸã§é€å»ããè «ç
ã§åŸããã现èååŠããŒã¿ãæ¯èŒç 究ããã°ãç
现èçæåŠã«é¢ãã深淵ã§éèŠãªçåç¹ã«ã€ããŠ
æŽã«æ å ±ãåŸãããã§ããããäŸãã°ãå åæ³åŠ
çããç现èæ¯éå£ã®ERéœæ§çŽ°èã®çŸåçããž
ããããšãã§ãããªãã°ãäžè¬ã«æªæ§çŽ°èã®ãã«
ã¢ã³äŸå床åã³ãã«ã¢ã³å容床éã®é¢é£ã«ãšã€ãŠ
匷åãªèšŒæ ãšãªãã ããããã®ããšã¯åãäœæ ã
ãã€ãã®ERéœæ§è «çã¯å®å šã«èªçºçç¶æ ã«é²è¡
ããåã«ãã«ã¢ã³çæ³æéäžéšåçåã¯çæéã®
ã¿é®éãããã説æããããšãã§ãããåç §
Cancerã39ïŒ2934â2947ïŒ1977ïŒããããå容äœ
é°æ§è «çãŸã§å€æ¿ããããã«ã¢ã³äŸå床ã¯é£ç¶åŸ
é ã®æŠå¿µããåããã§ã«ææ¡ãããŠãã
ïŒCancerã39ïŒ1971â1977ïŒ1977ïŒïŒã æ¬çºæãçšããã°ããã®ãããªç 究ã«åœ¹ç«ã€èŠ³
å¯ãå¯èœãšãªããäŸãã°ãæ¬çºæã«ããã°å®éã
倧æµã®ä¹³çè «ã¯ãERéœæ§ç现èãå«ã¿ãçãã
ãåæšæ¬ã®æªæ§åºŠãæ±ããšãã«ãä¹³çãèå¥ãã
ã®ã«å©ããšãªããšããããšã瀺ãããŠããã æŽã«ãæ£è ã®äœæ¶²äžã埪ç°ããŠããå çã®ãšã¹
ããã²ã³ã¯ãè «çã®ãšã¹ããã²ã³å容ãµã€ããå
ãåã¯é£œåããŠããŠãå容äœã®åæã劚害ãããš
ããããšãèããããã æ¬çºæã®å®æœäŸã«ã€ããŠç€ºãããããŠäžè¿°ãã
ããã«ãåã ã®ç现èã®éã«çµåããŠããå質ãª
ãšã¹ããã²ã³ã®æ¬ ä¹ã¯ãè «çã®çå®ã®ãšã¹ããã²
ã³å容åã®æž¬å®ã®éã®äž»ãªé害ã§ããã®ã§ãå²åŒ
ããŠçŸããã ïŒããããªãããããã¯ãäœçœ®çã«è «çå ã§ç
ç£ãããåã ã®çŽ°èã®äžæ§ã§ãªã飜åãå°ããŠã
ããã«ã¢ã³ã«ãã圹å²ãä»ãããã®ã§ãªããïŒ æ¬çºæã®å®æœã«ããåŸããã现èååŠçããŒã¿
ã¯åãç¹ç¶è ºè «åã³å¥³æ§ã®ä¹³è ºè «ã®èžã®çµç¹ãã
äžç®çŽ°èã«ãåºè³ªçŽ°èã«ããä»æ€åºãããããšã
ãã®ãšã¹ããã²ã³å容åãå¢å ããããšãã芳å¯
ãæ¯æããã ãåãã®ããã«ãæ¬çºæã¯ãäŸãã°ãç¹å¥ã®å
ç §äŸãšããŠ17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒâ
ã«ã«ããã·ã¡ãã«ïŒãªãã·ã ïŒåçã®è¡æž ã¢ã«ã
ãã³ïŒãã«ãªã¬ãã»ã³ã»ã€ãœããªã·ã¢ããŒãè€å
äœã®å©çšã«ã€ããŠè¿°ã¹åäŸèšŒããããã®è€åå€ã®
ååæ§é ã¯æ¬¡ã®ããã«å³ç€ºã§ããã ããã²ã¹ããã³ã®å ·äœäŸ äžè¿°ã®ããã«ãæ¬çºæã¯åãããã²ã¹ããã³â
èçœè³ªâææè€åäœãçšããŠãå®æœã§ããããã®
å ·äœçãªæ¹æ³ãããã§è¿°ã¹ãå³ç€ºãããã æ¹æ³ïŒ11âäœã®ããã²ã¹ããã³çµå 11αâãã€ãããã·ããã²ã¹ããã³ã»ãããµã¯ã·
ãã€ãã®åæ ãšã«ã©ã³ã¬ãŒçïŒå ç«åŠåå ç«ååŠã®æ¹æ³ã
å·»ãp.148ãC.A.WilliamsåM.W.Chaseèãã¢ã«
ãããã¯ãã¬ã¹ãN.Y.ã1967ïŒåãããã€çïŒJ.
Med.Chem.10ïŒ199ã1967ïŒã«ãã€ãŠèŠçŽããã
äžè¬çãªåçã«åŸã€ãŠã11αâãã€ãããã·ãã
ã²ã¹ããã³ïŒ10ïœïŒïŒSigma Chem.Co.ãSt.
LouisãMOïŒãšç¡æ°Žã³ãã¯é žïŒ10ïœïŒã®ä¹Ÿç¥ã
ãªãžã³ïŒ100mlïŒæº¶æ¶²ã調補ãã20æéçªçŽ ã¬ã¹
äžã§éæµãããå·åŽããåå¿æ··å液ãç æ°·ãå«ã
ã å·ãå¡©é žæ°Žæº¶æ¶²ïŒ3N.500mlïŒã«æ³šãå ¥ããã¯
ãããã«ã ã§æœåºãããã¯ãããã«ã ãèžçºãã
åŸãæ®äœãã¢ã»ãã³âãããµã³ãåã³ã¢ã»ãã³ã§
ãããããåçµæ¶ãããšãèç¹ã148â152âã®çœ
ãçµæ¶ã4.5ïœïœåŸãããã0.1NâNaOHäžã§ã®
åžåã®æ倧ã¯243nïœã§ãã€ãããããã®ç¹åŸŽã¯
11αâãã€ãããã·ããã²ã¹ããã³ãããµã¯ã·ã
ãŒãã«å¯Ÿããæç®ïŒãªã³ãããŒçSteroids 19ïŒ
357â375ã1972ïŒã«æžããããã®ãšäžèŽããŠã
ãã FITCâBSAè€åäœã®èª¿è£œ äžè¿°ãšåãæ¹æ³ãåã³æ¡çšã§ããã 11αâãã€ãããã·ããã²ã¹ããã³ã»ãããµã¯ã·
ããŒãâBSAâFITCïŒè¢å ããã²ã¹ããã³â11
âè€åäœïŒã®èª¿è£œ 17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒâã«ã«ãã
ã·ã¡ãã«ïŒãªãã·ã ã®ä»£ãã«ã11αâãã€ããã
ã·ããã²ã¹ããã³ã»ãããµã¯ã·ããŒããçšãã以
å€ã¯ãè¢å ãšã¹ãã©ãžãªãŒã«è€åäœã®èª¿è£œã«çšã
ãäžè¿°ã®æ¹æ³ãåã³çšããããšãã§ããã çããæçµè€åäœã®æ§é ãäžèšã«ç€ºãã ãã®æçµã®è¢å ã®ããããã²ã¹ããã³â11âè€
åäœã«éçããã¹ããã€ãæ®åºã®æ°ã¯ããšã«ã©ã³
ã¬ãŒçã«ããæ¹æ³ïŒJ.Biol.Chem.228ïŒ713ã
1957ïŒãçšããŠããžãããããšããŒã«åã«ãã決
å®ããããå¹³åããŠã11ã¢ã«ã®è¢å ææãš26ã®ã
ã«ã¢ã³ãïŒã¢ã«ã®åçã®è¡æž ã¢ã«ããã³ã«éçã
ãã ãã®æè¡ã®ç¹å¹æ§ã¯ãè¢å ããã²ã¹ããã³è€å
äœã§ç现èäžã®ããã²ã¹ããã³å容äœã®çè²ã¯ã
éè¢å 11αâãã€ãããã·ããã²ã¹ããã³ã»ãã
ãµã¯ã·ããŒãâåçã®è¡æž ã¢ã«ããã³ååç©ã«æŒ
ãçµç¹çã®äºãã€ã³ããŠããŒã·ãšã³ã«ãã€ãŠããŸ
ã劚ãããããšããäºå®åã³è¢å ããã²ã¹ããã³
è€åäœã¯ããç¥ãããéç®ççµç¹ãäŸãã°ãæé
è ºãè«æ§çªèµ·ããªã³ãè ºçµç¹åèè žç®¡ã®çè «ã®ã
ããªãã®ãçè²åºæ¥ãªããšããäºå®ã«ãã€ãŠæ¯æ
ã§ããã æ¹æ³ïŒïŒâäœã®ããã²ã¹ããã³çµå ïŒâããã¢ããã²ã¹ããã³ã®åæ ãŸã³ããã€ããŒçã®æ¹æ³ïŒJ.Am.Chem.
Soc.75ïŒ4712ã1953ïŒã«ãããããã²ã¹ããã³
ïŒ10ïœïŒãšïŒ®âããã¢ãµã¯ã·ã³ã€ããïŒïŒïœïŒã
ïŒæéåå¡©åççŽ ïŒ250mlïŒäžã§ç°æµããããã®
æ··å液ãéåŸã溶åªãèžçºãããæ®ã€ããã®ã
ãããµã³ã§æ©ç ãããšãèç¹ãçŽ139â142âã®ïŒ
âããã¢ããã²ã¹ããã³ãïŒïœåŸããããã¢ã»ã
ã³âãããµã³ããçµæ¶ãããããããŠãèç¹ã
141â144âã®åæãµã³ãã«ãšããã ããã²ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒã
ãªãšãŒãã«ã®åæ ãªã³ãããŒçã®æ¹æ³ïŒSteroids 19ïŒ357ã
1972ïŒã«ãã€ãŠãïŒâããã¢ããã²ã¹ããã³
ïŒ2.4ïœïŒãšããªã°ãªã³ãŒã«é žïŒ0.8ïœïŒããKOH
ïŒïŒïœïŒãå«ãã¡ã¿ããŒã«ïŒ100mlïŒã«å ãããã
ã®æ··å液ãïŒæéç°æµãããã¡ã¿ããŒã«ã®å€§éšå
ãèžçºãããåŸãæ®ããæ°ŽïŒ100mlïŒã§ãšãããŠ
ãããPHïŒã«ãªããŸã§HClïŒ10ïŒ ïŒã§é žæ§ã«ãã
ãšãŒãã«ã§æœåºããããããããšãŒãã«å±€ã
NaHCO3æ°ŽïŒ0.1NïŒã§æœåºãããHClïŒ10ïŒ ïŒã§
ã¢ã«ã«ãªæœåºç©ãé žæ§ã«ãããšãæ²æŸ±ãçããã®
ã§ããããéããŠéããæ°ŽæŽãã也ç¥ããé ¢é ž
ãšãã«âç³æ²¹ãšãŒãã«ã§åçµæ¶ããããæçµçæ
ç©ïŒ0.55ïœïœïŒã¯146â149âã®èç¹ããã€ãŠã
ãã ããã²ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒâã
ãªãšãŒãã«âBSAâFITCïŒè¢å ããã²ã¹ããã³
âïŒâè€åäœïŒã®èª¿è£œ ãžã¡ãã«ãã«ã ã¢ã«ãããïŒïŒmlïŒäžã®ããã²
ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒããªãšãŒ
ãã«ïŒ100mgïŒãšãæ°ŽïŒ10mlïŒäžã®ïŒâãšãã«â
ïŒâïŒïŒâãžã¡ãã«âã¢ãããããã«ïŒã«ã«ããž
ã€ããã»ãã€ããã¯ãã©ã€ãïŒ100mgïŒã®æ··å液
ãã宀枩ã§20åéæ¹æãããªã³é žå¡©ç·©è¡¡æ¶²ãçšã
ãªãã§åœéã®èçœè³ª100mgãå«ãåçã®è¡æž ã¢ã«
ããã³âãã«ãªã¬ãã»ã³ã»ã€ãœããªã·ã¢ããŒã
ïŒ10mlïŒã®æ°Žæº¶æ¶²ã«å ããããããïŒâã§ïŒæ¥é
æ¹æããåŸãNaHCO3ïŒ0.05MïŒæº¶æ¶²ã§äžæ¥éæ
ãã次ã«ïŒæ¥éããªã³é žå¡©ã§ç·©è¡¡åããå¡©ïŒPH
7.4ïŒã§æŽã«éæããããã®æçµè€åäœãæ²æŸ±ã
é€ãããã«é å¿åé¢ããããã®äžæŸæ¶²ã«ãé²è å€
ãšããŠã¢ãžåãããªãŠã ãïŒmgïŒmlã®æ¿åºŠã«ãªã
ããã«å ããã æçµçãªè€åäœã®æ§é ã次ã«ç€ºãã æçµçãªè¢å ããã²ã¹ããã³âïŒâè€åäœã«é
çããã¹ããã€ãæ®åºã®æ°ã¯ããšã«ã©ã³ã¬ãŒçã®
æ¹æ³ïŒJ.Biol.Chem.228ïŒ713ã1957ïŒã«ãããžã
ããããšãã«åã«ãã決å®ãããå¹³åããŠ11ã¢ã«
ã®è¢å ææãš26ã¢ã«ã®ãã«ã¢ã³ãåçã®è¡æž ã¢ã«
ããã³ïŒã¢ã«ã«éçããã ç现èããã²ã¹ããã³å容äœãæ€åºããããã®
è¢å ããã²ã¹ããã³âïŒâè€åäœã®äœ¿çšæ¹æ³ã¯ã
è¢å ãšã¹ãã©ãžãªãŒã«è€åäœåã³è¢å ããã²ã¹ã
ãã³â11âè€åäœã«ã€ããŠäžè¿°ããã®ãšåãã§ã
ãã çè²ã®ç¹ç°æ§ã«ã€ããŠã¯ãéè¢å ããã²ã¹ãã
ã³âïŒâBSAè€åäœåã¯ãéè¢å ããã²ã¹ãã
ã³â11âBSAè€åäœãçšããæè¡ã«ããããã®
è€åäœãäžã«è¿°ã¹ãããã«éæšççµç¹ãçè²ã§ã
ãªãã€ãããšã«ããæ¯æãããã ïŒã€ã¯11ã®äœçœ®ãããïŒã€ã¯ïŒã®äœçœ®ã§ã®ãã
ãïŒã€ã®è¢å ããã²ã¹ããã³è€åäœã®èª¿è£œã«æå
ããããšã¯ã人éã®çµç¹ã«æŒããã«ã¢ã³å容äœã®
æ€åºãžã®çŽ°èååŠçãªå¯èœæ§ã瀺ããèçœè³ªãã€
ãªã€ãŒã«ã€ããŠããã°ãè¢å è€åäœäžã®ã¹ããã€
ããã«ã¢ã³ã®æ¿åºŠã¯ã人éã®äœæ¶²äžã®ççåŠçæ¿
床ã®10äžåãã100äžåã«éããããã®é«æ¿åºŠã¯ã
ççåŠçPHç¯å²ã®æ°Žæº¶æ¶²äžã«ããããã溶ããŠã
ããã«ãªã¬ãã»ã³âã¹ããã€ãååç©ããã€ããš
ããŠãã现èååŠçå容äœã®ãã¬ãŒãµãŒãšããŠã
æå¹ã«æ¡çšããããšã¯åºæ¥ãªããããå¿ ç¶çã§ã
ãã ãããïŒã€ã®è¢å è€åäœã®ãã¡ã11αâãã€ã
ããã·ããã²ã¹ããã³ã»ãããµã¯ã·ããŒãâ
BSAâFITCïŒæ¹æ³ïŒã¯å®¹æã«èª¿è£œã§ããåè
çœè³ªã®ããªãã®éãããã²ã¹ããã³âïŒâïŒã«ã«
ããã·ã¡ãã¬ã³ïŒããªãšãŒãã«âBSAâFITC
ïŒæ¹æ³ïŒã®èª¿è£œã®éã®æçµæ®µéã§å€æ§ãåãã
ã®ã§ãåéãé«ããããããªãããäž¡æ¹ã®äŒãŠã¯
å ±ã«ã䟿å©ãªããã²ã¹ããã³å容äœã®ãã¬ãŒãµãŒ
ã調補ããã®ã«å©çšãããããããã¯ããªã³ã°
ïŒïŒã®äœçœ®ïŒããªã³ã°ïŒ11ã®äœçœ®ïŒãã¹ããã€
ããã«ã¢ã³âããã²ã¹ããã³ã®ç¹ç°ãªæ©èœããã€
åºã«åœ±é¿ãäžããªãååŠçãªæãšããŠå©çšã§ãã
ãšããå ç«åŠç芳枬ãšäžèŽããŠããã ãã®å¿é¡è ã«ãã11äŸã®äººéã®ä¹³çã®ç 究ã¯ã
ããã²ã¹ããã³å容äœã¯ãã¯ããè «ç现èã®çŽ°è
æ žã«äœçœ®ããŠããŠããšã¹ããã²ã³å容äœéœæ§ç现
èããå«ãçã«æŒãŠèµ·ãããã«ã¿ãããšããããš
ã瀺ãããã®ã¯èå³æ·±ããããã²ã¹ããã³å容äœ
åã³ãšã¹ããã²ã³å容äœã®ã©ã¡ãããåžžã«äºã«äŒŽ
ã€ãŠçãããããŠåã现èäžã«ååšãããã©ãã
ã¯ããŸã å šã確ãããããŠããªãã ãšã¹ããã²ã³å容äœãšããã²ã¹ããã³å容äœçŽ°è
ã®åææ€åº æ¬çºæã®å®æœäŸã¯æŽã«ããšã¹ããã²ã³å容äœãš
ããã²ã¹ããã³å容äœçŽ°èã®åææ€åºã«ã€ããŠæ¬¡
ã«è§£èª¬ããã ããã§çšããããè©Šè¬ãšããŠãè©Šè¬ïŒ¡ã¯ã17β
âãšã¹ãã©ãžãªãŒã«âïŒâCMOâBSAâFITC
ãäžã«æŠç¥èª¬æããããã«ããŠèª¿è£œããã è©Šè¬ïŒ¢ã¯ã11αâãã€ãããã·ããã²ã¹ãã
ã³ã»ãããµã¯ã·ããŒãâBSAâããã©ã¡ãã«ã
ãŒããã³ã»ã€ãœããªã·ã¢ããŒãã§ããã ãã®è©Šè¬ã¯ãããã©ã¡ãã«ããŒããã³ã»ã€ãœã
ãªã·ã¢ããŒãããã«ãªã¬ãã»ã³ã»ã€ãœããªã·ã¢ã
ãŒãã®ä»£ãã«çšãã以å€ã¯11αâãã€ãããã·ã
ãã²ã¹ããã³ã»ãããµã¯ã·ããŒãâBSAâFITC
ã«ã€ããŠäžã«è¿°ã¹ãã®ãšåãæ¹æ³ã§èª¿è£œããã è©Šè¬ïŒ¡ãšè©Šè¬ïŒ¢ã¯æ¬¡ã«ãåœã¢ã«æ··åããçãã
æ··å液ã10-4ãã10-3Mã®çµåãããšã¹ãã©ãžãª
ãŒã«åã³ãããšã»ãŒåæ¿åºŠã®çµåããããã²ã¹ã
ãã³ãå«ããã®ãšãããã¹ããã€ã ãã«ã¢ã³æ
åã®ãã«ãªãã¯ããŒã ææåäœã«å¯Ÿããå¹³ååå
æ¯ã¯ãçŽïŒïŒïŒãšïŒïŒïŒã®éã§ãäžè¬ã«ã¯çŽïŒïŒ
ïŒã§ããã çè²ã®æ¹æ³ 次ã«æ€æ»ãã¹ãçµç¹çŽ°çãåããè©Šè¬ïŒ¡ãšè©Šè¬
ã®äžè¿°ã®æ··å液ã§çè²ããã ãã®ããã«ããŠçè²ãããçµç¹çã¯ã次ã«ïŒã»
ããã®ãã€ã«ã¿ãŒã§ãïŒã€ã¯ãã«ãªã¬ãã»ã³ã»ã€
ãœããªã·ã¢ããŒãã®åºæ¿ïŒåèµ·ïŒã«å¯ŸããŠéžææ§
ããããããïŒã€ã¯ãããŒããã³ã»ã€ãœãã¢ããŒ
ãã®åºæ¿ã«å¯Ÿãéžææ§ã®ãããã®ãè£ åããè¢å
é¡åŸ®é¡ã§æ€æ»ããããã®ãããªãã€ã«ã¿ãŒã䜿ã€
ãå©ç¹ã¯ããšã¹ããã²ã³å容äœäœçœ®ã¯ãèŒããã
ãªç·è²ã瀺ããäžæ¹ããã²ã¹ããã³å容äœäœçœ®
ã¯ãæããããªã¬ã³ãžè²âèµ€è²ã®è¢å ã瀺ããšã
ãããšã§ããããã®æè¡ã«ãããäžè¿°ã®æ··å液ã
䜿ã€ãŠããšã¹ããã²ã³å容äœãšããã²ã¹ããã³å
容äœãšäž¡æ¹ã®ååšãåæã«æ€åºã§ããããååäž
çµç¹æšæ¬ã§ç®ã§èŠãªããæ€æ»ã§ããã çµ æ æ¬çºæã®åèšã®å ·äœäŸã䜿ã€ãŠã12äŸã®ä¹³çå
ã³ïŒäŸã®åå®®å èçããã®ååãããå容äœåæ
æ¹æ³ã§æ€æ»ããããã®ç 究ã«ãããåã ã®ãã«ã¢
ã³ã«å¯Ÿããåäžç现èã®çµåèœåã¯ãåäžã¬ãã«
ã§ã¯ãªããããããªããã倧æµã®ãšã¹ããã²ã³å
容äœéœæ§ç现èã¯ãå®ã«ããã²ã¹ããã³å容äœã
å«ããšãã芳枬ã確ãããããã匱ããšã¹ããã²
ã³çµåã瀺ãè¯æ§ã®åºè³ªçŽ°èã¯ã女æ§ã®ä¹³æ¿ã®å Ž
åã«ã¯ãããã²ã¹ããã³çµåèœåãæã€ãŠããã
ãã«ã¯ã¿ããªããïŒäŸã®åå®®å èçã¯ãéåžžã«åŒ·
ãåºè³ªã®ããã²ã¹ããã³å容äœæŽ»æ§ã§ãã€ããã
åºè³ªäžã«ã¯ãå ±åãããšã¹ããã²ã³çµåã¯ãªãã€
ãã ãã®çµæã¯æŽã«ãïŒéšè€åååãšããŠçµåãã
æãè¢å ã¹ããã€ããã«ã¢ã³ã¯ããšã¹ããã²ã³å
容äœãšã¯å¥ãªå容äœåä¹³çãšã¯å¥ãªçµç¹ã®æ€æ»å
ã³åå®ã«äœ¿çšããããšããããšãå®èšŒããŠããã è¢å ããã²ã¹ããã³è€åäœã®åæã«é¢ããæ¬å®
éšã¯åãæ¬çºæã®å®æœããä»ã®å€©ç¶åã¯åæã®ã¹
ããã€ã ãã«ã¢ã³ïŒäŸãã°ããã¹ãã¹ããã³ã®
ãããªã¢ã³ããã²ã³ãã«ã¢ã³ãã17αâãã€ãã
ãã·ã³ã«ãã³ã¹ããã³ïŒå³ã¡ããã€ããã³ã«ããŸ
ã³ãã³ã«ããŸãŒã«ïŒã®ãããªã¢ãã¬ïŒã³ã«ãã»ã
ã«ã¢ã³ã®ïŒéšåè€åäœã䜿ããšããããšãå«ãã
ãšãæ瀺ããŠããããã¹ãã¹ããã³èçœè³ªææãš
ã³ã«ããŸãŒã«âèçœè³ªææã®è€åäœã調補ããã
ãã®å®éšæé ã¯ã次ã«ç€ºãéãã§ããã è¢å ãã¹ãã¹ããã³è€åäœã®èª¿è£œ æ¹æ³ïŒ11ã®äœçœ®ã®ãã¹ãã¹ããã³çµå 11αâãã€ãããã·ãã¹ãã¹ããã³â11âãã
ãµã¯ã·ããŒãã¯ãäŸãã°ã¹ãã©ãã€ã瀟ããŠã€ã«
ãœã³ãããŠãŒãã³ãã·ã€ãŒïŒãããå ¥æããããš
ãã§ããããããã·ãŠïŒã¹ããã€ãã23ïŒ699â
711ã1974ïŒã«åŸã€ãŠåæããããšãã§ããã 11αâãã€ãããã·ãã¹ãã¹ããã³â11âãã
ãµã¯ã·ããŒã BSAâFITCïŒè¢å ãã¹ãã¹ãã
ã³â11âè€åäœïŒã®èª¿è£œã¯ã11âãã€ãããã·ã
ã¹ãã¹ããã³â11âãããµã¯ã·ããŒããã11αâ
ãã€ããããã²ã¹ããã³ã»ãããµã¯ã·ããŒãã®ä»£
ãã«äœ¿ããã以å€ã¯äžè¿°ã®è¢å ããã²ã¹ããã³â
11âè€åäœã®èª¿è£œãšåãæ¹æ³ã§å®æãããã çããæçµè€åäœã®æ§é ãã次ã«ç€ºãã æ¹æ³ïŒïŒã®äœçœ®ã®ãã¹ãã¹ããã³çµå ãã¹ãã¹ããã³â7αâã«ã«ããã·ã¡ãã« ã
ãªãšãŒãã«ã¯ããŠãšã€ã³ã¹ãã€ã³ã®æ¹æ³ïŒã¹ãã
ã€ãã20ïŒ789â812ã1972ïŒã«åŸã€ãŠèª¿è£œããã
ãšãã§ããã ãã®åŸãã¹ãã¹ããã³âïŒâïŒã«ã«ããã·ãšã
ã«ïŒããªãšãŒãã«âBSAâFITCïŒè¢å ãã¹ãã¹
ããã³âïŒâè€åäœïŒã®èª¿è£œã¯ããžã¡ãã«ãã«ã
ã¢ãããå«ãåªäœäžã§ãçµåå€ãšããŠïŒâãšãã«
âïŒâïŒïŒâãžã¡ã«ã¢ãããããã«ïŒãçšããŠå®
æãããããããæ¹æ³ã¯ããã¹ãã¹ããã³â7α
âã«ã«ããã·ãšãã« ããªãšãŒãã«ãããã®å Ž
åãããã²ã¹ããã³âïŒâïŒã«ã«ããã·ã¡ãã¬ã³ïŒ
ããªãšãŒãã«ã®ä»£ãã«çšãããã以å€ã¯ãâïŒäœ
眮ã®ããã²ã¹ããã³çµåâã«å¯Ÿããæ¹æ³ãšããŠ
äžè¿°ããæ¹æ³ã«ãªããã çããæçµè€åäœã®æ§é ã¯æ¬¡ã«ç€ºãã ã³ã«ãŸããŸã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãª
ãã·ã âBSAâFITCè€åäœïŒè¢å ã³ã«ããŸã«è€
åäœã®èª¿è£œïŒ ã³ã«ããŸã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãª
ãã·ã ã¯ãã¢ãŒãã«ããšãžãšãŒã ã¹ã®æ¹æ³ïŒã¹ã
ãã€ã 18ïŒ789ã1971ïŒåã³ããã¢ãŒãã€çã®
æ¹è¯æ³ïŒã¹ããã€ã 26ïŒ267ã1975ïŒãçšããŠ
åæã§ããã ã³ã«ããŸã«âïŒâCMOâBSAâFITCã®èª¿è£œ
ã¯ãã³ã«ããŸã«âïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒ
ãªãã·ã ãã17βâãšã¹ãã©ãžãªãŒã«âïŒâïŒïŒ¯
âã«ã«ããã·ã¡ãã«ïŒãªãã·ã ã®ä»£ãã«çšããã
ã以å€ã¯ãã¯ããè¿°ã¹ã17βâãšã¹ãã©ãžãªãŒã«
âïŒâCMOâBSAâFITCè€åäœãšåãæ¹æ³ã
çšããŠå®æããã æçµè€åäœã®æ§é ã¯æ¬¡ã«ç€ºãã ãã¹ãã¹ããã³åã¯ã³ã«ããŸã«ãå«ãæçµè¢å
è€åäœã«éçããFITCååã®æ°ã¯ã0.1Nâ
NaOHäž495nïœã§ã®è€åäœã®åžåããèšç®ã§ã
ããæçµè€åäœã«éçããã¹ããã€ãæ®åºã®æ°
ã¯ããšã«ã©ã³ã¬ãŒçã®æ¹æ³ïŒClin.Chem.16ïŒ24ã
1970ïŒãçšãããžãããããšãã«ååã¯ãããªã
ãããã³ãŒã³ã¹ã«ãã³é žã«ããã¢ããåºã®æ±ºå®æ¹
æ³ïŒClin.Chem.16ïŒ24ã1970ïŒãçšããŠæ±ºå®ã§
ãããè€åäœã®åçã®è¡æž ã¢ã«ããã³ã®ååå
ã¯ãé«ãã¹ããã€ãïŒæææ¯ãšã溶液äžã®æå¹çµ
åã¹ããã€ããã«ã¢ã³ã®é«æ¿åºŠã確ä¿ãããã
ã«ã20ãã30ã®ãã¹ãã¹ããã³åã¯ã³ã«ããŸã«æ®
åºåã³ïŒãã11ååã®ãã«ãªã¬ãã»ã³ãæ ãã ä»æ¥ãŸã§èç©ãããçµéšãããåçµçµç¹çŽ°çäž
ã®å容äœããããåºããããè¢å ã¹ããã€ããã«
ã¢ã³è€åäœã䜿ãããã«ã¯ãïŒéšã®è€åäœããå
容äœã«å¯Ÿããé«ã芪ååãä¿æããããã¹ããã€
ãæ®åºã®é©åœãªæ°ãæ ãçã§ãããããã€ãªã¢ãŒ
ãŠãããã«éçãããã«ãªãã¯ããŒã ææååã®
æ°ã¯ãã»ã©æ±ºå®çã§ãªããšããããšãåã€ãŠã
ãããã€ãªã€ãŒãšããŠåçã®è¡æž ã¢ã«ã ãã³ã䜿
çšããå Žåã«ããã«ãªãã¯ããŒã ãšãã«ã¢ã³ã®æ¯
ã¯äžè¬çã«ã¯çŽïŒïŒïŒãããïŒïŒ25ãæå°ã§ã
ïŒïŒ50ã®ç¯å²å ã§ããã åç«è ºçµç¹åé è¡çµç¹ã«æŒããè¢å ãã¹ãã¹ã
ãã³åè¢å ã³ã«ããŸã«è€åäœã®é©çšã¯ããã§ã«è¿°
ã¹ãã®ãšåãäžè¬çæ¹æ³ã«åŸã€ãŠåæ±ãããã æ¬çºæã®ä»ã®å®æœäŸã«ã€ããŠè¿°ã¹ãã ãããããã¡ããã®ããšãšããŠã(a)äŸãã°ã«ã«
ããã·ã«åºãªã©ãæããããããéã®ãããªãç
æã®å¯èœæ§ã®ããé©åœãªèŠªæ°Žæ§ãã€ãªã¢ãŒæå
(b)ãäžè¿°ã®ãã€ãªã¢ãŒïŒäŸãã°ããããµã¯ã·ããŒ
ãåã¯ã«ã«ããã·ã¡ãã¬ã³ ããªãšãŒãã«èªå°äœ
ã®åœ¢ã§ã®ãšã¹ããã²ã³ãåãããã¹ãã¹ããã³ã
ã³ã«ãã«ã«ãã«ã¢ã³èªå°äœçïŒãžã®çµåã«å¯Ÿãé©
åœãªååŠçãªæããã€æŽ»æ§ãã«ã¢ã³å€ããããŠ
(c)ãåè¿°ã®èçœè³ªæåã«çµåãããã«ãªãã¯ããŒ
ã æææãšããæ¬è³ªçãªç¹åŸŽããã®è©Šè¬ããã€é
ãããã®ãããªè©Šè¬ã®æ¹åŒãå€ããããåæ¬çºæ
ã®ç¯å²å ã§ããã«ã¢ã³âãã€ãªã¢ãŒâãã«ãªãã¯
ããŒã ææã®ä»ã®ååç©ã®çµåããå©çšããããš
ãã§ãããšããããšã¯ç解ã§ããã§ãããã äžã«ç€ºãããããªå ·äœäŸã®çš®ã ã®ç¹å¥ã®æ¹è¯ã¯
åœæ¥è ã«ãã€ãŠé©å®æ¡çšãããã§ãããã äŸãã°ããã«ã¢ã³æåãšãããŠãã«ãªãã¯ããŒ
ã ææãå³ã¡ã倧å€æ°ã®ã¢ããåºãå«ããããã®
èçœè³ªãšåæ§ã®ååŠçååç©ãšäž¡æ¹ãšçµåããå¯
èœæ§ããã€ã¢ããåºãå«ããªãã°ãä»ã®èçœè³ªã
ã€ãªã¢ãŒãéžãã§ãããã ãããã亀äºã®èçœè³ªãã€ãªã¢ãŒã®äŸãšããŠæ¬¡
ã«ååããããã åçŽèçœè³ªïŒã¢ã«ããã³é¡ãã°ãããªã³é¡ãã°ã«
ããªã³é¡ããããã©ã³é¡ãã¢ã«ãããã€ãé¡ã
ãã¹ãã³é¡åã³ããã¿ãã³é¡ã è€åäœèçœè³ªïŒæ žèçœè³ªãç³èçœè³ªãã ã³èçœ
質ããªã³èçœè³ªãè²çŽ èçœè³ªããªãèçœè³ªåã³
éå±èçœè³ªã èªå°èçœè³ªïŒç©ççååŠçæ¹æ³ã«ããå€æ§ããè
çœè³ªãããããªãŒã¹é¡ããããã³é¡ããããã
é¡ãïŒã€ã®ã¢ããæ³ã®ãžã±ãããã©ãžã³ç°ç¶ç¡
æ°Žç©ã å°ããšãïŒã€ã®ç¬¬äžçŽã¢ããïŒâNH2ïŒåºã
ãã€ã¢ããé žããèªå°ããããªããããé¡ã¯ãç
ããè€åäœãå å溶解æ§ããããªãã°ãããèªäœ
èçœè³ªã®ä»£ãã«å©çšã§ããã å ããŠãäºè æäžçã«ãäŸãã°ããªã°ãªã³ãŒã«
ãããªã°ãªã»ããŒã«ã®ãããªå€æ°ã®æ°Žé žåºããã€
ä»ã®æ°Žåæ§ååããã€ãªã¢ãŒïŒäŸãã°ãšã¹ãã«ã
ãšãŒãã«éãéããŠããã§çµåããïŒãšããŠå©çš
ã§ããã ä»ããã«ãªã¬ãã»ã³ããèªèº«ãéžæå©çšããã
ææã§ããäžæ¹ãããããã®ä»ã®ãã«ãªãã¯ããŒ
ã ææãã(1)ããã«è¿°ã¹ãçšéã«ä¿æãããããª
ãã¯ã€ããããè¢å ç¹æ§åã³(2)åè¿°ã®ããªâã¢ã
ãâã¿ã€ãã®èçœè³ªãã€ãªã¢ãŒç©è³ªãšçµåããå¯
èœæ§ãšããåºç€çãªèŠæ±ã«å¿ããããããã°ã圩
çšã§ãããããããŠæ¡çšãããŠããããã«ãªãã¯
ããŒã ææãäžèšã«ç€ºãã ãªãŒã©ãã³ïŒ¯ãããŒããã³ïŒ¢ãããŒããã³3Gã
ã¢ã¯ãªã°ã©ãã³ãã¢ã¯ãªãžã³ã»ãªã¬ã³ãžãã³ãªã
ã¹ãã€ã³ãã¢ã¯ãªãžã³ã»ã€ãšããŒãããªã¹ãã€
ã³ããã³ãŸãã©ãã³ãããªãã©ãã³TCNããã
ã€ã³ãã€ã³ããã°ãã©ã¬ããããã«ããªã³ããã
ã¯ãªã³ããªãããŒã«ãããã©ãµã€ã¯ãªã³ããã¢ãž
ã³ã¬ããããã¢ãŸãŒã« ã€ãšããŒïŒ§ãã³ã³ãŽã¬
ãããã¢ã·ãããã¯ã·ã³ãã¹ã«ããªããŒããã³
ããšãªã·ã³ïŒ¹ãããªã ãªã³ãããªãã©ãã³ïŒ³ã
ããã©ã¡ãã«ããŒããã³åã³ãžãããã«ã¢ãã³ã¹
ã«ãã³é žã æŽã«ãä»ã®ãšã¹ããã²ã³åãã«ã¢ã³ã17βâãš
ã¹ãã©ãžãªãŒã«ã®ä»£ãã«æ¡çšã§ãããããã¯ããš
ã¹ãã©ãžãªãŒã«ã¯ããšã¹ãã©ã²ã³ã®ãã¡ã®ïŒã€
ïŒæãéèŠãªåœ¢ã§ãããïŒã«ãããªãããæ¬çºæ
ã®å®æœã«åœã€ãŠã倧åãªããšã¯ãçæã®ç现èã
å容ãããããšã¹ããã²ã³ãæ¡çšãããšããããš
ã§ãããä»ã®ãã®ãããªååç©ãšããŠã¯ããã¡ã
ãããã®ïŒâïŒïŒ¯âã«ã«ããã·ã¡ãã«ïŒãªãã·ã
èªå°äœã®åœ¢ã§ã®17αâãšã¹ãã©ãžãªãŒã«ãã¯ãã
ã«æããããšãã§ããã ãã®ååç©ã¯ãäžã®äŸã§ãæ¡çšãã17βååç©
ã«æºæ ããããã¹ããã€ãç°ã®é¢ããäžã®17äœçœ®
ã«ãã«ã¢ã³ã®æ°Žé žåºã®ããååç©ã§ãããåºæ¬ç
ã«ã¯ãã·ã¯ããã³ããããšãã³ã¹ã¬ã³æ žãå«ã¿ã
ãã€ãïŒââã«ã«ããã·ã¡ãã« ãªãã·ã èªå°
äœãçæããèœåããã€ã©ããªãšã¹ããã²ã³åã
ãã¹ããã€ããã«ã¢ã³ã§ããæ¬çºæã®åè¿°ã®ãšã¹
ãã©ãžãªãŒã«ã®ãšããã«æ¡çšããŠãããããã
ã¯ããšã¹ããªãªãŒã«ããšã¹ããã³ãåæ§ã®ååç©
ãå«ãã§ããã åæ§ã«ãããã²ã¹ããã³ããã¬ã°ãã³ãžãªãŒ
ã«ããã¬ã°ãã³ããªãªãŒã«ãåã³ãã¬ã°ããããŒ
ã³ã®ãããªå€©ç¶ã®ããã²ãã·ãšã³ãã«ã¢ã³ããå
åç©R5020ããã«ãšãã³ããã³ããã«ãšãããã¬
ã«çãå«ãåæã®ããã²ã¹ããã³ãå«ããä»ã®ã
ãã²ã¹ããã³ ãã«ã¢ã³ã䜿ãããšãã§ãããã
ããã®ååç©ã¯ãããã²ã¹ããã³ã«ã€ããŠäžè¿°ã
ãåæ§ã®æ¹æ³ã§ãïŒäœçœ®åã¯11äœçœ®ã«ååŠççµå
ã«ãã€ãŠããã¿ã€ããã€ãªã¢ãŒã«çµåãããã ãã®ããã«ããŠãç现èäžã®ãã«ã¢ã³å容äœã
æ¢ãåºãããã«ïŒåæååè€åäœã䜿ããã®æ¹æ³
ã¯ãè¢å é¡åŸ®é¡ã§ãã®çžåœããå容äœãåŸãåºã
æ€åºããã®ã«é©åœãªããã²ã¹ããã³ããã¹ãã¹ã
ãã³ãã³ã«ããŸãŒã«ïŒè³¢èµç®è³ªãã«ã¢ã³ããã€ã
ãã³ã«ããŸã«ãšããŠãç¥ãããïŒãå«ãè¢å è€å
äœãåæããã®ã«é©å¿ããããšãã§ããããšãæ
ãããšãªãã ããã äžè¿°ã®å®äŸã¯ãäŸãã°ãïŒäŸã®å¥³æ§ãã«ã¢ã³
ïŒãšã¹ãã©ãžãªãŒã«åããã²ã¹ããã³ïŒãïŒäŸã®ç·
æ§ãã«ã¢ã³ïŒãã¹ãã¹ããã³ïŒåã³ïŒäŸã®è èç®
質ãã«ã¢ã³ïŒã³ã«ããŸãŒã«ïŒã䜿çšããå Žåãå«
ãã§ããããæ¬çºæããããã ãã«éå®ããŠè§£é
ããã¹ãã§ãªãã åæã§è¿°ã¹ãã®ã¯ãåµå·£ãçŸäžžåã³è èã®ç®è³ª
ã«æŒãŠå€©ç¶ã«çæããæãéèŠãªã¹ããã€ããã«
ã¢ã³ã§ããããä¹³æ¿ããéé¢ããããåã¯ååŠç
ã«åæãããŠãåµå·£ãçŸäžžåè èç®è³ªã«ããçæ
ãããã¹ããã€ããã«ã¢ã³ã«ããçããã®ãšåæ§
ã®ççåŠçæ©èœãåãããããšã®ã§ããå€ãã®ã
ã«ã¢ã³å é§ç©è³ªããã«ã¢ã³ä»£è¬ç©è³ªãåã³ãã«ã¢
ã³é¡äŒŒç©ããããæããã«ãäžã«äŸèšŒãããšã¹ã
ã©ãžãªãŒã«ãããã²ã¹ããã³ããã¹ãã¹ããã³å
ã³ã³ã«ããŸãŒã«ã®ä»£çšã«çšãããããååŠç©è³ªã®
ãã¹ãŠãæ£ç¢ºã«ãªã¹ãããããšã¯äžå¯èœãªããšã§
ããããæ¬çºæããäŸãã°äººéã®æªæ§ã®çµç¹äžã®
察å¿ããå容äœã®æ€åºåå¿ã«é©åœã§ããïŒéšè€å
äœã®åœ¢ã®ä»ã®å€©ç¶åã³åæãšã¹ããã²ã³ã倩ç¶ã
ãã²ã¹ããã³ååæã®ããã²ã¹ãã€ã·ãšã³å€ãã
ããŠå€©ç¶åã³åæã®è èç®è³ªã¹ããã€ãåã¯ã¹ã
ãã€ãé¡äŒŒäœã®ãã¹ãŠã䜿çšããããšãŸã§æ倧é
åºãæŠå¿µã«æ¡å€§ãããšããããšããã®éã®å°é家
ã§ããã°ãèªèã§ããã ãããïŒåç §ãäŸãã°ã
ããã«ããšã€ããŒããŒèãççååŠè©è«ã第11
çãã©ã³ã²ããã€ã«ã« ãããªã±ã€ã·ãšã³ãºãã
ã¹ã¢ã«ãã¹ãã«ãªããªã«ãã¢ã1967ãã®436â
437ãå444ããŒãžã®ããããªååç©ã®äŸç€ºïŒ æŽã«ãèçœè³ªãã€ãªã¢ãŒã§ã€ãªããããã«çšã
ãååŠçãªæããæãéèŠãªå€©ç¶ã®çççæ©èœåº
ãšããã«ã¢ã³ååé 眮ãä¿æããããã«ã¹ããã€
ãååã®ïŒâãïŒâã7αâãããŠïŒåã¯11αâäœ
ã«äœçœ®ãããããšãã§ããã ããããªããããã®ååŠçãªæããããã«éå®
ããããã®ã§ã¯ãªãããååã®9αâã17âãå
ã³21äœãå«ãã¹ããã€ããã«ã¢ã³ã®ä»ã®å Žåã«ã
äœçœ®ããããšãã§ããã åäžã«è¿°ã¹ãããã«ãè€åäœäžã®èçœè³ªååã«
éçããå°ããšãïŒã€ã®ãã«ãªãã¯ããŒã ææå
åãšå°ããšãïŒã€ã®ãã«ã¢ã³ååãååšãããã
ãã®è€åäœãçšããããšã¯äŸ¿å©ã§ãããçµç¹å容
äœãžã®è€åäœã®èŠªååã匷ããããã«ãææåå
ã«å¯Ÿãããã«ã¢ã³ååã®æ¯ã¯ïŒä»¥äžã§ããããšã
æãŸãããåŸã€ãŠããã«ã¢ã³ã«å¯Ÿãããã«ãªãã¯
ããŒã ã®ååæ¯ã¯çŽïŒïŒïŒããïŒïŒ25ã®é床å ã§
ããã¹ãã§ãããçŽïŒïŒïŒããïŒïŒ10ãæãŸã
ãã äŸãã°25000ãã100000ã®å¹³åååéããã€è
çœè³ªãã€ãªã¢ãŒã«ã€ããŠã¯ãè€åäœäžã®èçœè³ªå
åã«å¯Ÿãããã«ãªãã¯ããŒã ææåååãã«ã¢ã³
ååã®æ¯ã¯ããã«ãªãã¯ããŒã ã«å¯ŸããŠã¯çŽïŒïŒ
ïŒãã20ïŒïŒããã«ã¢ã³ã«å¯ŸããŠã¯çŽ10ïŒïŒãš
40ïŒïŒã®éã®ç¯å²å ã§å€ããããã®ã¯äŸ¿å©ãªããš
ã§ããã æ¬æ¹æ³ã«é¢ãããããã¯äžã§ç¹ã«äŸç€ºãã以å€
ã®ååŠççµåããè€åæ§é ã«ãã«ã¢ã³æåãçµå
ãããããã«æ¡çšããŠãåãããšã§ãããšããã
ãšãå°é家ã§ããã°èªèããã ãããäŸãã°ãã«
ã«ããã·ã¡ãã«ã¢ãã³ã®ãšããã«ãåæã®ã¢ãã³
æ©èœåã³ã«ã«ããã·æ©èœããã€ä»ã®è£œå€ãããã®
ã¢ãã³ãã€ãã³æ§é æåãçæãããåã¯ãã«ã¢
ã³å®äœãšã®çµåãçæãããããŠãã«ã«ããã·åº
ãææå®äœãšã®ã«ã«ããã·ã¢ããçµåãšããŠãã®
åŸã®çµåã«å©çšã§ãããªãã°ãæ¡çšã§ããããã
ããè©Šè¬ã¯ã HO2CïŒCH2ïŒxONH2 ããã§ïœã¯ãäŸãã°ïŒä»¥äžã®å°ããæŽæ°ã§ãã
ãããªå€åãå«ãã æŽã«ãç¡æ°Žç¥çé žã®ä»£ãã«ã11âããã²ã¹ãã
ã³ãããµã¯ã·ããŒãèªå°äœãçæããããã«ãç¡
æ°Žã¢ãžãã³é žããããã¯ãåŽéã眮æããç¡æ°Žç¥
çé žãç¡æ°Žã¢ãžãã³é žã®ãããªä»ã®è©Šè¬ããç¡æ°Ž
ãã¿ãŒã«é žãç¡æ°Žããªã¡ãªããé žã®ãããªç¡æ°Žè³
éŠæé žãšåãæ§ã«æ¡çšã§ãããããªã°ãªã³ãŒã«é ž
ã®ä»£ãã«ãäºè æäžçã«ãä»ã®ã¡ã«ã«ããâã«ã«
ããã·é žããïŒâããã²ã¹ããã³èªå°äœãäŸãã°
βâã¡ã«ã«ããããããªã³é žãã¡ã«ã«ããç¥ç
é žãåã³ããªå®æ¯éŠé žã®ãããªèªå°äœãçæãã
ããã«ã䜿çšãããããã®ããã«ãè€åäœãã€ã
ãã®ã«äœ¿ããããã«ã¢ã³æåã¯æ¬¡ã®æ§é ããã€ã
ãšãæ©æ¢°çãªå¿ èŠæ¡ä»¶ã§ããã ãhormoreãââCO2H ããã§ïŒ¡ã¯ãã¹ããã€ãæ žãžã®ã«ã«ããã·ã«åº
ã®çµåã®çºã«æ¡çšãããè©Šè¬ã®ååæ®åºã§ããã æŽã«ãã«ã«ããžã€ããã¯ãçµåå€ã®å¯äžã®åºã§
ãããä»ã®ã¯ãã¹âãªã³ãã³ã°ã®ååŠçåå¿ãã
é©åœãªååŠçãªæã芪ååã«å°å ¥ããããªãã°ã
ãã€ãªã¢ãŒãšã¹ããã€ãåã¯ææãšãã€ãªã¢ãŒã®
çµåã«å©çšã§ããããã®äŸã¯äŸãã°ã (1) ããªãŒã«âããã«ã¢ãã³ãšã€ãœããã«ã¯ãã
ã«ã«ãããŒããçšããæ··åã¢ã³ãã€ãã©ã€ãæ³
ïŒãšã«ã©ã³ã¬ãŒçãJ.Biol.Chem.228ïŒ713ã
1958åã³J.Biol.Chem.234ïŒ1909ã1959ïŒ (2) ã·ã³ã¬ãŒãšã·ãã¯ã«ããå©çšããããžã€ãœã·
ã¢ããŒãæ³ïŒJ.BiophysãBnochem.Cytol.9ïŒ
519ã1961ïŒïŒ (3) ã¢ã¬ããµã³ããŒçã«ãããžããã²ã³åãããž
ããããã³ãŒã³æ³ïŒBio chem.J.52ïŒ177ã
1952ïŒïŒ ãå«ãã ãã«ã¢ã³ããã€ãªã¢ãŒãã«ãªãã¯ããŒã ææè€
åäœã«éçããåã«ããã«ãªãã¯ããŒã ææãæ
åã«ãã€ãªã¢ãŒååã«çµåããããšãçµåã®é åº
ãšããŠéèŠãªããšã§ãããšããããšã¯èšæ¶ããã¹
ãã§ãããã€ãœã·ã¢ããŒãåã³ã€ãœããªã·ã¢ããŒ
ããã¹ããã€ãã®ããªãŒã®ãã€ãããã·ã«åºãšå¥
ã«çž®åããå Žåãããã®ã§ãç¹ã«ããã«ãªãã¯ã
ãŒã ææã®ã€ãœã·ã¢ããŒãåã¯ã€ãœããªã·ã¢ããŒ
ãé¡ãè¢å æ瀺è¬ãšããŠçšããããæã«ã¯ããã
ãã¹ããã€ãã®æ°Žé žåºã®ãããªã¹ããã€ããã«ã¢
ã³ã®çççãªå®èœåºã®æ¶æ» ãé¿ããã ããããã
åŸè ã®åå¿ãèµ·ããªãã°ãå容äœã®ãã¬ãŒãµãŒãš
ããŠã®æåŸã®è¢å è€åäœã®ç¹ç°æ§ã¯åœ±é¿ããã
ããæèšããã°ãæçµã®ïŒæåè€åäœã¯ããã€ãª
ã¢ãŒâãã«ã¢ã³âææåã¯ããã«ã¢ã³âææâã
ã€ãªã¢ãŒè€åäœã®åœ¢ãããããããã«ã¢ã³âãã€
ãªã¢ãŒâææã®åœ¢ã§ããã¹ãã§ããã åŸã€ãŠããšã¹ããã²ã³åã¯ããã²ã¹ããã³åã¯
ä»ã®ã¹ããã€ãã®åã¯ãã«ã¢ã³ã®å容äœèœåãã
ã€ãšçãããŠããä¹³çåã¯ä»ã®çè «çµç¹ãµã³ãã«
ã«æŒãŠãæªæ§çŽ°èã®æ±ºå®ãšåå®ã®æ¹è¯ã«ãçŸåšå ¬
éãããŠããæ¹æ³ãšæè¡ã«ãã€ãŠæ¡çšããããæ°
ããã¯ã©ã¹ã®è¬å€ããæ¬çºæãæäŸããããšã¯ã
å è¿°ã®è°è«ããåãã§ãããã ããããŠã蚺çåã³èšºæãžã®éèŠãªè²¢ç®ãšã
ãŠããã«ã¢ã³çæ³ã®å©çšã«ããé®éã«ææãªæªæ§
ç©ããã€ä¹³çåã³ä»ã®çæ£è ã®æ€åºãšåå®ã®éã®
å©ããšããŠçºå±ããã ãã¡ãããç¹èš±è«æ±ã®ç¯å²ã®çæãšç®çã®ç¯å²
å ã§ãããã§è¿°ã¹ãæ¬çºæã®è²¢ç®ã®ç¹å¥ã®å®æœãš
å©çšã¯ããã¶ãããã®äžã§äŸç€ºããããã«å©çšã
ããç¹å¥ã®å ·äœçãªããæ¹ããé¢ããå€åããã§
ãããããšã¯ãå°é家ã§ããã°åšç¥ã®ããšã§ã
ãã ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äºã€ã®å§é»æ¯ååãšã äžèšäºã€ã®å§é»æ¯ååã®éã«åŒµèšããŠããæ¯æ
éšæãšã ãã®æ¯æéšæã«è£ çãããééãšã äžèšäºã€ã®å§é»æ¯ååã®ãããããçºæ¯ããã
äºã€ã®çºæ¯åè·¯ãšã äžèšäºã€ã®çºæ¯åè·¯ã®åºååšæ³¢æ°ã®å·®ããšãå
è·¯ãšãå ·åãã äžèšåºååšæ³¢æ°ã®å·®ããšãåè·¯ã®åºåã«ããå
é床ã枬å®ããããšãç¹åŸŽãšããå é床ã»ã³ãµã
Claims (1)
- å¹ãªæ€åºå€ã ïŒ äžèšããã«ã¢ã³ãã17βâãšã¹ãã©ãžãªãŒ
ã«ã17αâãšã¹ãã©ãžãªãŒã«ããšã¹ããã³ãåãš
ã¹ããªãªãŒã«ãã«ã¢ã³é¡ã®ã¯ã©ã¹ã§ãããšã¹ãã
ã²ã³ ãã«ã¢ã³ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒ äžèšããã«ã¢ã³ãããããã²ã¹ããã³ããã¬
ã°ãã³ãžãªãŒã«ããã¬ã°ãã³ããªãªãŒã«ãåãã¬
ã°ãããã³ãã«ã¢ã³é¡åã³ãååç©R5020ããã«
ãšã·ã€ã³ããã³ããã«ãšã·ããã¬ã«ã®åæã®ãã
ã²ã¹ãã€ã³ã®ã¯ã©ã¹ã®ããã²ã¹ããã³ãã«ã¢ã³ã
ãæãããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®æ€åºå€ã ïŒ äžèšããã«ã¢ã³ããã倩ç¶ãŸãã¯åæã®ãã¢
ã³ããã²ã³ãã«ã¢ã³ã§ããããšãç¹åŸŽãšããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒ äžèšããã«ã¢ã³ããã倩ç¶ãŸãã¯åæã®ã¢ã
ã¬ãã³ã«ãã«ã«ãã«ã¢ã³ã§ããããšãç¹åŸŽãšãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒ äžèšååæ¯çãçŽïŒïŒïŒããïŒïŒ25ã§ããã
ãšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã
ãããïŒé ã«èšèŒã®æ€åºå€ã ïŒ äžèšãã€ãªã¢ãŒããã¢ã«ããã³é¡ãã°ãããª
ã³é¡ãã°ã«ããªã³é¡ãããã©ãã³é¡ãã¢ã«ããã
ã€ãé¡ããã¹ãã³é¡åããã¿ãã³é¡ïŒæ žèçœè³ªã
ç³èçœè³ªãã ã³èçœè³ªããªã³èçœè³ªãè²çŽ èçœ
質ããªãèçœè³ªåã³éå±èçœè³ªïŒããããªãŒã¹
é¡ããããã³é¡ãããããé¡ãäºã€ã®ã¢ããé žã®
ãžã±ãããã©ãžã³ç°ç¶ç¡æ°Žç©ïŒåã³ãããªãã€ã
ããã·ååç©ããæã矀ããéžã°ãã芪氎æ§åäœ
ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã
第ïŒé ã®ããããïŒé ã«èšèŒã®æ€åºå€ã ïŒ äžèšãã«ãªãã¯ããŒã ãããªãŒã©ãã³ïŒ¯ãã
ãŒããã³ïŒ¢ãããŒããã³3Gãã¢ã¯ãªãã©ãã³ã
ã¢ã¯ãªãžã³ãªã¬ã³ãžãã³ãªããªã¹ãã€ã³ãã¢ã¯ãª
ãžã³ã€ãšããŒãããªã¹ãã€ã³ããã³ãŸãã©ãã³ã
ããªãã©ãã³TCNãããã€ã³ãã€ã³ããã°ãã©
ã¬ããããã«ããªã³ãããã¯ãªã³ããªãããŒã«ã
ããã©ãµã€ã¯ãªã³ããã¢ãžã³ã¬ããããã¢ãŸãŒ
ã«ã€ãšããŒïŒ§ãã³ã³ãã¬ãããã¢ã·ãããã¯ã·
ã³ãã¹ã«ãããŒããã³ïŒ¢ããšãªã·ã³ïŒ¹ãããªã ãª
ã³ãããªãã©ãã³ïŒ³ãããã©ã¡ãã«ããŒããã³å
ã³ããžãããã«ã¢ãã³ã¹ã«ãã³é žãåã³ãã«ãªã¬
ãã»ã³ ããæãã¯ã©ã¹ã®ææã§ããããšãç¹åŸŽãšããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ããããïŒé ã«èš
èŒã®æ€åºå€ã ïŒ äžèšããã«ã¢ã³ããã17βâãšã¹ãã©ãžãªãŒ
ã«ã§ãããäžèšèçœè³ªãã€ãªã¢ãŒããçã®è¡æž ã¢
ã«ããã³ã§ãããäžèšãã«ãªãã¯ããŒã ææãã
ãã«ãªã¬ãã»ã³ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒïŒ äžèšãã«ãªãã¯ããŒã ææã®ããã«ã¢ã³ã
ã«å¯Ÿããååæ¯çããçŽïŒïŒïŒããïŒïŒ10ã®éã§
ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®æ€åºå€ã ïŒïŒ èçœè³ªãã€ãªã¢ãŒããçŽ25000ãã100000
ã®éã®å¹³åååéããã€ããšãç¹åŸŽãšããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒïŒ ãã«ãªãã¯ããŒã ææã®èçœè³ªã«å¯Ÿããå
åæ¯çãçŽïŒïŒïŒãã20ïŒïŒã®éã§ãããããã«
ã¢ã³ãã®èçœã«å¯Ÿããååéæ¯ãçŽ10ïŒïŒãã
40ïŒïŒã®éã§ãããåŸã€ãŠãçµåããããã«ã¢
ã³ãæåããçççPHã®å®å®ãã氎溶液äžã§çŽ
10-2M以äž10-5MãŸã§ã®æ¿åºŠããã¡ããããšãç¹
城ãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ€åºå€ã ïŒïŒ (i) ããã«ã«ããã·ã«åºå°å ¥è©Šè¬ã®æ®åº
ã§ãããã¹ããã€ããââCO2Hæ§é ããã€
ãšã¹ããã²ã³ãã«ã¢ã³åã¯ããã²ã¹ããã³ãã«
ã¢ã³èªå°äœ (ii) ã«ã«ããã·ã¢ããéãéããŠãäžèšãã«ã¢ã³
ã«çµåããèçœè³ªåã¯ããªãããããã€ãªã¢ãŒ (iii) ã¢ããåºãéããŠäžèšãã€ãªã¢ãŒã«çµåãã
ãã«ãªãã¯ããŒã ææãšãããªãããã€äžèšã
ã«ãªãã¯ããŒã ææã®ãã«ã¢ã³ã«å¯Ÿããå¹³åå
åæ¯çãçŽïŒïŒïŒããïŒïŒ50ã®éã§ãããçµå
ããã¹ããã€ããã«ã¢ã³ãçççPHã®æ°Žæº¶æ¶²äž
ã§çŽ10-2Mãã10-5Mã®æ¿åºŠããã€ååè€åäœ
ããæ¬è³ªçã«æãããšãç¹åŸŽãšããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒïŒ (i) ãšã¹ããã²ã³ãã«ã¢ã³ã®ïŒâïŒïŒ¯âã«
ã«ããã·ã¡ãã«ïŒãªãã·ã èªå°äœ (ii) ã«ã«ããã·ã¢ããéãéããŠäžèšãã«ã¢ã³ã«
çµåããèçœè³ªåã¯ããªãããããã€ãªã¢ãŒå
ã³ (iii) ã¢ããåºãéããŠäžèšãã€ãªã¢ãŒã«çµåãã
ãã«ãªãã¯ããŒã ææãããªãããã€äžèšãã«
ã¢ã³ã«å¯Ÿããäžèšãã«ãªãã¯ããŒã ææã®å¹³å
ååæ¯çãçŽïŒïŒïŒãšïŒïŒ50ã®éã§ãããåã
氎溶液äžã§ã®ã¹ããã€ããã«ã¢ã³ã®æ¿åºŠãçŽ
10-2Mãã10-5Mã§ããååè€åäœããæ¬è³ªç
ã«æãããšãç¹åŸŽãšãããšã¹ããã²ã³å容äœç¹
æ§ããã€ççµç¹çŽ°èã®æ€åºã«æå¹ãªç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒïŒ (i) 11αâãã€ãããã·ããã²ã¹ããã³
ãããµã¯ã·ããŒã (ii) ã«ã«ããã·ã¢ããéã«ãã€ãŠäžèšãã«ã¢ã³ã«
çµåããŠããèçœè³ªåã¯ããªãããããã€ãªã¢
ãŒãåã³ (iii) ã¢ããåºã«ãã€ãŠäžèšãã€ãªã¢ãŒã«çµåãã
ãã«ãªãã¯ããŒã ææãããªãããããŠäžèšã
ã«ã¢ã³ã«å¯Ÿããäžèšãã«ãªãã¯ããŒã ææã®å¹³
åååæ¯çãçŽïŒïŒïŒãšïŒïŒ50ã®éã§ãããå
å°ããšãçŽ10-2Mãã10-5Mã®çµåããã¹ãã
ã€ããã«ã¢ã³æ¿åºŠããã€æº¶æ¶²ãæ°Žåªæ¶²äžã«çã
ãã§ããããããªååè€åäœããæ¬è³ªçã«æã
ããšãç¹åŸŽãšããããã²ã¹ããã³å容äœç¹æ§ã
ãã€ççµç¹çŽ°èã®æ€åºã«æå¹ãªç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®æ€åºå€ã ïŒïŒ (i) ããã²ã¹ããã³âïŒâã«ã«ããã·ã¡ã
ã¬ã³ããªãšãŒãã« (ii) ã«ã«ããã·ã¢ããéã«ãã€ãŠäžèšãã«ã¢ã³ã«
çµåããèçœè³ªåã¯ãã«ãããããã€ãªã¢ãŒã
åã³ (iii) ã¢ããåºã«ãã€ãŠäžèšãã€ãªã¢ãŒã«çµåãã
ãã«ãªãã¯ããŒã ææãããªãããã€äžèšãã«
ã¢ã³ã«å¯Ÿããäžèšãã«ãªãã¯ããŒã ææã®å¹³å
ååæ¯çãçŽïŒïŒïŒããïŒïŒ50ã®éã§ãããçµ
åããã¹ããã€ããã«ã¢ã³ããççPHã®æ°Žæº¶æ¶²
äžã§çŽ10-2Mãã10-5Mã®æ¿åºŠãã〠ååè€åäœããæ¬è³ªçã«æãããšãç¹åŸŽãšããã
ãã²ã¹ããã³å容äœç¹æ§ããã€ççµç¹çŽ°èã®æ€åº
ã«æå¹ãªç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ€åºå€ã ïŒïŒ çã®çãã®ããçµç¹ãåé€ããåçµããæª
çç¶ã§ä¹Ÿç¥ããååŠçã«åºå®ãããªãæ¡ä»¶ã«ç¶æ
ããŠããã (1) ãã®çµç¹çããã»ãŒççåŠçPHç¯å²ãæã€ã
ãªã³é žå¡©âç·©è¡¡åãããå®è³ªçã«ç匵ã®å¡©æº¶æ¶²
äžã§æ°ŽååŠçããã (2) åŒ ããã«ã¢ã³ãâããâãèçœè³ªåã¯ããªããã
ããã€ãªã¢ãŒãâããã«ãªãã¯ããŒã ã ãæãããã®ã§ãã€ãŠã (a) äžèšããã«ã¢ã³ããå ±æçµåã§ââã«çµ
åããã¹ããã€ãåååäœã§ããã (b) äžèšââããå ±æçµåããååŠçéã§ã
ãã (c) äžèšããã€ãªã¢ãŒãããããããïŒä»¥äžã®
ããã«ã¢ã³ãââç©è³ªããã³æŽã«ïŒä»¥äžã®ã
ã«ãªãã¯ããŒã ææç©è³ªã«å ±æçµåããããš
ã®ã§ããå€æ©èœãªèŠªæ°Žæ§ååã§ããããã
ãŠã (d) äžèšããã«ãªãã¯ããŒã ãããäžèšãã€ãª
ã¢ãŒã«å ±æçµåãåãå ç §å°ã®äžã§ç®ã«èŠã
ãŠã¯ã€ãããšèŠ³å¯ã§ããè²ã瀺ãããšã®ã§ã
ãå°ããšãïŒã€ã®ææåäœã瀺ãããã€äžèš
ãã«ã¢ã³ã«å¯Ÿããäžèšãã«ãªãã¯ããŒã ææ
ã®å¹³åååæ¯çãçŽïŒïŒïŒãšïŒïŒ50ã®éã§ã
ããåçµåããã¹ããã€ããã«ã¢ã³ããçç
åŠçPHã®æ°Žæº¶æ¶²äžã§çŽ10-2Mãã10-5Mã®æ¿
床ããã¡ãã ååè€åäœãäžèšã®ããã«åŠçãããçµç¹çã«
ã³ãŒãã€ã³ã°ããããš (3) ãã®åŸäžèšçµç¹æšæ¬ããäžèšååè€åäœã®ã³
ãŒãã€ã³ã°ãé€å»ãããããŠãã»ãŒçççPHç¯
å²ããã€ãªã³é žå¡©âç·©è¡¡åãããæ¬è³ªçã«ç匵
ã®å¡©æº¶æ¶²ã§è©²æšæ¬ããããããã®åŸããããŠæ
åºãããçµç¹çã®çŽ°èã®äžã«æ®ãè¢å ææã®åº
çŸã®æç¡ãè©Šéšããããš ããæ¬è³ªçã«æãããšãç¹åŸŽãšããã¹ããã€ãã
ã«ã¢ã³å容äœç¹æ§ããã€ççµç¹çŽ°èã®æ€åºæ¹æ³ã
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87656478A | 1978-02-10 | 1978-02-10 | |
| US94770078A | 1978-09-29 | 1978-09-29 | |
| US06/001,205 US4215102A (en) | 1979-01-05 | 1979-01-05 | Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS54119993A JPS54119993A (en) | 1979-09-18 |
| JPH022104B2 true JPH022104B2 (ja) | 1990-01-16 |
Family
ID=27356864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1488879A Granted JPS54119993A (en) | 1978-02-10 | 1979-02-10 | Method and cytochemical agent for detecting steroid hormone acceptor in human tissue |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0003583B1 (ja) |
| JP (1) | JPS54119993A (ja) |
| AU (1) | AU529917B2 (ja) |
| CA (1) | CA1129758A (ja) |
| DE (1) | DE2961490D1 (ja) |
| IL (1) | IL56467A (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3167327D1 (en) * | 1980-09-08 | 1985-01-03 | Int Diagnostic Tech | Fluorescent reagent and immunofluorescent determination method |
| US4571388A (en) * | 1983-01-24 | 1986-02-18 | Becton Dickinson And Company | Detection of reticulocytes |
| EP0134307B1 (de) * | 1983-07-29 | 1989-04-19 | Henning Berlin GmbH Chemie und Pharmawerk | Voraktivierte KunststoffoberflÀchen zur Immobilisierung von organisch-chemischen und biologischen Materialien, Verfahren zur Herstellung und Verwendung derselben |
| AU620327B2 (en) * | 1987-04-08 | 1992-02-20 | Salutar, Inc. | Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor |
| US5008099A (en) * | 1987-04-08 | 1991-04-16 | Salutar, Inc. | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor |
| CA2283597C (en) * | 1998-10-02 | 2008-02-05 | Ortho-Clinical Diagnostics, Inc. | Reduced cortisol conjugates |
| EP1238285A1 (en) * | 1999-11-30 | 2002-09-11 | Akzo Nobel N.V. | Steroid compounds for steroid receptor binding assays |
| GR1004274B (el) * | 2002-07-16 | 2003-06-23 | Medexis ￜￜￜￜ | Î£Ï ÎŒÏλοκα ÏÏεÏοειΎÏÎœ οÏΌοΜÏÎœ Όε ÏÏÏÏειΜεÏ: ÎœÎµÎµÏ Î¿Ï ÏÎ¹ÎµÏ Î³Î¹Î± ÏηΜ ειΎικη αΜιÏÎœÎµÏ Ïη και καÏαÏÏÏοÏη καÏκιΜικÏÎœ ÎºÏ ÏÏαÏÏÎœ ÏÏοεÏÏοΌεΜÏÎœ αÏο ÏÏεÏÎµÎ¿Ï Ï Î¿Î³ÎºÎ¿Ï Ï ÎºÎ±Î¹ αιΌαÏÎ¿Î»Î¿Î³Î¹ÎºÎµÏ ÎºÎ±ÎºÎ¿Î·ÎžÎµÎ¹ÎµÏ |
| FR2848857B1 (fr) | 2002-12-20 | 2005-09-16 | Gambro Lundia Ab | Dispositif et ligne a usage unique pour le traitement extracorporel du sang par anticoagulation au citrate |
| DE102008046781A1 (de) * | 2008-09-11 | 2010-03-18 | Mitsubishi Polyester Film Gmbh | SiegelfÀhige, biaxial orientierte Polyesterfolie |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | UniversitÀtsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| CN115353541B (zh) * | 2022-09-01 | 2024-06-18 | è±ç§æ°åïŒèå·ïŒçç©ç§ææéå ¬åž | éäºéè¡çç©çå¶å€æ¹æ³ïŒäžéŽäœãå ¶å¶å€æ¹æ³ååºçš |
-
1979
- 1979-01-19 IL IL5646779A patent/IL56467A/xx unknown
- 1979-01-25 AU AU43676/79A patent/AU529917B2/en not_active Ceased
- 1979-01-31 CA CA320,580A patent/CA1129758A/en not_active Expired
- 1979-02-05 EP EP19790100329 patent/EP0003583B1/en not_active Expired
- 1979-02-05 DE DE7979100329T patent/DE2961490D1/de not_active Expired
- 1979-02-10 JP JP1488879A patent/JPS54119993A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| CA1129758A (en) | 1982-08-17 |
| DE2961490D1 (en) | 1982-01-28 |
| JPS54119993A (en) | 1979-09-18 |
| IL56467A (en) | 1982-04-30 |
| EP0003583A1 (en) | 1979-08-22 |
| AU4367679A (en) | 1979-08-16 |
| EP0003583B1 (en) | 1981-12-02 |
| AU529917B2 (en) | 1983-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4215102A (en) | Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues | |
| Lee | Cytochemical study of estrogen receptor in human mammary cancer | |
| Horwitz et al. | MCF-7: a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors | |
| Dandliker et al. | Investigation of hormone-receptor interactions by means of fluorescence labeling | |
| Menon et al. | Characterization of the binding of a potent synthetic androgen, methyltrienolone, to human tissues | |
| JP4448642B2 (ja) | å€ç³ã§è¢«èŠãããæ äœããã®è£œé ããã³äœ¿çš | |
| EP2167963B1 (en) | Polymeric carriers for immunohistochemistry and in situ hybridization | |
| Landry et al. | Systemic lupus erythematosus. Studies of the antibodies bound to skin | |
| Cowan et al. | Binding of methyltrienolone (R1881) to a progesterone receptor-like component of human prostatic cytosol | |
| JPS63501506A (ja) | ããããã²ã¹ããã³å容äœã«å¯Ÿããæäœåã³è©Šè¬åã³äœ¿çšæ¹æ³ | |
| JPH022104B2 (ja) | ||
| JPH08501390A (ja) | ç¹æ®çŽ°èéå£ãããã¯æ··å现èéå£ããã³æ··å现èéå£ãå«æãã溶液äžã®ç¹ç°æšç现èã®æ€åºæ¹æ³ | |
| McCarty Jr et al. | Comparison of biochemical and histochemical techniques for estrogen receptor analyses in mammary carcinoma | |
| Kontula et al. | Progesterone-binding protein in human myometrium. Ligand specificity and some physicochemical characteristics | |
| US4341758A (en) | Immunochemical assay reagent for the determination of haptens, and assay method therewith | |
| Niel et al. | Progesterone receptors in normal, dysplastic and tumourous feline mammary glands. Comparison with oestrogen receptors status | |
| Edwards et al. | Subcellular compartmentalization of estrogen receptors in human breast cancer cells | |
| JP2011148821A (ja) | éå åã³ã«ããŸãŒã«æ¥åäœ | |
| CA2214085A1 (en) | Determination of steroids by competitive immunoassay | |
| Sirett et al. | Androgen binding in cytosols and nuclei of human benign hyperplastic prostatic tissue | |
| PIETRAS et al. | Surface modifications evoked by estradiol and diethylstilbestrol in isolated endometrial cells: evidence from lectin probes and extracellular release of lysosomal protease | |
| Adams et al. | Dehydroepiandrosterone and androst-5-ene-3β, 17β-diol in human mammary cancer cytosolic and nuclear compartments and their relationship to estrogen receptor | |
| Ciocca et al. | Estrogen receptors, progesterone receptors and heatâshock 27âkD protein in liver biopsy specimens from patients with hepatitis B virus infection | |
| Nenci et al. | Estrogen receptor cytochemistry by fluorescent estrogen. | |
| Joyce et al. | Studies with steroid-fluorescein conjugates on oestrogen target tissues |